WO2001062242A1 - Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors - Google Patents

Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors Download PDF

Info

Publication number
WO2001062242A1
WO2001062242A1 PCT/US2001/005862 US0105862W WO0162242A1 WO 2001062242 A1 WO2001062242 A1 WO 2001062242A1 US 0105862 W US0105862 W US 0105862W WO 0162242 A1 WO0162242 A1 WO 0162242A1
Authority
WO
WIPO (PCT)
Prior art keywords
reacting
compound
product
ethyl
amino
Prior art date
Application number
PCT/US2001/005862
Other languages
French (fr)
Inventor
Yarlagadda S. Babu
Pooran Chand
John A. Montgomery
Karen Bush Watts
Dennis J. Hlasta
Gary W. Caldwell
Original Assignee
Biocryst Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharmaceuticals, Inc. filed Critical Biocryst Pharmaceuticals, Inc.
Priority to AU2001243253A priority Critical patent/AU2001243253A1/en
Publication of WO2001062242A1 publication Critical patent/WO2001062242A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/39—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups
    • C07C205/42—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/43—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/16—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Definitions

  • This invention relates to novel and useful prodrugs of substituted cyclopentane and cyclopentene compounds which are useful as neuraminidase inhibitors, to pharmaceutical compositions containing said compounds useful for the prevention, treatment or amelioration of viral, bacterial and other infections, and to methods of using said compounds.
  • the present invention is also concerned with methods for producing the novel compounds of the present invention.
  • influenza remains a potentially devastating disease of man, lower mammals, and birds. No effective vaccine exists and no cure is available once the infection has been initiated.
  • Influenza viruses consist of eight pieces of single stranded RNA, packaged in orderly fashion within the virion. Each piece codes for one of the major viral proteins.
  • the replication complex is enclosed with a membrane composed of matrix protein associated with a lipid bilayer. Embedded in the lipid bilayer are two surface glycoprotein spikes, hemagglutinin (HA) and the enzyme neuraminidase (NA) . All of the viral genes have been cloned and the three-dimensional structures of the surface glycoprotems have been determined.
  • HA hemagglutinin
  • NA neuraminidase
  • Influenza viruses continually undergo antigenic variation in the two surface antigens, HA and NA, toward which neutralizing antibodies are directed. For this reason, vaccines and a subject's natural immune system have not been very effective. Attention is now being directed to finding other potential antiviral agents acting at other sites of the virion.
  • This invention is directed to novel compounds which are useful in inhibiting the viral surface enzyme NA.
  • NA-possessing organisms are also major pathogens of man and/or mammals, including Vibrio cholerae, Clostridium perfringen, Streptococcus pneumoniae, Arthrobacter si ⁇ lophilas, and other viruses, such as parainfluenza virus, mumps virus, Newcastle disease virus, fowl plague vims, and Sendai virus.
  • viruses such as parainfluenza virus, mumps virus, Newcastle disease virus, fowl plague vims, and Sendai virus.
  • Compounds of this invention are also directed to inhibiting NA of these organisms.
  • NA exists as a tetramer made of four roughly spherical subunits and a DC rauy-aiiacne ⁇ s ⁇ a ⁇ containing a ny ⁇ ropnooic region by wnicn it is embedded in the organism's membrane.
  • the enzyme catalyzes cleavage of the ⁇ -ketosidic linkage between terminal sialic acid and an adjacent sugar residue. Removal of the sialic acid lowers the viscosity and permits access of the virus to the epithelial cells.
  • NA also destroys the HA receptor on the host cell, thus allowing elution of progeny virus particles from infected cells.
  • influenza neuraminidase remains substantially unchanged for the major strains of influenza. For example, a comparison of sequences from influenza A subtypes and influenza B shows conserved residues with crucial structural and functional roles. Even though the sequence homology is only about 30% , many of the catalytic residues are conserved. Furthermore, the three-dimensional structures of influenza A and B neuraminidases have been determined. Superposition of the various structures shows remarkable structural similarity of the active site.
  • an inhibitor that is effective against different strains of influenza A and/or B neuraminidase can be designed based on the three-dimensional structure of a neuraminidase.
  • NA In general, the role of NA is thought to be for the mobility of the virus both to and from the site of infections.
  • Compounds that inhibit neuraminidase' s activity may protect a subject from infection and/or cure a subject once infection has set in. It is a further object of this invention to provide a method of using compounds of this invention for treating and/or curing a viral infection.
  • Analogs of neuraminic acid such as 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) and its derivatives are known to inhibit HA in vitro; however, these compounds are inactive in vivo.
  • DANA 2-deoxy-2,3-didehydro-N-acetylneuraminic acid
  • Palese and Schulman in CHEMOPROPHYLAXIS AND VIRUS INFECTION OF THE UPPER RESPIRATORY TRACT, Vol. 1 (J.S. Oxford, Ed.), CRC Press, 1977, at PS 189-205.
  • A is O, C or S in Formula (a), and N or C in Formula (b);
  • R 1 is CO2H, PO3H2, NO2, SO 2 H, SOaH, tetrazolyl-, CH2CHO, CHO, or CH(CHO) 2 ;
  • R 2 is H, OR 6 , F, Cl, Br, CN, NHR 6 , SR 6 or CH2X, where X is NHR 6 halogen, OR 6 ;
  • R 4 is NHR 6 , SR 6 , OR 6 , CO2R 6 , NO2, C(R 6 )s, CH2CO2R 6 , CH2NO2 or CH2NHR 6 ;
  • R 5 is CH2YR 6 , CHYR 6 CH 2 YR 6 or CHYR 6 CHYR 6 CH 2 YR 6 ;
  • R 6 is H, acyl, alkyl, allyl, or aryl;
  • Y is O, S, NH, or H; and pharmaceutical salts thereof, useful as antiviral agents.
  • WO 96/26933 to Gilead Sciences, Inc. describes certain 6-membered ring compounds as possible inhibitors of neuraminidase.
  • WO 99/14191 to BioCryst Pharmaceuticals, Inc. the assignee of the present application, and WO 99/582999 to Abbott Laboratories, Inc. describe various pyrrolidine compounds as possible inhibitors of neuraminidase.
  • WO 95/54290 to Abbott Laboratories, Inc. describes certain cyclopentane or cyclopentene derivatives as possible inhibitors of neuraminidase.
  • An aspect of the present invention relates to compounds represented by the formulae:
  • each R2 and R3 individually is H, (CH2)mOH, -C(O)OR, -C(O)R_, -C(O)SR, (CH_)m-C(O)- NRsR's, -O-C(O)-O-R5, an amino acid and/or a dipeptide;
  • R is Rs, H, (CH 2 ) m -
  • R 4 is H, OH, -OC(O)-Rs, -OC(O)-N-Rs(R' 5 ), -O-C(O)-O-Rs;
  • each Rs, R'5 and Rs" is independently H, alkyl, substituted alkyl, aryl, substituted aryl, alkenyl, alkynyl, substituted alkenyl, substituted alkynyl, heterocycle, substituted heterocycle, alkylaryl, substituted alkylaryl, cycloalkyl, substituted cycloalkyl, or -CH2CO2 alkyl; and wherein Rs can also be (dialkyl)CO alkyl;
  • each R7 and R'7 individually is alkyl, alkylaryl, substituted alkylaryl, cycloalkyl, substituted cycloalkyl;
  • Rs is alkyl, or halo substituted alkyl
  • the present invention is also concerned with compositions for inhibiting influenza virus neuraminidase comprising a pharmaceutically acceptable carrier and an amount effective for inhibiting influenza virus neuraminidase of a compound as defined above.
  • a further aspect of the present invention involves a method for inhibiting influenza virus that comprises administering to a patient in need thereof a compound as defined above in an amount effective for inhibiting influenza virus neuraminidase.
  • a still further aspect of the present invention is concerned with treating influenza virus infection comprising administering to a patient in need thereof a compound as defined above in an amount effective for inhibiting influenza virus neuraminidase.
  • process 1 A process (referred to as process 1) aspect of the present invention for preparing compounds represented by formula A comprising the following steps:
  • step 6 Hydrolyzing the product from step 6 to obtain the corresponding acid.
  • a further aspect of the present invention (referred to as process 2) relates to preparing compounds represented by formula B comprising the following steps:
  • process 3 relates to forming ester prodrugs of structure A or structure B which comprises:
  • process 4 Another aspect of the present invention (referred to as process 4) relates to forming ester prodrugs of structure A or structure B which comprises:
  • a still further aspect of the present invention (referred to as process 5) relates to forming ester prodrugs of structure A or structure B which comprises: 1. Converting a compound obtained from step 4 of process 1 above or step 6 of process 2 above to the corresponding acid;
  • process 6 Another aspect of the present invention (referred to as process 6) relates to forming ester prodrugs of structure A or structure B which comprises: 5
  • a further aspect of the present invention (referred to as process 7) related to forming ester prodrugs of structure A or structure B which comprises:
  • a still further aspect of the present invention (referred to as process 8) relates to forming esters of prodrugs of structure A or structure B which comprises:
  • process 9 Another process aspect of the present invention (referred to as process 9) relates to preparing prodrugs of formula A or formula B which comprises:
  • process 10 Another process aspect of the present invention (referred to as process 10) relates to preparing prodrugs of formula A or formula B which comprises:
  • process 11 Another process of the present invention (referred to as process 11) relates to preparing compounds represented by formula A or formula B which comprises:
  • a still further process of the present invention relates to preparing compounds represented by formula A or formula B which comprises: 1. Converting the product from step 1 of process 10 to an amide; and
  • step 2 Reacting the product from step 1 with an amino acid. Furthermore, when disubstituted guanidine and ester prodrugs of structures A and B are desired, about 2 equivalents of the reactive reagents are employed.
  • the present invention relates to compounds represented by the formulae:
  • each Ri and Rs individually is H, (CH 2 )mOH, -C(O)OR, -C(O)Rs, -C(O)SR, (CH 2 )m-C(O)- NRsR'5, -O-C(O)-O-R5, an amino acid and/or a dipeptide; R 5 Rs
  • R is Rs, H,
  • R4 is H, OH, -OC(O)-Rs, -OC(O)-N-Rs(R's), -O-C(O)-O-Rs; each Rs , R'5 and R " s is independently H, alkyl, substituted alkyl, aryl, substituted aryl, alkenyl, alkynyl, substituted alkenyl, substituted alkynyl, heterocycle, substituted heterocycle, alkylaryl, substituted alkylaryl, cycloalkyl, substituted cycloalkyl, or -CH2CO2 alkyl; and wherein Rs can also be (dialkyl)CO alkyl;
  • each R7 and R'7 individually is alkyl, araalkyl, substituted araalkyl, cycloalkyl, substituted cycloalkyl;
  • alkyl refers to straight or branched chain unsubstituted hydrocarbon groups of 1 to 20 carbon atoms, preferably 1 to 8 carbon atoms.
  • lower alkyl refers to unsubstituted alkyl groups of 1 to 4 carbon atoms.
  • substituted alkyl refers to an alkyl, alkenyl or alkynyl group substituted by, for example, one to four substituents, such as halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, cycloalkyloxy, heterocylooxy, oxo, alkanoyl, aryloxy, alkanoyloxy, amino, alkylamino, arylamino, aralkylamino, cycloalkylamino, heterocycloamino, disubstituted amines in which the 2 amino substituents are selected from alkyl, aryl or aralkyl, alkanoylamine, aroylamino, aralkanoylamino, substututed alkanoylamino, substituted arylamino, substituted a
  • halogen refers to fluorine, chlorine, bromine and iodine.
  • aryl refers to monocyclic or bicyclic aromatic hydrocarbon groups having 6 to 12 carbon atoms in the ring portion, such as phenyl, naphthyl, biphenyl and diphenyl groups, each of which may be substituted.
  • aralkyl or “alkylaryl” refers to an aryl group bonded directly through an alkyl group, such as benzyl or phenethyl.
  • substituted aryl or “substituted alkylaryl” refers to an aryl group or alkylaryl group substituted by, for example, one to four substituents such as alkyl; substituted alkyl, halo, trifluoromethoxy, trifluoromethyl, hydroxy, alkoxy, cycloalkyloxy, heterocycloooxy, alkanoyl, alkanoyloxy, amino, alkylamino, aralkylamino, cycloalkylamino, heterocycloamino, dialkylamino, alkanoylamino, thiol, alkylthio, cycloalkylthio, heterocyclothio, ureido, nitro, cyano, carboxy, carboxyalkyl, carbamyl, alkoxycarbonyl, alkylthiono, arylthiono, alkysulfonyl, sulfonamido, aryl
  • the substituent may be further substituted by halo, hydroxy, alkyl, alkoxy, aryl, substituted aryl, substituted alkyl or aralkyl.
  • substituted benzyl refers to a benzyl group substituted by, for example, any of the groups listed above for substituted aryl.
  • cycloalkyl refers to optionally substituted, saturated cyclic hydrocarbon ring systems, preferably containing 1 to 3 rings and 3 to 7 carbons per ring which may be further fused with an unsaturated C3-C7 carbocyclic ring.
  • exemplary groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl and adamantyl.
  • substituents include one or more alkyl groups as described above, or one or more groups described above as alkyl substituents.
  • heterocycle refers to an optionally substituted, fully saturated or unsaturated, aromatic or nonaromatic cyclic group, for example, which is a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom-containing ring.
  • Each ring of the heterocyclic group containing a heteroatom may have 1, 2 or 3 heteroatoms selected from nitrogen atoms, oxygen atoms and sulfur atoms, where the nitrogen and sulfur heteroatoms may also optionally be oxidized and the nitrogen heteroatoms may also optionally be quaternized.
  • the heterocyclic group may be attached at any heteroatom or carbon atom.
  • Exemplary monocyclic heterocyclic groups include pyrrolidinyl, pyrrolyl, indolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2- oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxazepinyl, azepinyl, 4-piperidonyl, pyridyl, N-oxo-pyridyl,
  • bicyclic heterocyclic groups include benzothiazolyl, benzoxazolyl, benzothienyl, quinuclidinyl, quinolinyl, quinolinyl-N-oxide, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,l-b]pyridinyl, or furo[2,3-b]pyridinyl), dihydroisoindolyl, diyhydroquinazolinyl (such as 3,4-dihydro-4-oxo-quinazolinyl), benzisothiazolyl, benz
  • Exemplary substituents include one or more alkyl groups as described above or one or more groups described above as alkyl substituents.
  • heteroatoms shall include oxygen, sulfur and nitrogen.
  • amino acid means any naturally occurring amino acid including D and L amino acids.
  • dipeptide means a di-amino acid containing two linked naturally occurring amino D and L acids.
  • Preferred alkyl groups are lower alkyl groups containing 1 to about 8 carbon, and more preferably 1 to about 5 carbon atoms, and can be straight, branched-chain or cyclic saturated aliphatic hydrocarbon groups.
  • suitable alkyl groups include methyl, ethyl and propyl.
  • Examples of branched alkyl groups include isopropyl and t-butyl.
  • An example of a suitable alkylaryl group is phenethyl.
  • suitable cycloalkyl groups typically contain 3-8 carbon atoms and include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • the aromatic or aryl groups are preferably phenyl or alkyl substituted aromatic groups (aralkyl) such as phenyl C1-3 alkyl such as benzyl.
  • the N-heterocyclic rings preferably contain 3-7 atoms in the ring and a heteroatom such as N, S or O in the ring.
  • suitable preferred heterocyclic groups are pyrrolidino, azetidino, piperidino, 3,4-didehydropiperidino, 2-methylpiperidino and 2- ethylpiperidino.
  • the above substitutions can include halo such as F, Cl, Br, lower alkyl, lower alkoxy and halo substituted lower alkoxy.
  • suitable amino acids are L-Ala, L-Val, L-Isoleu, L-Phe, Gly and L-Leu.
  • Examples of suitable dipeptides are L-Ala-L-Ala and Gly-Gly.
  • R7 and R'7 are CH3, C2H5, n-CsHz and 11-C4H9 and most preferred groups for R7 and R'7 are C2H5 and n-C3H7.
  • Preferred groups for Rs are CH3, C2H5 and C3H7 and most preferred is CH3.
  • Pharmaceutically acceptable salts of the compounds of formula (I) include those derived from pharmaceutically acceptable, inorganic and organic acids and bases.
  • suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, gly collie, lactic, salicyclic, succinic, toluene-p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic, trifluoroacetic and benzenesulphonic acids.
  • Salts derived from appropriate bases include alkali such as sodium and ammonia. It is of course understood that the compounds of the present invention relate to all optical isomers and stereo-isomers at the various possible atoms of the molecule.
  • Lactam (1, -, + , or racemic mixture) is heated at reflux temperature with methanolic HCI. The solvent is evaporated' and the residue is washed with ether to give methyl 4-amino-2-cyclopenten- 1-carboxylate hydrochloride, which is further reacted with di- tert-butyl dicarbonate and triethylamine to give methyl 4-t-rt-butoxycarbonylamino-2- cyclopenten- 1-carboxylate (2).
  • Compound (2) is reacted with 2-ethyl-l- nitrobutane/triethylamine and phenylisocyanate to give the cycloadduct (3).
  • Cycloadduct (3) may also be obtained by the reaction of (2) with 2-ethylbutyrohydroximinoxyl chloride and triethylamine. The desired isomer is separated and is hydrogenated in the presence of a catalyst to give the corresponding amine, which is acetylated with acetic anhydride to give methyl 3- (1 '-acetylamino-2'-ethyl)butyl-4-tert-butoxycarbonylamino-2-hydroxycyclopentane- 1-carboxylate (4). Cycloadduct (3) can be converted to the amine using chemical reduction also.
  • Some catalyst such as acetic acid, HgCh, ZnCb, etc. may be desirable for the reaction.
  • the ester is hydrolyzed to acid (21), and converted to ester (22) following one of the above mentioned methods. Removal of Cbz group is achieved by hydrogenation and the target (11) is obtained.
  • Any other standard method for converting acid to ester may be used for these reactions.
  • the desired RiX or RiOH are either commercially available, or are prepared according to the literature procedures.
  • Compound (25) is prepared from either (5) by reacting with a guanylating agent, such as pyrazole carboxamidine, triazole carboxamidine, 4-nitropyazole carboxamidine or amino-iminomethanesulphonic acid or by esterification of compound (6) with methanol.
  • Compound (25) further reacts with 1 equivalent of R9OC(O)Cl or R9 ⁇ C(O)OC ⁇ H4-N ⁇ 2(p) in the presence of a base to give the desired target (26).
  • ii) Compound (26) is prepared from (5) also by reacting with one equivalent of appropriately substituted guanylating agent as shown in Scheme 4.
  • Substituted guanylating agents are prepared from the literature procedures. In some cases, a catalyst, such as HgCk, ZnCk, acetic acid, etc. may be desired for the reaction.
  • These compounds (27) are prepared from the standard methods of amides preparation from amine (25) and the desired amino acid in the presence of a coupling agent.
  • any other ester also can be used for the preparation of the desired targets.
  • alkyl group containing compounds may be prepared using the same methods.
  • esters obtained are hydrolyzed with a base, acid, methanol/water/triethylamine mixture or any otlier appropriate saponification reagent.
  • Reagent R 9 OC(0)CI, or R 9 OC(0)OC 6 H 4 -N0 2 (p))
  • 2A l-Benzyloxycarbonyl-3-tert-butoxycarbonyl-2-methyl-2-thiopseudourea
  • l-benzyloxycarbonyl-2 ⁇ methyl-2-thiopseudourea IA, 5.0 g, 22.0 mmol
  • dichloromethane 100 mL
  • triethylamine 9 mL, 66.0 mmol
  • di- tert-butyl dicarbonate (14.4 g, 66.0 mmol
  • the solution was washed with water; the organic layer was separated, concentrated and purified on silica gel column using hexane: ethyl acetate as an eluent to give 3.8 g (53 %) of 2A.
  • Example 15 Ethyl (lS,25,3R,4R4' ⁇ -(-)-3-(l'-acetylammo-2'-ethyl)butyl-4-[N-(2'-L-amino-3'- phenylpropanoyIamino)-imino]methylarnino-2-hydroxycyclopentan-l-carboxylate 15A: Ethyl (15,2S,3__,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L-amino-3'- phenyl)propanoylamino)-N'-(benzyloxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan-1-carboxylate To a solution of N-benzyloxycarbonyl L-phenylalanine (0.26 g, 0.87 mmol) in ethyl
  • N- hydroxysuccinimide 0.1 g, 0.87 mmol
  • the reaction mixture was washed with water and the organic layer separated, dried, filtered and concentrated to give 0.34 g of N-benzyloxycarbonyl L-phenylalanine succinimido ester.
  • N-benzyloxycarbonyl L-alanine (0.23 g, 1.0 mmol) in ethyl acetate (20 mL) was added 1, l'-carbonyldiimidazole (0.16 g, 1.0 mmol) and the mixture was stirred for 0.25 h.
  • N- hydroxysuccinimide (0.12 g, 1.0 mmol) and stirred for 2 h.
  • the reaction mixture was washed with water and the organic layer separated, dried, filtered and concentrated to give 0.32 g of N-benzyloxycarbonyl L-alanine succinimido ester.
  • N-benzyloxycarbonyl L-phenylalanine (0.0.3 g, 1.0 mmol) in ethyl acetate (20 mL) was added 1, l'-carbonyldiimidazole (0.16 g, 1.0 mmol) and the mixture was stirred for 0.25 h.
  • N- hydroxysuccinimide (0.12 g, 1.0 mmol) and stirred for 2 h.
  • the reaction mixture was washed with water and the organic layer separated, dried, filtered and concentrated to give 0.39 g of N-benzyloxycarbonyl L-phenylalanine succinimido ester.
  • 26B Benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyl- oxycarbonylamino-N'-tof-butoxycarbonylimino)methyl]amino-2-hydroxycyclo- pentan-1- carboxylate
  • 26D Benzyl (1S,2S,3R,4R, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy carbonylamino-N' -acetyloxymethoxycarbonylimino)methyl]amino-2-hydroxycyclo- pentan- 1-carboxylate
  • N-benzyloxycarbonyl L-phenylalanine (0.26 g, 0.87 mmol) in ethyl acetate (20 mL) was added 1, l'-carbonyldiimidazole (0.14 g, 0.87 mmol) and the mixture was stirred5 for 0.25 h.
  • N- hydroxysuccinimide 0.1 g, 0.87 mmol
  • the reaction mixture was washed with water and the organic layer separated, dried, filtered and concentrated to give 0.34 g of N-benzyloxycarbonyl L-phenylalanine succinimido ester.
  • N-benzyloxycarbonyl L-alanine (0.22 g, 1.0 mmol) in ethyl acetate (20 mL) was added 1, l'-carbonyldiimidazole (0.16 g, 1.0 mmol) and the mixture was stirred for 0.255 h.
  • N- hydroxysuccinimide (0.11 g, 1.0 mmol) and stirred for 2 h.
  • the reaction mixture was washed with water and the organic layer separated, dried, filtered and concentrated to give 0.32 g of N-benzyloxycarbonyl L-alanine succinimido ester.
  • 35A Benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-acetyloxy- methoxycarbonylamino-N'-acetyloxymethoxycarbonylimino)methyl]amino-2- l o hydroxycyclopentan-1-carboxylate
  • 35 To a solution of benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- acetyloxymethoxycarbonylamino-N'-acetyloxymethoxycarbonylimino)methyl]- amino-2- hydroxycyclopentan- 1-carboxylate (35A, 0.15 g, 0.23 mmol) in ethanol (16 mL) and water (4 mL) was added 10% Pd/C (50 mg) and the mixture was hydrogenated at 40 psi for 1 h. The 25 mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.056g (42%) of 35.
  • reaction mixture was added portion wise, over a period of 1 h, to a stirred mixture of 2-methyl-2-thiopseudourea sulfate (2.0 g, 7.2 mmol) in dichloromethane (100 mL) and aqueous sodium bicarbonate (100 mL), while maintaining the pH of the mixture basic by adding 40% sodium hydroxide.
  • the reaction mixture was further stirred for 1 h and the organic layer was separated. After drying, it was filtered and the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.4 g (16%) of 36A.
  • reaction mixture was concentrated and the residue was suspended in a mixture of chloroform: methanol (1: 1).
  • the solid was removed by filtration, the filtrate concentrated and the residue was purified by silica gel column using chloroform (80): methanol (18): ammonium hydroxide (2) mixture as an eluent to give 0.2 g (23 %) of 39B.
  • Methyl chloroformate (1.8 mL, 23.3 mmol) was added to a mixture of N- benzyloxycarbonylglycine (5.0 g, 23.9 mmol) and triethylamine (3.35 mL, 24.2 mmol) in THF (60 mL) at -20 °C over a period of 10 min. and further stirred for 20 min. To this mixture was then added, a solution of 4-aminobenzoic acid (3.28 g, 23.9 mmol) and triethylamine (3.35 mL, 24.2 mmol) in THF (45 mL) drop wise and stirred at the same temperature for 1 h.
  • Antibiotics 1987, XL, 370-384) was added to a mixture of (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)- butyl-4-tert- butoxycarbony lamin)-2-hy droxy cy clopentan- 1 -carboxylic acid (20B, 1.0 g, 2.6 mmol) and diisopropylamine (0.0.53 g, 5.2 mmol) in dimethyl acetamide (30 mL) at 0 °C. The reaction mixture was further stirred for 2 h at this temperature and diluted with water and ethyl acetate.
  • reaction mixture was further stirred for 2 h at this temperature and diluted with water and ethyl acetate.
  • Organic layer was separated, aqueous layer was extracted with ethyl acetate.
  • the combined organic layers were washed with sodium bicarbonate, water and brine and dried. After filtration, the filtrate was concentrated, and the residue was purified on silica gel column using hexane: ethyl acetate as eluent to give 0.7 g (57%) of 45A.
  • 45B ⁇ -Acetyloxyethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(N- benzyloxycarbonylamino-N'-benzyloxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan-1-carboxylate
  • 46 tert-Butylcarbonyloxomethyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)- butyl- 4-(amino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate 46A: tert-Butylcarbonyloxymethyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)- butyl- 4-tert-butoxycarbonylamino-2-hydroxycyclopentan-l-carboxylate
  • reaction mixture was further stirred for 2 h at this temperature and diluted with water and ethyl acetate.
  • Organic layer was separated, aqueous layer was extracted with ethyl acetate.
  • the combined organic layers were washed with sodium bicarbonate, water and brine and dried. After filtration, the filtrate was concentrated, and the residue was purified on silica gel column using hexane: ethyl acetate as eluent to give 0.7 g (59%) of 46A.
  • antibiotics 1987, XL, 370- 384) was added to a mixture of (15,25,322,422, l'5)-(-)-3-(l ' -acetylamino-2 ' -ethyl)butyl-4-tert- butoxycarbonylamino-2-hydroxycyclopentan-l -carboxylic acid (20B, 1.0 g, 2.6 mmol) and dusopropylamine (0.53 g, 5.2 mmol) in dimethyl acetamide (30 mL) at 0 °C. The reaction mixture was further stirred for 2 h at this temperature and diluted with water and ethyl acetate.
  • antibiotics 1987, XL, 370- 384) was added to a mixture of (15,25,3R,422,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-tert- butoxycarbonylamino-2-hydroxycyclopentan-l -carboxylic acid (20B, 1.0 g, 2.6 mmol) and dusopropylamine (0.53 g, 5.2 mmol) in dimethyl acetamide (30 mL) at 0 °C. The reaction mixture was further stirred for 2 h at this temperature and diluted with water and ethyl acetate. Organic layer was separated, aqueous layer was extracted with ethyl acetate.
  • Compounds of the present invention are useful as prodrugs for substituted cyclopentane and substituted cyclopentene compounds which are useful as neuraminidase inhibitors, or as active neuraminidase inhibitors themselves.
  • the term “prodrag” denotes a derivative of cyclopentane or cyclopentene, which derivative, when administered to a warm-blooded animal, "cleaves” in such a manner as to release the active drug form at its target site or sites of activity.
  • the enzymatic and/or chemical hydrolytic "cleavage" of the compounds of the instant invention occurs in a manner such that the active drag form is released while the remaining “cleaved” moiety remains nontoxic and is metabolized in such a manner that nontoxic, virologically inert products are produced.
  • the prodrug compounds of the present invention can be used to treat any condition for which the parent cyclopentane or cyclopentene containing drug, medicament or pharmaceutical is useful for.
  • the prodrugs may be administered in low amounts relative to the amounts of neuraminidase inhibitor that would ordinarily be administered.
  • the compounds of this invention can be administered as treatment for viral infections by any means that produces contact of the active agent's site of action with the viral neuraminidase in the body of a human, mammal, bird, or other animal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the dosage administered will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms, the kind of concurrent treatment; the frequency of treatment; and the effect desired.
  • a daily dosage of active ingredient can be expected to be about 0.001 to 1000 milligram (mg) per kilogram (kg) of body weight, with the preferred dose being 0.1 to about 30 mg/kg.
  • Dosage forms contain from about 1 mg to about 500 mg of prodrug per unit.
  • the compound of the present invention will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.
  • the prodrug can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.
  • the prodrug can also be administered intranasally (nose drops) or by inhalation of a drug powder mist.
  • Other dosage forms are potentially possible such as administration transdermally, via a patch mechanism or ointment.
  • Gelatin capsules contain the prodrug and powdered carriers, such as lactose, starch, cellulose derivatives, biocompatible polymers, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar-coated or film-coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
  • powdered carriers such as lactose, starch, cellulose derivatives, biocompatible polymers, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar-coated or film-coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in
  • Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. They may also contain buffering agents, surfactants and preservatives. Liquid oral products can be developed to have sustained-release properties. They may also contain cyclodextrin derivatives to enhance the solubility of the active ingredient and to promote its oral uptake.
  • parenteral solutions In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
  • Solutions for parenteral administration preferably contain a water-soluble salt of the active ingredient, suitable stabilizing agents, and, if necessary, buffering agents.
  • Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
  • citric acid and its salts and sodium EDTA are also used.
  • parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.
  • Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company and in the Handbook of Pharmaceuticals Excipients, American Pharmaceutical Association, both standard reference texts in this field.
  • Useful pharmaceutical dosage forms for administration of the compounds according to the present invention can be illustrated as follows: Hard Shell Capsules
  • a large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered prodrug, 150 mg of lactose, 50 mg of cellulose, and 6 5 mg of magnesium stearate.
  • a mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil, or0 olive oil is prepared and injected by means of a positive displacement pump into molten gelatin to form soft gelatin capsules containing 100 mg of the active ingredient.
  • the capsules are washed and dried.
  • the prodrug can be dissolved in a mixture of polyethylene glycol, glycerin and sorbitol to prepare a water miscible medicine mix. 5 Tablets
  • a large number of tablets are prepared by conventional procedures so that the dosage unit was 100 mg of active ingredient, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch, and 98.8 mg of lactose. o Appropriate aqueous and non-aqueous coatings may be applied to increase palatability improve elegance and stability or delay absorption.
  • Immediate Release Tablets/Capsules 5 These are solid oral dosage forms made by conventional and novel processes. These units are taken orally without water for immediate dissolution and delivery of the medication.
  • the prodrug is mixed in a liquid containing ingredient such as sugar, gelatin, pectin, and sweeteners. These liquids are solidified into solid tablets or caplets by freeze drying and solid state extraction techniques.
  • the compounds may be compressed with viscoelastic and o thermoelastic sugars and polymers or effervescent components to produce porous matrices intended for immediate release, without the need of water.
  • the compounds of the present invention can be administered in the form of nose drops, metered dose nasal or buccal inhalers.
  • the drug is delivered from a nasal solution5 as a fine mist or from a powder as an aerosol.

Abstract

A compound represented by the formulae (A) or (B) wherein R1 is H, R5, (a), (b), (c), (d), (e), (f), (g), — (CH2)nOC(O)R5, —(CH2)nOR5, or —(CH2)n-N-R6; each R2 and R3 individually is H, (CH2)mOH, -C(O)OR, -C(O)R5, -C(O)SR, (CH2)m-C(O)-NR5R'5, -O-C(O)-O-R5, an amino acid and/or a dipeptide; R is R5, H, (h), (i), (j), (k), (l), (m) or (n); R4 is H, OH, -OC(O)-R5, -OC(O)-N-R5(R'5), -O-C(O)-O-R5; each R5, R'5, and R5'' is independently H, alkyl, substituted alkyl, aryl, substituted aryl, alkenyl, alkynyl, substituted alkenyl, substituted alkynyl, heterocycle, substituted heterocycle, alkylaryl, substituted alkylaryl, cycloalkyl, substituted cycloalkyl, or -CH2CO2 alkyl; and wherein R5 can also be (dialkyl)CO alkyl; -NR6 is (o), (p), (q), (r) or (s) each R7 and R'7 individually is alkyl, alkylaryl, substituted alkylaryl, cycloalkyl, substituted cycloalkyl; R8 is alkyl, or halo substituted alkyl; n=1-5 and m=0-4; and pharmaceutically acceptable salts thereof; and method of preparation are provided. Compounds of the above formulae are useful as prodrugs for compounds that are useful as neuraminidase inhibitors. Accordingly, they may be used for preventing, treating or ameliorating infections including viral and bacterial.

Description

PRODRUGS OF SUBSTITUTED CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS DESCRIPTION
Technical Field
This invention relates to novel and useful prodrugs of substituted cyclopentane and cyclopentene compounds which are useful as neuraminidase inhibitors, to pharmaceutical compositions containing said compounds useful for the prevention, treatment or amelioration of viral, bacterial and other infections, and to methods of using said compounds. The present invention is also concerned with methods for producing the novel compounds of the present invention.
Background of the Invention
Despite the wealth of information available, influenza remains a potentially devastating disease of man, lower mammals, and birds. No effective vaccine exists and no cure is available once the infection has been initiated.
Influenza viruses consist of eight pieces of single stranded RNA, packaged in orderly fashion within the virion. Each piece codes for one of the major viral proteins. The replication complex is enclosed with a membrane composed of matrix protein associated with a lipid bilayer. Embedded in the lipid bilayer are two surface glycoprotein spikes, hemagglutinin (HA) and the enzyme neuraminidase (NA) . All of the viral genes have been cloned and the three-dimensional structures of the surface glycoprotems have been determined.
Influenza viruses continually undergo antigenic variation in the two surface antigens, HA and NA, toward which neutralizing antibodies are directed. For this reason, vaccines and a subject's natural immune system have not been very effective. Attention is now being directed to finding other potential antiviral agents acting at other sites of the virion. This invention is directed to novel compounds which are useful in inhibiting the viral surface enzyme NA.
Furthermore, many other organisms carry NA. Many of these NA-possessing organisms are also major pathogens of man and/or mammals, including Vibrio cholerae, Clostridium perfringen, Streptococcus pneumoniae, Arthrobacter siάlophilas, and other viruses, such as parainfluenza virus, mumps virus, Newcastle disease virus, fowl plague vims, and Sendai virus. Compounds of this invention are also directed to inhibiting NA of these organisms.
In viruses, NA exists as a tetramer made of four roughly spherical subunits and a cei rauy-aiiacneα sιaι containing a nyαropnooic region by wnicn it is embedded in the organism's membrane. Several roles have been suggested for NA. The enzyme catalyzes cleavage of the α-ketosidic linkage between terminal sialic acid and an adjacent sugar residue. Removal of the sialic acid lowers the viscosity and permits access of the virus to the epithelial cells. NA also destroys the HA receptor on the host cell, thus allowing elution of progeny virus particles from infected cells.
Research indicates that the active site for influenza neuraminidase remains substantially unchanged for the major strains of influenza. For example, a comparison of sequences from influenza A subtypes and influenza B shows conserved residues with crucial structural and functional roles. Even though the sequence homology is only about 30% , many of the catalytic residues are conserved. Furthermore, the three-dimensional structures of influenza A and B neuraminidases have been determined. Superposition of the various structures shows remarkable structural similarity of the active site. Since the active site amino acid residues are conserved in all known influenza A neuraminidases that have been sequenced so far, an inhibitor that is effective against different strains of influenza A and/or B neuraminidase can be designed based on the three-dimensional structure of a neuraminidase.
In general, the role of NA is thought to be for the mobility of the virus both to and from the site of infections. Compounds that inhibit neuraminidase' s activity may protect a subject from infection and/or cure a subject once infection has set in. It is a further object of this invention to provide a method of using compounds of this invention for treating and/or curing a viral infection.
Analogs of neuraminic acid, such as 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) and its derivatives are known to inhibit HA in vitro; however, these compounds are inactive in vivo. Palese and Schulman, in CHEMOPROPHYLAXIS AND VIRUS INFECTION OF THE UPPER RESPIRATORY TRACT, Vol. 1 (J.S. Oxford, Ed.), CRC Press, 1977, at PS 189-205.
Von Itzstein et al. describes cyclohexane analogs of α-D-neuraminic acid of the formula
Figure imgf000004_0001
(a) and (a) wnerem:
A is O, C or S in Formula (a), and N or C in Formula (b);
R1 is CO2H, PO3H2, NO2, SO2H, SOaH, tetrazolyl-, CH2CHO, CHO, or CH(CHO)2; R2 is H, OR6, F, Cl, Br, CN, NHR6, SR6 or CH2X, where X is NHR6 halogen, OR6; R3 and R3' are H, CN, NHR6, SR6, =NOR6, OR6, guanidino, NR6;
R4 is NHR6, SR6, OR6, CO2R6, NO2, C(R6)s, CH2CO2R6, CH2NO2 or CH2NHR6; R5 is CH2YR6, CHYR6CH2YR6 or CHYR6CHYR6CH2YR6; R6 is H, acyl, alkyl, allyl, or aryl; Y is O, S, NH, or H; and pharmaceutical salts thereof, useful as antiviral agents.
In addition, certain benzene derivatives are suggested in U.S. patent 5,453,533 as being inhibitors of influenza virus neuraminidase and various others are disclosed in U.S. Patent No. 5,602,277. Yamamoto et al. describe various sialic acid isomers as having inhibitory activity against neuraminidase in Synthesis of Sialic Acid Isomers With Inhibitory Activity Against Neuraminidase, TETRAHEDRON LETTERS, Vol. 33, No. 39, pp. 5791-5794, 1992.
WO 96/26933 to Gilead Sciences, Inc. describes certain 6-membered ring compounds as possible inhibitors of neuraminidase.
WO 99/14191 to BioCryst Pharmaceuticals, Inc. , the assignee of the present application, and WO 99/582999 to Abbott Laboratories, Inc. describe various pyrrolidine compounds as possible inhibitors of neuraminidase. WO 95/54290 to Abbott Laboratories, Inc. describes certain cyclopentane or cyclopentene derivatives as possible inhibitors of neuraminidase.
More importantly, in WO 97/47194 and WO 99/33781 to BioCryst Pharmaceuticals, Inc. are disclosed a number of cyclopentane and cyclopentene derivatives as being inliibitors of influenza virus neuraminidase.
However, none of these disclose the cyclopentane and cyclopentene derivatives of the present invention which are useful as prodrugs.
Summary of Invention
An aspect of the present invention relates to compounds represented by the formulae:
wherein Ri is H
Figure imgf000006_0001
, Rs,
Figure imgf000006_0002
— (CH2)nOR5 — (CH2)n-N-R6
, or ; each R2 and R3 individually is H, (CH2)mOH, -C(O)OR, -C(O)R_, -C(O)SR, (CH_)m-C(O)- NRsR's, -O-C(O)-O-R5, an amino acid and/or a dipeptide;
Rs R5
— C— (CH2)m-0-C(0)-R"5 (CH2)m-C-0-C(0)R"5 R'5 R'5
R is Rs, H, (CH2)m-
Figure imgf000007_0001
Figure imgf000007_0002
R4 is H, OH, -OC(O)-Rs, -OC(O)-N-Rs(R'5), -O-C(O)-O-Rs;
each Rs, R'5 and Rs" is independently H, alkyl, substituted alkyl, aryl, substituted aryl, alkenyl, alkynyl, substituted alkenyl, substituted alkynyl, heterocycle, substituted heterocycle, alkylaryl, substituted alkylaryl, cycloalkyl, substituted cycloalkyl, or -CH2CO2 alkyl; and wherein Rs can also be (dialkyl)CO alkyl;
Figure imgf000007_0003
each R7 and R'7 individually is alkyl, alkylaryl, substituted alkylaryl, cycloalkyl, substituted cycloalkyl;
Rs is alkyl, or halo substituted alkyl;
n= l-5 and m=0-4; and pharmaceutically acceptable salts thereof.
The present invention is also concerned with compositions for inhibiting influenza virus neuraminidase comprising a pharmaceutically acceptable carrier and an amount effective for inhibiting influenza virus neuraminidase of a compound as defined above. A further aspect of the present invention involves a method for inhibiting influenza virus that comprises administering to a patient in need thereof a compound as defined above in an amount effective for inhibiting influenza virus neuraminidase.
A still further aspect of the present invention is concerned with treating influenza virus infection comprising administering to a patient in need thereof a compound as defined above in an amount effective for inhibiting influenza virus neuraminidase.
A process (referred to as process 1) aspect of the present invention for preparing compounds represented by formula A comprising the following steps:
a. Reacting a lactam such as 2-azabicyclo[2.2.1]hept-5-en-3-one with an alcohol in the presence of an acid followed by reacting with a suitable anhydride or halide (e.g. chloride) and a base such as trialkylamine to give the corresponding alkoxycarbonyl protected amine- cyclopentene carboxylate (Scheme 1 shows BOC anhydride) ;
2. Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct;
3. Converting the cycloadduct from step 2 to the corresponding amine;
4. Acylating the amine from step 3 to provide the corresponding acylamine compound;
5. Reacting the product from step 4 with an acid to provide the corresponding amine compound; 6. Reacting the product from step 5 to provide the corresponding guanylated compound; and
optionally 7. Hydrolyzing the product from step 6 to obtain the corresponding acid.
A further aspect of the present invention (referred to as process 2) relates to preparing compounds represented by formula B comprising the following steps:
1. Reacting a lactam with an alcohol in the presence of an acid followed by reacting with a suitable anhydride or halide and a base such as trialkylamine to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate;
2. Reacting the compound from step 1 with an alk l-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct;
3. Converting the cycloadduct from step 2 to the corresponding amine;
4. Acylating the amine from step 3 to provide the corresponding acylamine compound;
5. Reacting the product from step 4 with an alkanesulphonyl halide to provide the corresponding O-SO2 alkyl derivative;
6. Treating the product from step 5 with a base to provide the corresponding unsaturated compound;
7. Treating the product from step 6 with an acid to provide the corresponding amine; and
8. Reacting the product from step 7 to provide the corresponding guanylated compound.
Still further aspects of the present invention (referred to as process 3) relates to forming ester prodrugs of structure A or structure B which comprises:
1. Reacting a guanylated compound obtained from one of the above-disclosed processes 1 or 2 with a base to provide the corresponding salt;
2. Reacting the product from step 1 with RiX wherein X is a halide to provide the desired product.
Another aspect of the present invention (referred to as process 4) relates to forming ester prodrugs of structure A or structure B which comprises:
1. Hydrolyzing a compound obtained from step 4 of process 1 above or step 6 of process 2 above with a base to give the corresponding salt;
2. Reacting the product from step 1 with RiX wherein X is a halide;
3. Hydrolyzing the product from step 2 to provide the corresponding amine; and
4. Reacting the product from step 3 to provide the corresponding guanylated compound.
A still further aspect of the present invention (referred to as process 5) relates to forming ester prodrugs of structure A or structure B which comprises: 1. Converting a compound obtained from step 4 of process 1 above or step 6 of process 2 above to the corresponding acid;
5 2. Reacting the product from step 1 with RiOH in the presence of a coupling agent to provide the corresponding ester;
3. Hydrolyzing the product from step 2 to provide the corresponding amine; and 0 4. Reacting the product from step 3 to provide the corresponding guanylated compound.
Another aspect of the present invention (referred to as process 6) relates to forming ester prodrugs of structure A or structure B which comprises: 5
1. Reacting the product from step 1 of process 4 or 5 with an alkylchloroformate in the presence of a base to form a mixed anhydride;
2. Reacting the product from step 1 with RiOH; 0
3. Hydrolyzing the product from step 2 to provide the corresponding amine; and
4. Reacting the product from step 3 to provide the corresponding guanylated compound. 5
A further aspect of the present invention (referred to as process 7) related to forming ester prodrugs of structure A or structure B which comprises:
1. Converting the cycloadduct (e.g. isooxazoline derivative) to its corresponding o alkali salt by reacting with a base;
2. Reacting the product from step 1 with RiX or with RiOH in the presence of a coupling agent to form the corresponding ester. X is a halide; 5 3. Hydrogenating the product from step 2;
4. Acetylating the product from step 3;
5. Hydrolyzing the product from step 4 to provide the corresponding amine; and0
6. Reacting the product from step 5 to provide the corresponding guanylated compound. A still further aspect of the present invention (referred to as process 8) relates to forming esters of prodrugs of structure A or structure B which comprises:
1. Reacting the product from step 5 of process 1 or the product from step 7 of process 2 with a protected guanylated agent;
2. Hydrolyzing the product from step 1 to provide the corresponding acid;
3. Converting the product from step 2 to the corresponding ester;
4. Removing the protecting group.
Another process aspect of the present invention (referred to as process 9) relates to preparing prodrugs of formula A or formula B which comprises:
1. Reacting the product from step 5 of process 1 or the product from step 7 of process 2 with a cyanogen halide to provide the corresponding cyanamine; and
2. Reacting the product from step 1 with a hydroxylamine.
Another process aspect of the present invention (referred to as process 10) relates to preparing prodrugs of formula A or formula B which comprises:
1. Reacting the product from step 5 of process 1 or the product from step 7 of process 2 with a guanylating agent; or reacting the product from step 6 of process 1 or step 8 of process 2 with an alcohol;
2. Reacting the product from step 1 with RsO C(O)X or R9O C(O)C6H*«Nθ2 in the presence of a base.
Another process of the present invention (referred to as process 11) relates to preparing compounds represented by formula A or formula B which comprises:
1. Reacting the product from step 5 of process 1 or the product from step 7 of process 2 with a guanylating agent.
A still further process of the present invention (referred to as process 12) relates to preparing compounds represented by formula A or formula B which comprises: 1. Converting the product from step 1 of process 10 to an amide; and
2. Reacting the product from step 1 with an amino acid. Furthermore, when disubstituted guanidine and ester prodrugs of structures A and B are desired, about 2 equivalents of the reactive reagents are employed.
Preferred Embodiments for Carrying Out Invention
The present invention relates to compounds represented by the formulae:
wherein Ri is H
Figure imgf000012_0001
, Rs,
Figure imgf000012_0002
-(CH2)nOR5 -(CH2)n-N-R6 or each Ri and Rs individually is H, (CH2)mOH, -C(O)OR, -C(O)Rs, -C(O)SR, (CH2)m-C(O)- NRsR'5, -O-C(O)-O-R5, an amino acid and/or a dipeptide; R5 Rs
— C— (CH2)m-0-C(0)-R"5 (CH2)m-C-0-C(0)R"5 R'5 R'5
R is Rs, H,
(CH2)m-
Figure imgf000013_0001
Figure imgf000013_0002
R4 is H, OH, -OC(O)-Rs, -OC(O)-N-Rs(R's), -O-C(O)-O-Rs; each Rs , R'5 and R"s is independently H, alkyl, substituted alkyl, aryl, substituted aryl, alkenyl, alkynyl, substituted alkenyl, substituted alkynyl, heterocycle, substituted heterocycle, alkylaryl, substituted alkylaryl, cycloalkyl, substituted cycloalkyl, or -CH2CO2 alkyl; and wherein Rs can also be (dialkyl)CO alkyl;
Figure imgf000013_0003
each R7 and R'7 individually is alkyl, araalkyl, substituted araalkyl, cycloalkyl, substituted cycloalkyl;
Rs is alkyl, or halo substituted alkyl; n= l-5 and m=0-4; and pharmaceutically acceptable salts thereof.
Listed below are definitions of various terms used to describe this invention. These definitions apply to the terms as they are used throughout this specification, unless otherwise limited in specific instances, either individually or as part of a larger group.
The term "alkyl" refers to straight or branched chain unsubstituted hydrocarbon groups of 1 to 20 carbon atoms, preferably 1 to 8 carbon atoms. The expression "lower alkyl" refers to unsubstituted alkyl groups of 1 to 4 carbon atoms.
The terms "substituted alkyl", "substituted alkenyl" or "substituted alkynyl" refer to an alkyl, alkenyl or alkynyl group substituted by, for example, one to four substituents, such as halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, cycloalkyloxy, heterocylooxy, oxo, alkanoyl, aryloxy, alkanoyloxy, amino, alkylamino, arylamino, aralkylamino, cycloalkylamino, heterocycloamino, disubstituted amines in which the 2 amino substituents are selected from alkyl, aryl or aralkyl, alkanoylamine, aroylamino, aralkanoylamino, substututed alkanoylamino, substituted arylamino, substituted aralkanoylamino, thiol, alkylthio, arylthio, ar alkylthio, cycloalkylthio, heterocyclothio, alk lthiono, arylthiono, aralkylthiono, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, sulfonamido (e.g. SO2NH2), substituted sulfonamido, nitro, cyano, carboxy, carbamyl (e.g. CONH2) substituted carbamyl (e.g. CONH alkyl, CONH aryl, CONH aralkyl or cases where there are two substituents on the nitrogen selected from alkyl, aryl or aralkyl), alkoxycarbonyl, aryl, substituted aryl, guanidino and heterocyclos, such as indolyl, imidazolyl, furyl, thienyl, thiazolyl, pyrrolidyl, pyridyl, pyrimidyl and the like. Where noted above where the substituent is further substituted it will be with halogen, alkyl, alkoxy, aryl or aralkyl.
The term "halogen" or "halo" refers to fluorine, chlorine, bromine and iodine.
The term "aryl" refers to monocyclic or bicyclic aromatic hydrocarbon groups having 6 to 12 carbon atoms in the ring portion, such as phenyl, naphthyl, biphenyl and diphenyl groups, each of which may be substituted. The term "aralkyl" or "alkylaryl" refers to an aryl group bonded directly through an alkyl group, such as benzyl or phenethyl.
The term "substituted aryl" or "substituted alkylaryl" refers to an aryl group or alkylaryl group substituted by, for example, one to four substituents such as alkyl; substituted alkyl, halo, trifluoromethoxy, trifluoromethyl, hydroxy, alkoxy, cycloalkyloxy, heterocycloooxy, alkanoyl, alkanoyloxy, amino, alkylamino, aralkylamino, cycloalkylamino, heterocycloamino, dialkylamino, alkanoylamino, thiol, alkylthio, cycloalkylthio, heterocyclothio, ureido, nitro, cyano, carboxy, carboxyalkyl, carbamyl, alkoxycarbonyl, alkylthiono, arylthiono, alkysulfonyl, sulfonamido, aryloxy and the like. The substituent may be further substituted by halo, hydroxy, alkyl, alkoxy, aryl, substituted aryl, substituted alkyl or aralkyl. "Substituted benzyl" refers to a benzyl group substituted by, for example, any of the groups listed above for substituted aryl.
The term "cycloalkyl" refers to optionally substituted, saturated cyclic hydrocarbon ring systems, preferably containing 1 to 3 rings and 3 to 7 carbons per ring which may be further fused with an unsaturated C3-C7 carbocyclic ring. Exemplary groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl and adamantyl. Exemplary substituents include one or more alkyl groups as described above, or one or more groups described above as alkyl substituents.
The terms "heterocycle", "heterocyclic" and "heterocyclo" refer to an optionally substituted, fully saturated or unsaturated, aromatic or nonaromatic cyclic group, for example, which is a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom-containing ring. Each ring of the heterocyclic group containing a heteroatom may have 1, 2 or 3 heteroatoms selected from nitrogen atoms, oxygen atoms and sulfur atoms, where the nitrogen and sulfur heteroatoms may also optionally be oxidized and the nitrogen heteroatoms may also optionally be quaternized. The heterocyclic group may be attached at any heteroatom or carbon atom.
Exemplary monocyclic heterocyclic groups include pyrrolidinyl, pyrrolyl, indolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2- oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxazepinyl, azepinyl, 4-piperidonyl, pyridyl, N-oxo-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl sulfone, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dixolane and tetrahydro-1, 1- dioxothienyl, dioxanyl, isothiazolidinyl, thietanyl, thiiranyl, triazinyl, and triazolyl, and the like.
Exemplary bicyclic heterocyclic groups include benzothiazolyl, benzoxazolyl, benzothienyl, quinuclidinyl, quinolinyl, quinolinyl-N-oxide, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,l-b]pyridinyl, or furo[2,3-b]pyridinyl), dihydroisoindolyl, diyhydroquinazolinyl (such as 3,4-dihydro-4-oxo-quinazolinyl), benzisothiazolyl, benzisoxazolyl, benzodiazinyl, benzofurazanyl, benzothiopyranyl, benzothrazolyl, benzpyrazolyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, dihydrobenzopyranyl, indolinyl, isochromanyl, isoindolinyl, naphthyridinyl, phthalazinyl, piperonyl, purinyl, pyridopyridyl, quinazolinyl, tetrahydroquinolinyl, thienofuryl, thienopyridyl, thienothienyl, and the like.
Exemplary substituents include one or more alkyl groups as described above or one or more groups described above as alkyl substituents.
The term "heteroatoms" shall include oxygen, sulfur and nitrogen.
The term "amino acid" means any naturally occurring amino acid including D and L amino acids. The term "dipeptide" means a di-amino acid containing two linked naturally occurring amino D and L acids.
Within the above-described definitions, certain embodiments are preferred. Preferred alkyl groups are lower alkyl groups containing 1 to about 8 carbon, and more preferably 1 to about 5 carbon atoms, and can be straight, branched-chain or cyclic saturated aliphatic hydrocarbon groups.
Examples of suitable alkyl groups include methyl, ethyl and propyl. Examples of branched alkyl groups include isopropyl and t-butyl. An example of a suitable alkylaryl group is phenethyl. Examples of suitable cycloalkyl groups typically contain 3-8 carbon atoms and include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The aromatic or aryl groups are preferably phenyl or alkyl substituted aromatic groups (aralkyl) such as phenyl C1-3 alkyl such as benzyl.
The N-heterocyclic rings preferably contain 3-7 atoms in the ring and a heteroatom such as N, S or O in the ring. Examples of suitable preferred heterocyclic groups are pyrrolidino, azetidino, piperidino, 3,4-didehydropiperidino, 2-methylpiperidino and 2- ethylpiperidino. In addition, the above substitutions can include halo such as F, Cl, Br, lower alkyl, lower alkoxy and halo substituted lower alkoxy.
Examples of suitable amino acids are L-Ala, L-Val, L-Isoleu, L-Phe, Gly and L-Leu.
Examples of suitable dipeptides are L-Ala-L-Ala and Gly-Gly.
Preferred groups for R7 and R'7 are CH3, C2H5, n-CsHz and 11-C4H9 and most preferred groups for R7 and R'7 are C2H5 and n-C3H7.
Preferred groups for Rs are CH3, C2H5 and C3H7 and most preferred is CH3.
Pharmaceutically acceptable salts of the compounds of formula (I) include those derived from pharmaceutically acceptable, inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, gly collie, lactic, salicyclic, succinic, toluene-p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic, trifluoroacetic and benzenesulphonic acids.
Salts derived from appropriate bases include alkali such as sodium and ammonia. It is of course understood that the compounds of the present invention relate to all optical isomers and stereo-isomers at the various possible atoms of the molecule.
The following schemes illustrate methods for preparing compounds of the present invention. In order to facilitate an understanding of the present invention, the methods will be discussed with respect to preparing various preferred compounds of the present invention.
The synthesis of these compounds is illustrated by taking the examples, wherein
Figure imgf000017_0002
and
Figure imgf000017_0001
in structures A and B
The synthesis of the starting materials for prodrugs in given in Schemes 1 and 2. Synthesis of the precursors for structure A:
SCHEME 1:
The starting material, Lactam (1, -, + , or racemic mixture) is heated at reflux temperature with methanolic HCI. The solvent is evaporated' and the residue is washed with ether to give methyl 4-amino-2-cyclopenten- 1-carboxylate hydrochloride, which is further reacted with di- tert-butyl dicarbonate and triethylamine to give methyl 4-t-rt-butoxycarbonylamino-2- cyclopenten- 1-carboxylate (2). Compound (2) is reacted with 2-ethyl-l- nitrobutane/triethylamine and phenylisocyanate to give the cycloadduct (3). Cycloadduct (3) may also be obtained by the reaction of (2) with 2-ethylbutyrohydroximinoxyl chloride and triethylamine. The desired isomer is separated and is hydrogenated in the presence of a catalyst to give the corresponding amine, which is acetylated with acetic anhydride to give methyl 3- (1 '-acetylamino-2'-ethyl)butyl-4-tert-butoxycarbonylamino-2-hydroxycyclopentane- 1-carboxylate (4). Cycloadduct (3) can be converted to the amine using chemical reduction also. Compound (4) is treated with HCI to give the corresponding amine (5), which is guanylated with pyrazole carboxamidine to give the guanidine derivative. The ester is hydrolyzed to acid to give the desired compound (6). Other guanylating agents, such as S- methylthiourea, cyanamide, amino-iminomethane sulphonic acid also may be used for the guanylation.
Synthesis of the precursors for structure B: SCHEME 2:
Compound (4) is reacted with methanesulphonyl chloride to give the -O-SO2CH3 derivative, which is then treated with a base to give the double bond compound (7). Acid treatment of (7) provides amine (8), which is then guanylated to give the product (9) using standard guanylation procedures.
Synthesis of the ester prodrugs of structure A:
SCHEME 3:
In structure A, when R_=R3=H;
Figure imgf000018_0001
alkyl, substituted alkyl, cycloalkyl, acylalkyl, or acyloxyalkyl, etc.
These compounds are prepared by using one of the following methods:
i) Compound (6) is reacted with a base (for example, sodium or potassium hydroxide) to give the corresponding salt, which is further reacted with RiX, where Ri is as described above and X is Cl, Br, or I to give the corresponding target 11. ii) Compound (4) on base hydrolysis gives the corresponding salt (12), which is further reacted with RiX to give (13). RiX is the same as described in the above method. Compound (13) on acid hydrolysis produces amine (14), which is reacted with a guanylating agent to give the target (11). iii) Compound (4) is converted to the acid corresponding to the compound (12), which is reacted with RiOH in the presence of a coupling agent, such as N,N'- dicyclohexylcabodiimide (DCC), l-cyclohexyl-3-(2-morpholinoethyl)carbodiimide, N,N'- diisopropylcarbodiimide (DIC), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride or methiodide to give the ester (13). The ester is further converted to (11) using the procedures described above.
iv) The corresponding acid of compound (12) also is converted to a mixed anhydride, using methyl or ethyl chloroformate in the presence of a base, such as triethylamine. The resultant mixed anhydride is reacted with RiOH to give compound (13), which is further converted to (11).
v) Compounds of the type (11) are also prepared from the isooxazoline derivative (3). Compound (3) is converted to the alkali salt (15) with a base and further reacted with RiX to give the ester (16). Compound (16) on hydrogenation in the presence of a catalyst, followed by acetylation gives (13), which is further converted to (11) as described above. vi) The corresponding acid of (15) also is reacted with RiOH in the presence of a coupling agent, such as N,N'-dicyclohexylcabodiimide (DCC), l-cyclohexyl-3-(2- morpholinoethyl)carbodiimide, N,N' -diisopropylcarbodiimide (DIC), l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride or methiodide to give (16), which is further converted to (11). vii) Amine (5) is reacted with a protected guanylating agent such as H3CS-C-
(NHBoc)=Nboc, Boc protected pyrazole carboxamidine, triazole carboxamidine, or 4- nitropyrazole carboxamidine to give protected guanylated derivative (17). Some catalyst, such as acetic acid, HgCb, ZnCb, etc. may be desirable for the reaction. The ester is hydrolyzed to acid (18), and converted to ester (19) following one of the above mentioned methods. Removal of the Boc group is achieved by using H + (HC1, trifluoroacetic acid, etc.) and the target (11) is obtained. viii) Amine (5) also is reacted with a protected guanylating agent such as H3CS-C- (NHCbz)=NCbz, Cbz protected pyrazole carboxamidine, triazole carboxamidine, or 4- nitropyrazole carboxamidine to give protected guanylated derivative (20). Some catalyst, such as acetic acid, HgCh, ZnCb, etc. may be desirable for the reaction. The ester is hydrolyzed to acid (21), and converted to ester (22) following one of the above mentioned methods. Removal of Cbz group is achieved by hydrogenation and the target (11) is obtained. ix) Any other standard method for converting acid to ester may be used for these reactions.
The desired RiX or RiOH are either commercially available, or are prepared according to the literature procedures.
Other compounds in the series, when R7 and R'7 are other than ethyl also are prepared following the same procedures.
Synthesis of ester prodrugs of structure B:
These compounds are prepared the same way as described above using the intermediates with a double bond from Scheme 2.
Synthesis of guanidine and ester prodrugs of structure A;
SCHEME 4
a. In structure A, Ri = CH3; R2 = OH; R3 = H; R4 = OH; R7 = R' 1 = C2H5; Rs = CH3
Compound (5) is reacted with cyanogen bromide to give corresponding cyanamine (23), which on reaction with hydroxyl amine gives the target (24). b. In structure A,
Figure imgf000020_0001
and
Figure imgf000020_0002
substituted alkyl, cycloalkyl, phenyl, substituted phenyl, alkoxy carbonylalkyl, substituted alkoxycarbonylalkyl, etc.
These compounds are prepared by one of the following method:
i) Compound (25) is prepared from either (5) by reacting with a guanylating agent, such as pyrazole carboxamidine, triazole carboxamidine, 4-nitropyazole carboxamidine or amino-iminomethanesulphonic acid or by esterification of compound (6) with methanol. Compound (25) further reacts with 1 equivalent of R9OC(O)Cl or R9θC(O)OCβH4-Nθ2(p) in the presence of a base to give the desired target (26). ii) Compound (26) is prepared from (5) also by reacting with one equivalent of appropriately substituted guanylating agent as shown in Scheme 4. Substituted guanylating agents are prepared from the literature procedures. In some cases, a catalyst, such as HgCk, ZnCk, acetic acid, etc. may be desired for the reaction.
Other standard literature procedures for the conversion of amine to a carbamate also may be used. c. In structure A,
Figure imgf000021_0001
R2=peptide.
These compounds (27) are prepared from the standard methods of amides preparation from amine (25) and the desired amino acid in the presence of a coupling agent.
In place of Ri as CH3, any other ester also can be used for the preparation of the desired targets.
In place of
Figure imgf000021_0002
another alkyl group containing compounds may be prepared using the same methods.
Synthesis of guanidine and ester prodrugs of structure B:
These compounds are prepared the same way as discussed above using the intermediates from Scheme 2 with a double bond.
Synthesis of di-substituted guanidine and ester prodrugs of structures A and B:
These compounds are prepared the same way as given in Scheme 4 using 2 equivalents of the reagents.
Synthesis of guanidine prodrugs of structures A and B:
These compounds are prepared the same way as given in Scheme 4. The esters obtained are hydrolyzed with a base, acid, methanol/water/triethylamine mixture or any otlier appropriate saponification reagent.
62242
SCHEME-1
Figure imgf000022_0001
Figure imgf000022_0002
Figure imgf000022_0003
(6) 0
SCHEME-2
BocHN COOCH, HN=*-NH,
H,N COOCH, "j"'
(4)
NHCOCH, NHCOCH3
NHCOCH,
(7) (8) (9)
SCHEME-3
Figure imgf000023_0001
(10) (11)
Figure imgf000023_0002
Figure imgf000023_0003
SCHEME-3 (Contnd)
Figure imgf000024_0001
Figure imgf000024_0002
Cbz= Benzyioxycarfaonyl
SCHEME
Figure imgf000025_0001
(23) (24)
Figure imgf000025_0002
(25) (26)
Reagent= R9OC(0)CI, or R9OC(0)OC6H4-N02(p))
H3CS-C(=NH)NHC(0)0R9 ,
Figure imgf000025_0003
Figure imgf000025_0004
The following are examples of illustrative compounds according to the present invention.
Methyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-ethoxycarbonyl-amino- imino)methyl] amino-2-hydroxy cy clopentan- 1 -carboxylate ;
Ethyl (1S,2S;3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylaminoimino) methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-methoxycarbonyl amino- imino)methyl] amino-2-hydroxy cy clopentan- 1 -carboxylate ;
Ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-tert-butoxycarbo- nylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (1S,2S,3R,4R, l'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-ethoxycarbonyl- amino- imino)methyl]amino-2-hydroxycy clopentan- 1 -carboxylate ;
Methyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-acetyloxy- methoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Methyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-acetyloxy- methoxycarbonylamino-imino)methyl] amino-2-hydroxycy clopentan- 1 -carboxylate ;
Ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-acetyloxymeth- oxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N(α-acetyloxyeth- oxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (1S,2S,3R,4R,1 'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-trimethylacetyl- oxymethoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate; Ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(r-acetylamino-2'-ethyl)butyl-4-[(N-(α-trimethyl- acetyloxyethoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-phenylacetyloxy- methoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-2,2,2-trichloro- ethoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-2,2,2-trifruoiO- ethoxycarbonylamino-imino)mefhyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[N-(2'-L-amino-3 ' phenylpropanoylamino)-imino]methylamino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[N-(2'-L-aminoprop- anoylamino)-imino]methylamino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(2'-L-amino-3'- methylpentanoylamino)-imino]methylamino-2-hydroxycyclopentan-l-carboxylate;
Methyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4- [N-(2'-L-amino- propanoylamino)-imino]methylamino-2-hydroxycy clopentan- 1 -carboxylate ;
Methyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[N-(2'-L-amino-3 ' phenylpropanoylamino)-imino]methylamino-2-hydroxycyclopentan-l-carboxylate;
(lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(amino-imino)methyl- amino-2-(3'- methy lbutanoyl)hydroxycy clopentan- 1-carboxy lie acid;
(1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-(amino-imino)methylamino-2-n- hexanoyloxy cy clopentan- 1 -carboxylic acid ; (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxycarbonyl- amino- imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid;
(1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-methoxycarbonyl- amino- imino)methyl] amino-2-hydroxy cy clopentan- 1 -carboxylic acid ;
(1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-tert-butoxycarbonyl- amino- imino)methyl] amino-2-hydroxy cy clopentan- 1 -carboxylic acid ;
(1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-ethoxycarbonylamino-imino) methyl] amino-2-hydroxycyclopentan-l -carboxylic acid;
(1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-acetyloxymethoxy- carbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid;
(1S,2S,3R,4R, l'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(α-acetyloxyethoxy- carbonylamino- imino)methyl] amino-2-hydroxy cy clopentan- 1 -carboxylic acid ;
(1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-trimethylacetyloxy- methoxycarbonylamino-imino)methyl] amino-2-hydroxycy clopentan- 1 -carboxylic acid;
(lS,2S,3R,4R,l'S)-(-)-3-(l'-Acetylamino-2'-ethyl)butyl-4-[(N-(α-trimethylacetyloxy- ethoxycarbonylamino-imino)methyl]aιnino-2-hydroxycyclopentan-l -carboxylic acid;
(lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-phenylacetyloxymeth- oxycarbonylamino-imino)methyl] amino-2-hy droxycy clopentan- 1 -carboxylic acid;
(1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(2'-L-amino-3 '-phenyl- propanoylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid;
(1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(2'-L-aminopropanoyl- amino- iminomethyl]amino-2-hydroxycyclopentan-l-carboxylic acid; (1S,2S,3R,4R, 1 'S)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4- [(2' -L-amino-3' -methylpen- tanoylamino-iminomethyl] amino-2-hy droxy cy clopentan- 1 -carboxylic acid ;
Ethyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-acetyloxymeth- oxycarbonylamino-N ' -acetyloxymethoxycarbonylimino)methyl] amino-2-hy droxy- cy clopentan- 1-carboxylate;
(1S,2S,3R,4R, 1 'S)-(-)-3-(l '-Acetylamino-2'-etlιyl)butyl-4-[(N-acetyloxymethoxy- carbonylamino-N ' -acetyloxymethoxycarbonyl nino)methyl] amino-2-hy droxy- cyclopentan- 1 - carboxylic acid;
Ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(N-2, 2, 2-trifluoro- ethoxycarbonylamino-N'-2,2,2-trifluoroethoxycarbonylimino)methyl]amino-2- hy droxy cyclopentan- 1 -carboxylate ;
Ethyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-ethoxycarbonyl- amino-N'- ethoxy carbonylimino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylate ;
Ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4- [(hydroxy lamino- imino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylate ;
(lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(hydroxylamino-imino) methyl] amino-2-hydroxycyclopentan- 1 -carboxylic acid;
l-[(4,-Aminomethylcarbonylamino)benzoyloxymethyl] (lS,2S,3R,4R,l'S)-(-)-3-(l'- acetylamino-2 ' -ethyl)butyl-4-(amino-imino)methyl]amino-2-hydroxycyclopentan- 1 -carboxylate ;
l-[(4'-Aminomethylcarbonyloxy)benzoyloxymethyl] (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino- 2'-ethyl)butyl-4-(amino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
n-Hexyl (1S,2S,3R,4R, 1 'S)-(-)-3-(r-acetylamino-2'-ethyl)butyl-4-(amino-imino)methyl]amino- 2-hydroxycyclopentan- 1 -carboxylate ; 2-Methylpropyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-(amino- imino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylate ;
α-(Ethoxycarbonyloxy)ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2 '-ethyl)- butyl-4- (amino-imino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylate ; -Acetyloxyethyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(amino- imino)methyl] amino-2-hydroxycyclopentan- 1 -carboxylate ;
tert-Butylcarbonyloxomethyl ( 1 S ,2S , 3R, 4R, 1 ' S)-(-)-3-( 1 ' -acetylamino-2 '-ethyl)- butyl-4- (amino-imino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylate ;
α-(methoxycarbonyloxy)ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2 '-ethyl)- butyl-4- (amino-imino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylate ; and
α-(iso-Propyloxycarbonyloxy)ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4- (amino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate.
The following non-limiting examples are presented to further illustrate the present invention.
Example 1
Methyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-ethoxycarbonylamino- imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000030_0001
IA: l-Benzyloxycarbonyl-2-methyl-2-thiopseudourea
To a mixture of 2-methyl-2-thiopseudourea sulfate (27.8 g, 100 mmol), water (20 mL) and benzyl chloroformate (17.0 g, 100 mmol) at 5 °C was added 40% aqueous sodium hydroxide dropwise until the pH became neutral. The mixture was diluted with dichloromethane (50 mL). Additional benzyl chloroformate (17.0 g, 100 mmol) was added portion wise over a period of 0.5 h maintaining the pH of the mixture neutral with the addition of 40% NaOH. The mixture was stirred for an additional 0.5 hours and the organic layer was separated. The aqueous layer was extracted with dichloromethane (3 times) after diluting with water. The combined organic layers were dried and after filtration, the filtrate was concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give: i) l,3-Bis(benzyloxycarbonyl)-2-methyl-2-thiopseudourea (14.0 g, 19%). ii) l-Benzyloxycarbonyl-2-methyl-2-thiopseudourea (24.0 g, 53 %)
IB: l-Benzyloxycarbonyl-3-ethoxycarbonyl-2-methyl-2-thiopseudourea
To a solution of l-benzyloxycarbonyl-2-methyl-2-thiopseudourea (IA, 1.0 g, 4.46 mmol)) in dichloromethane (20 mL) were added triethylamine (1.85 mL, 13.4 mmol) and ethyl chloroformate (1.45 g, 13.4 mmol) and stirred for 1 hour. The solution was washed with water, the organic layer was separated, concentrated and purified on silica gel column using hexane: ethyl acetate as an eluent to give 1.30g (99%) of IB.
IC: Methyl (15,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-ethoxy carbonylamino-N'-benzyloxycarbonylimino)methyl]an ino-2-hydroxycyclopentan-l- carboxylate
To a solution of methyl (15,2,_ ,3R,4_-,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-amino-2- hydroxycyclopentan- 1-carboxylate trifluoroacetate (1.03 g, 2.5 mmol, disclosed in WO 99/33781) in dimethyl formamide (20 mL) were added triethylamine (1.22 mL, 8.75 mmol), 1- benzyloxycarbonyl-3-ethoxycarbonyl-2-methyl-2-thiopseudourea (IB, 1.30 g, 4.4 mmol) and mercury (II) chloride (1.2 g, 4.4 mmol) and the mixture was stirred for 2 hours. After dilution with ethyl acetate (50 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 1.0 g (73 %) of IC.
1: To a solution of methyl (l,S,25,3R,4R,l'_ -(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- ethoxycarbonylamino-N'-benzyloxycarbonyl_tnino)methyl]amino-2-hydroxycyclo- pentan-l- carboxylate (IC, l.O g, 1.8 mmol) in methanol (50 mL) and water (5 mL) were added 5 drops of HCI and 10% Pd/C (200 mg) and the mixture was hydrogenated at 40 psi for 16 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was taken in ethyl acetate and aqueous sodium bicarbonate. The organic layer was separated, dried, filtered and concentrated. The residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.7 g (93%) of 1. Anal, calcd. for C19H34N4O6: %C 55.06 %H 8.27 %N 13.52 Found: %C 54.61 %H 8.07 %N 13.48
MS (ES+): 416.0 (M+ l)
Example 2
Ethyl (lS,2S,3R,4R,l'5 -(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000032_0001
2A: l-Benzyloxycarbonyl-3-tert-butoxycarbonyl-2-methyl-2-thiopseudourea To a solution of l-benzyloxycarbonyl-2~methyl-2-thiopseudourea (IA, 5.0 g, 22.0 mmol)) in dichloromethane (100 mL) were added triethylamine (9 mL, 66.0 mmol) and di- tert-butyl dicarbonate (14.4 g, 66.0 mmol) and stirred for 16 h. The solution was washed with water; the organic layer was separated, concentrated and purified on silica gel column using hexane: ethyl acetate as an eluent to give 3.8 g (53 %) of 2A.
2B: Ethyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-tert-butoxy- carbonylamino-N'-benzyloxycarbonylimino)methyl]amino-2-hydroxycyclopentan-l- carboxylate
To a solution of ethyl (15,2,S,3R,4R,l'_ -(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-amino-2- hydroxycyclopentan- 1-carboxylate trifluoroacetate (4.5 g, 10.5 mmol, given in WO 99/33781) in dimethyl formamide (50 mL) were added trietliylamine (5.1 mL, 36.7 mmol), 1- benzyloxycarbonyl-3-t_rt-butoxycarbonyl-2-mefhyl-2-thiopseudourea (2A, 3.4 g, 10.5 mmol) and mercury(II) chloride (2.85 g, 10.5 mmol) and the mixture was stirred for 2 h. After dilution with ethyl acetate (250 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 3.2 g (51 %) of 2B.
2: To a solution of ethyl (l1S,2,S,3R,4_-,l')S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-t_rt- butoxycarbonylamino-N '-benzyloxycarbonylimino)methyl] arnino-2-hydroxycyclo- pentan- 1 - carboxylate (2B, 1.2 g, 2.0 mmol) in dicliloromethane (20 mL) was added trifluoroacetic acid (4.0 mL) and was stirred for 4 h. After concentration, the residue was taken in ethyl acetate and aqueous sodium bicarbonate. The organic layer was separated, dried, filtered and concentrated. The residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.80 g (81 %) of 2.
Anal, calcd. for C25H38N4O6: %C 61.21 %H 7.81 %N 11.42
Found: %C 61.23 %H 7.73 %N 11.50
MS (ES+): 491.6 (M + l) Example 3
Ethyl (lS,2S,3R,4__,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-methoxycarbonyl amino-imino)methyl]amino 2-hydroxycyclopentan-l-carboxylate
Figure imgf000033_0001
3 A: l-Benzyloxycarbonyl-3-methoxycarbonyl-2-methyl-2-thiopseudourea
To a solution of l-benzyloxycarbonyl-2-methyl-2-thiopseudourea (IA, 5.0 g, 22.0 mmol) in dichloromethane (100 mL) were added triethylamine (9 mL, 66.0 mmol) and methyl chloroformate (6.2 g, 66.0 mmol) and stirred for 16 h. The solution was washed with water; the organic layer was separated, concentrated and purified on silica gel column using hexane: ethyl acetate as an eluent to give 2.8 g (45 %) of 3 A.
3B: Ethyl (lS,2S,3__,4_-,l'S)-(-)-3-(l'-acetyIamino-2'-ethyI)butyl-4-[(N-methoxy- crbonylamino-N'-benzyloxycarbonylimino)methyl]amino-2-hydroxycyclopentan-l- carboxylate To a solution of ethyl (l.S,2S,3R,4_-,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-amino-2- hydroxycyclopentan- 1-carboxylate trifluoroacetate (3.9 g, 9.2 mmol, given in WO 99/33781) in dimethyl formamide (40 mL) were added triethylamine (4.5 mL, 32.2 mmol), 1- benzyloxycarbonyl-3-methoxycarbonyl-2-methyl-2-thiopseudourea (3A, 2.6 g, 9.2 mmol) and mercury(II) chloride (2.5 g, 9.2 mmol) and the mixture was stirred for 2 h. After dilution with ethyl acetate (200 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 1.9 g (37%) of 3B.
3: To a solution of ethyl (1S,2S,3RAR, 1 'S)-(-)-3-(l ' -acetylamino-2 ' -ethyl)butyl-4-[(N- methoxycarbonylamino-N'-benzyloxycarbonylimino)methyl]amino-2-hydroxycyclo- pentan-l- carboxylate (IC, 1.6 g, 2.9 mmol) in ethanol (27 mL) and water (3 mL) were added 5 drops of HCI and 10% Pd/C (100 mg) and the mixture was hydrogenated at 40 psi for 2 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was taken in ethyl acetate and aqueous sodium bicarbonate. The organic layer was separated, dried, filtered and concentrated. The residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.8 g (66%) of 3.
Anal, calcd. for Ci9H34N4O6»0.5H2O: %C 53.89 %H 8.33 %N 13.23
Found: %C 53.98 %H 8.06 %N 13.10
MS (ES+): 415.7 (M+ l)
Example 4
Ethyl (lS,2S,3R,4R5l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-..rt-butoxycarbo- nylamino-imino)methyl]aminθ 2-hydroxycyclopentan-l-carboxylate
Figure imgf000034_0001
To a solution of ethyl (15,25,3_.,4_-,l')S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-t-rt- butoxycarbonylamino-N ' -benzyloxycarbonylimino)mefhyl] amino-2-hydroxycy clopentan - 1 - carboxylate (2B, 2.8 g, 4.7 mmol) in ethanol (40 mL) and water (4 mL) were added 5 drops of HCI and 10% Pd/C (200 mg) and the mixture was hydrogenated at 40 psi for 2 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was taken in ethyl acetate and aqueous sodium bicarbonate. The organic layer was separated, dried, filtered and concentrated. The residue was purified on silica gel column using chloroform: methanol as an eluent to give 1.5 g (70%) of 4.
Anal, calcd. for C22H40N4O6: %C 57.87 %H 8.83 %N 12.27
Found: %C 57.88 %H 8.83 %N 12.09
MS (ES+): 457.4 (M + l)
Example 5
Ethyl (lS,2S,3__,4__,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-ethoxycarbonyl- amino- imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000035_0001
5A: Ethyl (lS,2,S,3__,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-ethoxycarbo- nylamino-N'-benzyloxycarbonylimino)methyl]aniino-2-hydroxycyclopentan-l-carboxylate
To a solution of ethyl (15',2S,3__,4_.,l'l_)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-amino-2- hydroxycyclopentan- 1-carboxylate trifluoroacetate (3.9 g, 9.1 mmol, given in WO 99/33781) in dimethyl formamide (40 mL) were added triethylamine (4.4 mL, 31.9 mmol), 1- benzyloxycarbonyl-3-ethoxycarbonyl-2-methyl-2-thiopseudourea (IB, 2.7 g, 9.1 mmol) and mercury (II) chloride (2.5 g, 9.1 mmol) and the mixture was stirred for 2 h. After dilution with ethyl acetate (200 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 3.5 g (68%) of 5A.
5: To a solution of ethyl (l,S,2)S,3R,4_-,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- ethoxycarbonylamino-N ' -benzyloxycarbonylimino)methyl]amino-2-hy droxy cyclopentan - 1 - carboxylate (5A, 2.0 g, 3.5 mmol) in ethanol (40 mL) and water (4 mL) were added 5 drops of HCI and 10% Pd/C (200 mg) and the mixture was hydrogenated at 40 psi for 3 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was taken in ethyl acetate and aqueous sodium bicarbonate. The organic layer was separated, dried, filtered and concentrated. The residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.7 g (47%) of 5.
Anal, calcd. for QoHse^Oe: %C 56.06 %H 8.07 %N 13.07
Found: %C 55.77 %H 8.43 %N 12.99
MS (ES+): 429.5 (M+ l) Example 6
Methyl (lS,25,3i?,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-acetyloxy- methoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000036_0001
6A: Methyl (15,25,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino-N'-.er^-butoxycarbonylimino)methyl]amino-2-hydroxycyclopentan-l- carboxylate
To a solution of methyl (^^^^--^-.^'^-(^^-( -acetylamino^'-ethy butyM-amino^- hydroxycyclopentan- 1-carboxylate trifluoroacetate (5.9 g, 14.3 mmol, given in WO 99/33781) in dhnethyl formamide (50 mL) were added triethylamine (7.0 mL, 50.1 mmol), 1- benzyloxycarbonyl-3-t-rt-butoxycarbonyl-2-methyl-2-fhiopseudourea (IB, 5.2 g, 15.7 mmol) and mercury (II) chloride (4.3 g,, 15.7 mmol) and the mixture was stirred for 2 h. After dilution with ethyl acetate (200 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 6.8 g (82%) of 6A.
6B: Methyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
To a solution of methyl (15,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-t-rt- butoxycarbonylamino-N'-benzyloxycarbonylimino)methyl]amino-2-hydroxycyclopentan -l- carboxylate (6A, 6.8 g, 11.7 mmol) in dichloromethane (120 mL) was added trifluoroacetic acid (16.0 mL) and was stirred for 4 h. After concentration, the residue was taken in ethyl acetate and aqueous sodium bicarbonate. The organic layer was separated, dried, filtered and concentrated. The residue was purified on silica gel column using chloroform: methanol as an eluent to give 4.5 g (80%) of 6B.
6C: Methyl (15,25,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino-N' -acetyloxymethoxycarbonylimino)methyl]amino-2-hy droxy c clopentan- 1-carboxylate To a solution of methyl (15,25,3R,4R,l'_ -(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- benzyloxycarbonylamino-imino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylate (6B , 0.48 g, 1 mmol) in hexamethylphosphoramide (6.0 mL) was added acetyloxymethyl 4-nitrophenyl carbonate (0.76 g, 3.0 mmol, prepared by using the method disclosed in Alexander et al. J. Med. Chem. 1988, 3 , 318-322) and heated at 45 °C for 16 h. An additional amount of acetyloxymethyl 4-nitrophenyl carbonate (0.25 g, 1 mmol) was added to the reaction mixture and again heated at 45 °C for 8 h. The mixture was cooled and diluted with water. After saturating with salt, the mixture was extracted with ethyl acetate (3 X). The combined organic extracts were washed with water and brine and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using ethyl acetate: hexane as an eluent to give 0.25 g (42%) of 6C.
6: To a solution of methyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l ' -acetylamino-2 '-ethy l)butyl-4-[(N- benzyloxycarbonylammo-N'-acetyloxymethoxycarbonylimino)methyl]amino-2- hydroxycyclopentan- 1-carboxylate (6C, 0.25 g, 0.42 mmol) in methanol (8 mL) and water (2 mL) was added 10% Pd/C (50 mg) and the mixture was hydrogenated at 40 psi for 2 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.095 g (49%) of 6.
Anal, calcd. for C2oH34N4θs»H2θ: %C 50.41 %H 7.61 %N 11.76
Found: %C 50.63 %H 7.40 %N 11.69
MS (ES+): 459.4 (M + l)
Example 7
Methyl (15,2S,3R,4R,l'5)-(-)-3-(l'-acetylammo-2'-ethyl)butyl-4-[(N-acetyloxy- methoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000037_0001
7A: Methyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino)-N'-( -acetyloxyethoxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan-1-carboxylate
To a solution of methyl (lS,2»S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- benzyloxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan- 1-carboxylate (6B , 0.48 g, 1 mmol) in hexamethylphosphoramide (6.0 mL) was added α-acetyloxy ethyl 4-nitrophenyl carbonate (0.8 g, 3.0 mmol, prepared by using the method disclosed in Alexander et al. J. Med. Chem. 1988, 31, 318-322) and heated at 45 °C for 16 h. An additional amount of α- acetyloxymethyl 4-nitrophenyl carbonate (0.27 g, 1 mmol) was added to the reaction mixture and again heated at 45 °C for 8 h. The mixture was cooled and diluted with water. Agter saturating with salt, the mixture was extracted with ethyl acetate (3 X). The combined organic extracts were washed with water and brine and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using ethyl acetate: hexane as an eluent to give 0.32 g (53 %) of 7A. 7: To a solution of methyl (1S,2S,3R,4R, V )-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(N- benzyloxycarbonyIamino)-N'-(α-acetyloxymethoxycarbonylimino)methyl]amino-2- hy droxy cyclopentan- 1-carboxylate (7A, 0.32 g, 0.53 mmol) in methanol (8 mL) and water (2 mL) was added 10% Pd/C (60 mg) and the mixture was hydrogenated at 40 psi for 2 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.12 g (48%) of 7.
Anal, calcd. for C_ιH36N4θs»H2θ: %C 51.42 %H 7.81 %N 11.42
Found: %C 51.54 %H 7.48 %N 11.26
MS (ES+): 473.2 (M + l)
Example 8
Ethyl (15,25,3__,4__,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-acetyloxymeth- oxycarbonylamino-imino)rnethyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000038_0001
8A: Ethyl (l,S,2S,3R,4__,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino-N'-acetyloxymethoxycarbonylimino)methyl]amino-2-hydroxycyclopentan-
1-carboxylate To a solution of ethyl (1S,2S,3R,4R, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)buty 1-4- [(N- benzyloxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example 2, 0.5 g, 1 mmol) in hexamethylphosphoramide (6.0 mL) was added acetyloxymethyl 4- nitrophenyl carbonate (0.76 g, 3.0 mmol, prepared by using the method disclosed in Alexander et al. J. Med. Chem. 1988, 31, 318-322) and heated at 45 °C for 16 h. An additional amount of acetyloxymethyl 4-nitrophenyl carbonate (0.25 g, 1 mmol) was added to the reaction mixture and again heated at 45 °C for 8 h. The mixture was cooled and diluted with water. After saturating with salt, the mixture was extracted with ethyl acetate (3 X). The combined organic extracts were washed with water and brine and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using ethyl acetate: hexane as an eluent to give 0.32 g (53 %) of 8A.
8: To a solution of methyl (15,2S,3__,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- benzyloxycarbonylamino-N'-acetyloxymethoxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan-1-carboxylate (8A, 0.32 g, 0.53 mmol) in ethanol (20 mL) and water (5 mL) was added 10% Pd/C (50 mg) and the mixture was hydrogenated at 40 psi for 2 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.22 g (88%) of 8.
Anal, calcd. for C21H36N4O8: %C 53.37 %H 7.67 %N 11.85
Found: %C 53.50 %H 7.63 %N 11.68
MS (ES+): 472.9 (M+ l)
Example 9
Ethyl (lS,2S,3R,4__,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N(α-acetyloxyeth- oxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000039_0001
9A: Ethyl (lS,25,3__,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino)-N'-(α-acetyloxyethoxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan-1-carboxylate
To a solution of ethyl (lS,21S,3R,4_-,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- benzyloxycarbonylammo-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example 2, 0.49 g, 1 mmol) in hexamethylphosphoramide (6.0 mL) was added α-acetyloxyethyl 4- nitrophenyl carbonate (0.8 g, 3.0 mmol, prepared by using the method disclosed in Alexander et al. J. Med. Chem. 1988, 31, 318-322) and heated at 45 °C for 16 h. An additional amount of α-acetyloxymethyl 4-nitrophenyl carbonate (0.27 g, 1 mmol) was added to the reaction mixture and again heated at 45 °C for 8 h. The mixture was cooled and diluted with water. After saturating with salt, the mixture was extracted with ethyl acetate (3 X). The combined organic extracts were washed with water and brine and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using ethyl acetate: hexane as an eluent to give 0.32 g (52%) of 9A.
9: To a solution of ethyl (15,2,S,3__,4_.,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- benzyloxycarbonylamino)-N'-(α-acetyloxyethoxycarbonylimino)methyl]amino-2- hydroxycyclopentan- 1-carboxylate (9A, 0.32 g, 0.52 mmol) in ethanol (20 mL) and water (5 mL) was added 10% Pd/C (60 mg) and the mixture was hydrogenated at 40 psi for 2 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.2 g (79%) of 9.
Anal, calcd. for C22H38N4O8: %C 54.30 %H 7.87 %N 11.51 Found: %C 53.97 %H 7.74 %N 11.26
MS (ES+): 487.1 (M+ l)
;an_ple 10
Ethyl (15,25,3R,4_-,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-trimethylacetyl- oxymethoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000040_0001
10A: Trimethylacetyloxymethyl 4-nitrophenyl carbonate
A mixture of iodomethyl 4-nitrophenyl carbonate (8.4 g, 26.0 mmol, prepared from literature method: Alexender et al. J. Med Chem. 1988, 31, 318-322) and mercuric pivalate (12.0 g, 30 mmol, prepared from literature method: Bunce J. Org. Chem. 1972, 37, 664-669) in benzene (240 mL) was heated at reflux temperature for 1 h. The reaction mixture was concentrated and ether (100 mL) was added to the residue and left at room temperature for 16 h. The precipitate was removed by filtration and the filtrate after concentration was purified on silica gel column using ethyl acetate: hexane as an eluent to give 5.0 g (64%) of 10A.
10B: Ethyl (15,2S,3R,4__,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino)-N'-(trimethylacetyloxymethoxycarbonylimino)methyl]amino-2- hydroxycyclopentan-1-carboxylate
To a solution of ethyl (lS,25,3R,4R,l'.S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- benzyloxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example 2, 0.49 g, 1 mmol) in hexamethylphosphoramide (6.0 mL) was added trimethylacetyloxymethyl 4-nitrophenyl carbonate (10A, 0.9 g, 3.0 mmol) and heated at 45 °C for 16 h. An additional amount of trimethylacetyloxymethyl 4-nitrophenyl carbonate (0.3 g, 1 mmol) was added to the reaction mixture and again heated at 45 °C for 8 h. The mixture was cooled and diluted with water. After saturating with salt, the mixture was extracted with ethyl acetate (3 X). The combined organic extracts were washed with water and brine and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using ethyl acetate: hexane as an eluent to give 0.13 g (20%) of 10B.
10: To a solution of ethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- benzyloxycarbonylamino)-N'-(trnτιethylacetyloxymethoxycarbonylimino)methyl]amino-2- hydroxycyclopentan-1-carboxylate (10B, 0.13 g, 0.21 mmol) in ethanol (8 mL) and water (2 mL) was added 10% Pd/C (30 mg) and the mixture was hydrogenated at 40 psi for 2 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.05 g (45%) of 10.
Anal, calcd. for O_4H42N4θ8«0.5H2θ: %C 55.05 %H 8.28 %N 10.70
Found: %C 55.30 %H 8.14 %N 10.40
MS (ES+): 515.4 (M+ l)
Example 11
Ethyl (15,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-(α-trimethyl- acetyloxyethoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000041_0001
11A: Ethyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino)-N'-(α-trimethylacetyloxyethoxycarbonylimino)methyl]amino-2- hydroxycyclopentan-1-carboxylate
To a solution of ethyl (lS,25,3R,4R,l'1S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- benzyloxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example 2, 0.49 g, 1 mmol) in hexamethylphosphoramide (6.0 mL) was added α-acetyloxy ethyl 4- nitrophenyl carbonate (0.8 g, 3.0 mmol, prepared by using the method disclosed in Alexander et al. J. Med. Chem. 1988, 31, 318-322) and heated at 45 °C for 16 h. An additional amount of α-acetyloxymefhyl 4-nitrophenyl carbonate (0.27 g, 1 mmol) was added to the reaction mixture and again heated at 45 °C for 8 h. The mixture was cooled and diluted with water. After saturating with salt, the mixture was extracted with ethyl acetate (3 X). The combined organic extracts were washed with water and brine and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using ethyl acetate: hexane as an eluent to give 0.12 g (18%) of 11A. 11: To a solution of ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l ' -acetylamino-2 ' -ethyl)butyl-4-[(N- benzyloxycarbonylamino)-N'-(α-trimethylacetyloxyethoxycarbonylimino)mefhyl]amino-2- hy droxy cyclopentan- 1-carboxylate (HA, 0.12 g, 0.18 mmol) in ethanol (10 mL) and water (2 5 mL) was added 10% Pd/C (40 mg) and the mixture was hydrogenated at 40 psi for 2 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.045 g (46%) of 11.
Anal, calcd. for C25H44N4θ8«0.5H2θ: %C 55.85 %H 8.44 %N 10.42 0 Found: %C 56.03 %H 8.24 %N 10.17
MS (ES+): 529.4 (M+ l)
5 Example 12
Ethyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-phenylacetyloxy- methoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000042_0001
o 12A: Phenylacetyloxymethyl 4-nitrophenyl carbonate
A mixture of iodomethyl 4-nitrophenyl carbonate (15.0 g, 46.0 mmol, prepared from literature method: Alexender et al. J. Med. Chem. 1988, 31, 318-322) and mercuric phenyl acetate (30.0 g, 64 mmol, prepared from literature method: Bunce J. Org. Chem. 1972, 37, 664-669) in benzene (500 mL) was heated at reflux temperature for 20 h. The reaction mixture was5 concentrated and the residue was purified on silica gel column using ethyl acetate: hexane as an eluent to give 3.0 g (20%) of 12A.
12B: Ethyl (lS,2S,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino)-N'-(phenylacetyloxymethoxycarbonylimino)methyl]amino-2- o hydroxycyclopentan-1-carboxylate
To a solution of ethyl (l1S,2,S,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- benzyloxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example 2, 0.49 g, 1 mmol) in hexamethylphosphoramide (6.0 mL) was added phenylacetyloxymethyl 4-nitrophenyl carbonate (12A, 0.99 g, 3.0 mmol) and heated at 45 °C for 16 h. An additional5 amount of trimethylacetyloxymethyl 4-nitrophenyl carbonate (0.33 g, 1 mmol) was added to the reaction mixture and again heated at 45 °C for 8 h. The mixture was cooled and diluted with water. After saturating with salt, the mixture was extracted with ethyl acetate (3 X). The combined organic extracts were washed with water and brine and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using ethyl acetate: hexane as an eluent to give 0.17 g (25%) of 12B.
5
12: To a solution of ethyl (l_?,2_?,3i_,4i_, 1 'S)-(-)-3-(l ' -acetylamino-2 '-ethy l)butyl-4-[(N- benzyloxycarbonylammo)-N'-(phenylacetyloxymemoxycarbonylimino)methyl]amino-2- hydroxycyclopentan- 1-carboxylate (12B, 0.16 g, 0.23 mmol) in ethanol (8 mL) and water (2 mL) was added 10% Pd/C (30 mg) and the mixture was hydrogenated at 40 psi for 2 h. After0 removing the catalyst by filtration, the filtrate was concentrated and the residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.1 g (79%) of 12.
Anal, calcd. for C27H40N O8: %C 59.11 %H 7.35 %N 10.21
Found: %C 59.09 %H 7.32 %N 9.83 5 MS (ES+): 549.4 (M + l)
Example 13
o Ethyl (15,25,3R,4_.,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-2,2,2-trichloro- ethoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000043_0001
13A: Ethyl (lS,2S,3__,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-te^-butoxy-5 carbonylamino-N'-2,2,2-trichloroetlιoxycarbonylimino)methyl]amino-2-lιydroxy- cyclopentan-1-carboxylate
To a mixture of ethyl (llS,2lS,3_-,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-t-rt- butoxycarbonylamino-imino)methyl] amino-2-hydroxy cyclopentan- 1 -carboxylate (example 4 , 0.65 g, 1.42 mmol) in dichloromethane (25 mL) and aqueous saturated sodium bicarbonate (400 mL) was added 2,2,2-trichloroethyl chloroformate (0.25 mL, 1.8 mmol) and stirred for 2 h at room temperature. The organic layer was separated, and the aqueous layer was extracted further with dichloromethane. The combined organic layers were dried, filtered and concentrated to give 0.88 g of the crude product 13A. 13. To a solution of ethyl (15,2S,3R,4R,l'S)-(-)-3-(l'-acetylanιino-2'-efhyl)butyl-4-[(N-t-rt- butoxy carbonylamino-N '-2,2, 2-trichloroethoxycarbonylimino)methyl] amino-2- hydroxycyclopentan- 1-carboxylate (13 A, 0.88 g, 1.42 mmol) in dichloromethane (20 mL) was added trifluoroacetic acid (4.0 mL) and was stirred for 4 h. After concentration, the residue was taken in ethyl acetate and aqueous sodium bicarbonate. The organic layer was separated, dried, filtered and concentrated. The residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.4 g (53 %) of 13.
Anal, calcd. for C20H33N4O6CI3: %C 45.17 %H 6.25 %N 10.53
Found: %C 45.30 %H 6.29 %N 10.33
MS (ES+): 533.2 (M+ l)
Example 14
Ethyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-2,2,2-trifluoro- ethoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000044_0001
14A: l-.er^-Butoxycarbonyl-2-methyl-2-thiopseudourea
To a mixture of 2-methyl-2-thiopseudourea sulfate (2.78 g, 10 mmol) in dichloromethane (100 mL) and saturated aqueous sodium bicarbonate (100 mL) was added di- tert-butyl dicarbonate (2.18 g, 10 mmol) and the mixture was stirred for 4 h. The organic layer was separated and concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 2.5 g (65 %) of 14A.
14B: l-tot-Butoxycarbonyl-3-(2,2,2-trifluoroethoxy)carbonyl-2-methyl-2-thio- pseudourea
To a solution of 2,2,2-trifluoroethanol (3.22 g, 32.2 mmol) in dichloromethane (25 mL) was added ethyl chlorothioformate (5.0 g, 40.0 mmol) over a period of 2 min., followed by drop wise addition of FeCb in nitromethane (0.35 g FeCb in 0.7 mL nitromethane) over a period of 5 min. The reaction mixture was further stirred for 0.5 h, and diluted with dichloromethane (100 mL). The mixture was washed with IN HCI (100 mL) and water (4 X 100 mL), and organic layer separated and dried. After filtration, the filtrate was concentrated to give 6.7 g of the residue of 2,2,2-trifTuoroethyl ethylthioformate. To this residue were added 1,2- dichloroethane (50 mL) and sulfuryl chloride (15.0 mL) and the solution was heated at gentle reflux for 7 h and then stirred at room temperature for 16 h. The reaction mixture was divided into 2 parts. One part of this mixture was added portion wise over a period of 1 h, to a stirred mixture of l-tert-butoxycarbonyl-2-methyl-2-thiopseudourea (14A, 2.5 g, 13.1 mmol) in dichloromethane (100 mL) and aqueous sodium bicarbonate (100 mL), while maintaining the pH of the mixture basic by adding 40% sodium hydroxide. The reaction mixture was further stirred for 1 h and the organic layer was separated. After drying, it was filtered and the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 2.4 g (58%) of 14B.
14C: Ethyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-tert-butoxy- carbonylamino-N'-2,2,2-trifluoroethoxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan-1-carboxylate
To a solution of ethyl (15,25,3_-,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-amino-2- hydroxycyclopentan-1-carboxylate trifluoroacetate (0.85 g, 2 mmol, disclosed in WO 99/33781) in dimethyl formamide (20 mL) were added triethylamine (1.4 mL, 10.0 mmol), 1- tert-butoxycarbonyl-3-(2,2,2-trifluoroethoxycarbonyl)-2-methyl-2-fhiopseudo- urea (14B, 0.76 g, 2.4 mmol) and mercury(II) chloride (0.65 g, 2.4 mmol) and the mixture was stirred for 2 h.
After dilution with ethyl acetate (100 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.32 g (27%) of 14C.
14. To a solution of ethyl (1S,2S,3R,4R, 1 ',S)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4- [(N-tert- butoxy carbonylamino-N '-2,2, 2-trifluoroethoxycarbonylimino)methyl] amino-2- hydroxycyclopentan- 1-carboxylate (14C, 0.32 g, 0.54 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (1.0 mL) and was stirred for 3 h. After concentration, the residue was taken in ethyl acetate and aqueous sodium bicarbonate. The organic layer was separated, dried, filtered and concentrated. The residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.2 g (77%) of 14.
Anal, calcd. for C20H33N4O6F3: %C 45.40 %H 5.63 %N 9.21
Found: %C 44.90 %H 5.56 %N 8.91
MS (ES+): 483.3 (M+ l)
Example 15 Ethyl (lS,25,3R,4R4'^-(-)-3-(l'-acetylammo-2'-ethyl)butyl-4-[N-(2'-L-amino-3'- phenylpropanoyIamino)-imino]methylarnino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000045_0001
15A: Ethyl (15,2S,3__,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L-amino-3'- phenyl)propanoylamino)-N'-(benzyloxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan-1-carboxylate To a solution of N-benzyloxycarbonyl L-phenylalanine (0.26 g, 0.87 mmol) in ethyl acetate (20 mL) was added 1, l'-carbonyldiimidazole (0.14 g, 0.87 mmol) and the mixture was stirred for 0.25 h. To this solution was added N- hydroxysuccinimide (0.1 g, 0.87 mmol) and stirred for 2 h. The reaction mixture was washed with water and the organic layer separated, dried, filtered and concentrated to give 0.34 g of N-benzyloxycarbonyl L-phenylalanine succinimido ester.
To a mixture of ethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N- (benzyloxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example 2, 0.33 g, 0.67 mmol) in dichloromethane (20 mL) and saturated aqueous sodium bicarbonate (20 mL) was added above prepared N-benzyloxycarbonyl L-phenylalanine succinimido ester (0.34 g, 0.87 mmol) and the mixture was stirred for 16 h at room temperature. The organic layer was separated, aqueous layer was further extracted with dichloromethane (20 mL) and the combined organic layers were dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.41 g (79%) of 15 A.
15: To a solution of ethyl (1S,2S,3R,4R, VS)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[N-(2'-L- amino-3'-phenyl)propanoylamino)-N'-(benzyloxycarbonylimino)methyl]amino-2- hydroxycyclopentan- 1-carboxylate (15A, 0.41 g, 0.53 mmol) in ethanol (22 mL) and water (6 mL) was added 10% Pd/C (60 mg) and cone. HCI (3 drops) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.3 g (89%) of 15.
Anal, calcd. for C26H4iN5O5«2HCl«2.5H2θ: %C 50.24 %H 7.78 %N 11.27 Found: %C 50.49 %H 7.51 %N 10.85
MS (ES+): 504.4 (M+ l)
Example 16
Ethyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L-aminoprop- anoylamino)-imino]methylamino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000046_0001
16A: Ethyl (l)S,25,3__,4__Jl'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L-amino- propanoylamino)-N'-(benzyloxycarbonylimino)methyl]amino-2-hydroxycyclo- pentan-1- carboxylate
To a solution of N-benzyloxycarbonyl L-alanine (0.19 g, 0.87 mmol) in ethyl acetate (20 mL) was added 1, l'-carbonyldiimidazole (0.14 g, 0.87 mmol) and the mixture was stirred for 0.25 h. To this solution was added N- hydroxysuccinimide (0.1 g, 0.87 mmol) and stirred for 2 h. The reaction mixture was washed with water and the organic layer separated, dried, filtered and concentrated to give 0.28 g of N-benzyloxycarbonyl L-alanine succinimido ester. To a mixture of ethyl (1S,2S,3R,4R, 1 ',S)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[N-
(benzyloxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example 2, 0.33 g, 0.67 mmol) in dichloromethane (20 mL) and saturated aqueous sodium bicarbonate (20 mL) was added above prepared N-benzyloxycarbonyl L-alanine succinimido ester (0.28 g, 0.87 mmol) and the mixture was stirred for 16 h at room temperature. The organic layer was separated, aqueous layer was further extracted with dichloromethane (20 mL) and the combined organic layers were dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.37 g (79%) of 16A. 16: To a solution of ethyl (1S,2S ,3R,4R, 1 ',S)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[N-(2'-L- aminopropanoylamino)-N'-(benzyloxycarbonylimino)methyl]amino-2-hydroxycyclopentan-l- carboxylate (16A, 0.37 g, 0.53 mmol) in ethanol (24 mL) and water (6 mL) was added 10% Pd/C (50 mg) and cone. HCI (3 drops) and the mixture was hydrogenated at 40 psffor 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.26 g (84%) of 16.
Anal, calcd. for
Figure imgf000047_0001
%C 45.36 %H 8.48 %N 12.02 Found: %C 45.52 %H 8.04 %N 12.14
MS (ES+): 428.1 (M + l) Example 17
Ethyl (lS,2S,3__,4_.,l'S)-(-)-3-(l'-acetyIamino-2'-ethyl)butyI-4-[(2'-L-amino-3'- methylpentanoylamino)-imino]methylamino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000047_0002
17A: Ethyl (lS,25,3__,4__,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L-amino-
3'methylpentanoylamino)-N'-(benzyloxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan-1-carboxylate To a solution of N-benzyloxycarbonyl L-isoleucine (0.3 g, 1.12 mmol) in ethyl acetate (20 mL) was added 1, -carbonyldiimidazole (0.9 g, 1.12 mmol) and the mixture was stirred for 0.25 h. To this solution was added N- hydroxysuccinimide (0.13 g, 1.12 mmol) and stirred for 2 h. The reaction mixture was washed with water and the organic layer separated, dried, filtered and concentrated to give 0.41 g of N-benzyloxycarbonyl L-isoleucine succinimido ester.
To a mixture of ethyl (lS,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N- (benzyloxycarbonylamino-imino)methyl] amino-2-hydroxycyclopentan- 1 -carboxylate (example 2, 0.37 g, 0.75 mmol) in dichloromethane (20 mL) and saturated aqueous sodium bicarbonate (20 mL) was added above prepared N-benzyloxycarbonyl L-isoleucine succinimido ester (0.41 g, 1.12 mmol) and the mixture was stirred for 16 h at room temperature. The organic layer was separated, aqueous layer was further extracted with dichloromethane (20 mL) and the combined organic layers were dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.45 g (81 %) of l7A.
17: To a solution of ethyl (15',2S,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L- amino-3'methylpentanoylamino)-N'-(benzyloxycarbonylimino)methyl]amino-2- hydroxycyclopentan- 1-carboxylate (17A, 0.31 g, 0.42 mmol) in ethanol (24 mL) and water (6 mL) was added 10% Pd/C (50 mg) and cone. HCI (3 drops) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.23 g (84%) of 17.
Anal, calcd. for C23H43N5O5«3HCM.5C2H5OH: %C 48.18%H 8.32 %N 10.81 Found: %C 48.25 %H 8.38 %N 10.77 MS (ES+): 470.5 (M+ l)
Example 18
Methyl (lS,2S,3__,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L-amino- propanoylamino)-imino]methylamino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000048_0001
18A: Methyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L- aminopropanoylamino)-N'-(benzyloxycarbonylimino)methyl]amino-2-hydroxycyclo pentan-1-carboxylate
To a solution of N-benzyloxycarbonyl L-alanine (0.23 g, 1.0 mmol) in ethyl acetate (20 mL) was added 1, l'-carbonyldiimidazole (0.16 g, 1.0 mmol) and the mixture was stirred for 0.25 h. To this solution was added N- hydroxysuccinimide (0.12 g, 1.0 mmol) and stirred for 2 h. The reaction mixture was washed with water and the organic layer separated, dried, filtered and concentrated to give 0.32 g of N-benzyloxycarbonyl L-alanine succinimido ester.
To a mixture of methyl (15,25,3R,4R,l',S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N- (benzyloxycarbonylamino-imino)methyl] amino-2-hydroxycyclopentan- 1 -carboxylate ( example 6B, 0.32 g, 0.67 mmol) in dichloromethane (20 mL) and saturated aqueous sodium bicarbonate (20 mL) was added above prepared N-benzyloxycarbonyl L-alanine succinimido ester (0.32 g, 0.87 mmol) and the mixture was stirred for 16 h at room temperature. The organic layer was separated, aqueous layer was further extracted with dichloromethane (20 mL) and the combined organic layers were dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.31 g (68 %) of 18A. 18: To a solution of methyl (lS,2S,3R,4R,VS)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[N-(2'- L-aminopropanoylamino)-N'-(benzyloxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan- 1-carboxylate (18A, 0.3 g, 0.44 mmol) in ethanol (24 mL) and water (6 mL) was added 10% Pd/C (60 mg) and cone. HCI (3 drops) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.13 g (53 %) of 18.
Anal, calcd. for C19H35N5O5.3HCl-l.5H2O: %C 41.50 %H 7.51 %N 12.74
Found: %C 41.60 %H 7.38 %N 12.64
MS (ES+): 414.4 (M+ l)
Example 19
Methyl (lS,25,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L-amino-3' phenylpropanoylamino)-imino]methylamino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000049_0001
19A: Methyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L-amino-3'- phenylpropanoylamino)-N'-(benzyloxycarbonylimino)methyl]amino-2- hydroxycyclopentan-1-carboxylate
To a solution of N-benzyloxycarbonyl L-phenylalanine (0.0.3 g, 1.0 mmol) in ethyl acetate (20 mL) was added 1, l'-carbonyldiimidazole (0.16 g, 1.0 mmol) and the mixture was stirred for 0.25 h. To this solution was added N- hydroxysuccinimide (0.12 g, 1.0 mmol) and stirred for 2 h. The reaction mixture was washed with water and the organic layer separated, dried, filtered and concentrated to give 0.39 g of N-benzyloxycarbonyl L-phenylalanine succinimido ester.
To a mixture of methyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N- (benzyloxycarbonylamino-imino)methyl] amino-2-hydroxycyclopentan- 1 -carboxylate (example 6B, 0.32 g, 0.67 mmol) in dichloromethane (20 mL) and saturated aqueous sodium bicarbonate (20 mL) was added above prepared N-benzyloxycarbonyl L-phenylalanine succinimido ester (0.39 g, 1.0 mmol) and the mixture was stirred for 16 h at room temperature. The organic layer was separated, aqueous layer was further extracted with dichloromethane (20 mL) and the combined organic layers were dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.18 g (35 %) of 19A.
19: To a solution of methyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l ' -acetylamino-2 ' -ethyl)butyl-4-[N-(2 '- L-amino-3'-phenylpropanoylamino)-N'-(benzyloxycarbonylimino)methyl]amino-2- hy droxy cyclopentan- 1-carboxylate (19A, 0.18 g, 0.23 mmol) in ethanol (16 mL) and water (4 mL) was added 10% Pd/C (40 mg) and cone. HCI (2 drops) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.1 g (64%) of 19.
Anal, calcd. for
Figure imgf000050_0001
%C 44.75 %H 7.51 %N 10.44
Found: %C 45.24 %H 7.10 %N 10.30 MS (ES+): 490.7 (M+ l)
Example 20
(lS,2S,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(amino-imino)methyl- amino-2- (3'-methylbutanoyl)hydroxycyclopentan-l-carboxylic acid
Figure imgf000050_0002
20A: l,3-Bis(benzyloxycarbonyl)-2-methyl-2-thiopseudourea
To a mixture of 2-methyl-2-thiopseudourea sulfate (27.8 g, 100 mmol), water (20 mL) and benzyl chloroformate (17.0 g, 100 mmol) at 5 °C was added 40% aqueous sodium hydroxide 5 drop wise till pH became neutral. The mixture was diluted with dichloromethane (50 mL). Additional benzyl chloroformate (17.0 g, 100 mmol) was added portion wise over a period of 0.5 h maintaining the pH of the mixture neutral with the addition of 40% NaOH. The mixture was stirred for additional 0.5 h and the organic layer was separated. The aqueous layer was extracted with dichloromethane (3 X) after diluting with water. The combined organic layers0 were dried and after filtration, the filtrate was concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give: i) l,3-Bis(benzyloxycarbonyl)-2-methyl-2-thiopseudourea (14.0 g, 19%). ii) l-Benzyloxycarbonyl-2-methyl-2-thiopseudourea (24.0 g, 53 %) 5 20B: (15,2S,3R,4R,l'S)-(-)-3-(l'-Acetylamino-2'-ethyl)butyl-4-tert-butoxycarbonyl- amino-2-hydroxycyclopentan-l-carboxylic acid
To a solution of methyl (lJS,25,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-tert- butoxycarbonylamino-2-hydroxycyclopentan-l-carboxylate (27.7 g, 69.3 mmol, given in WO 99/33781) in methanol (350 mL) and water (35 mL) was added lithium hydroxide (5.9 g, 1400 mmol) and stirred for 1 h. The reaction mixture was concentrated to half, and acidified with acetic acid and stirred for 2 h. The precipitate was collected by filtration, washed with water and dried to give 19.0 g (71 %) of 20B.
20C: Benzyl (15,2S,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-to-t-butoxy- 5 carbonylamino-2-hydroxycyclopentan-l-carboxylate
To a solution of l,S',2S,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-tert-butoxy- carbony lamino-2-hy droxy cyclopentan- 1 -carboxylic acid (20B, 15.0 g, 38.9 mmol) in dichloromethane (300 mL) was added l,l'-carbonyldiimidazole (6.34 g, 38.9 mmol) and stirred for 1 h. To this solution was then added benzyl alcohol (12.0 mL, 116 mmol) and the o mixture was further stirred for 2 h. The reaction mixture was washed with water and brine, organic layer was dried, filtered and concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 16.2 g (87%) of 20C.
20D: Benzyl (lS,25,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-to-t-butoxy-5 carbonylamino-2-(3'-methylbutanoyloxy)cyclopentan-l-carboxylate
To a solution of benzyl lS,2lS,3R,4R,l'.S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-tert- butoxycarbonylamino-2-hy droxy cyclopentan- 1-carboxylate (20C, 0.71 g, 1.5 mmol) in pyridine (20 mL) were added isovaleryl chloride (0.73 mL, 6.0 mmol) and 4- (dimethylamino)pyridine (18 mg, 0.15 mmol) and stirred for 1 h. The reaction mixture was0 extracted with ethyl acetate (2 X) after dilution with water. The combined organic extracts were washed with water (1 X), 0.2 N HCI (2 X), water (1 X) and brine (1 X) and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.7 g (83 %) of 20D. 20E: Benzyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(N-benzyIoxy- carbonylamino-N'-benzyloxycarbonylimino)-2-(3'-methylbutanoyloxy)cyclopentan-l- carboxylate To a solution of benzyl (15,25,322,422, 1 '5)-(-)-3-(l ' -acetylamino-2 ' -ethyl)butyl-4-tert- butoxycarbonylamino-2-(3'-methylbutanoyloxy)cy clopentan- 1-carboxylate (20D, 0.7 g, 1.25 mmol) in dichloromethane ((50 mL) was added trifluoroacetic acid (3.5 mL) and stirred for 2 h. The solvent was evaporated, the residue was co-evaporated with ether (2 X) and washed with ether- hexane and dried. The residue was then dissolved in dimethyl formamide (5 mL) and to this solution were added triethylamine (0.87 mL, 6.25 mmol), 1,3- bis(benzyloxycarbonyl)-2-methyl-2-thiopseudourea (20A, 0.45 g, 1.25 mmol) and mercury(II) chloride (0.34 g, 1.25 mmol) and the mixture was stirred for 2 h. After dilution with ethyl acetate (25 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.5 g (52%) of 20E.
20: To a solution of benzyl (15,25,322,42?, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-(N- benzyloxycarbonylamino-N'-benzyloxycarbonylimino)-2-(3'-methylbutanoyloxy)cyclo- pentan- 1-carboxylate (20E, 0.35 g, 0.45 mmol) in ethanol (30 mL) and water (7 mL) were added 4 drops of HCI and 10% Pd/C (70 mg) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was filtered through a pad of Celite and silica gel and the filtrate was concentrated and dried to give 0.12 g (52%) of 20.
Anal, calcd. for C2oH36N4θ5»2HCl»1.5H2θ: %C 46.87 %H 8.06 %N 10.93 Found: %C 47.06 %H 7.80 %N 10.93
MS (ES+): 413.3 (M+ l)
Example 21
(15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(amino-imino)methylamino-2-n- hexanoyloxycyclopentan-1-carboxylic acid
Figure imgf000053_0001
21A: Benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-tert-butoxy- carbonylamino-2-n-hexanoyloxycyclopentan-l-carboxylate
To a solution of benzyl 15,25,322,422, l'5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-tert- butoxycarbonylamino-2- hydroxycyclopentan- 1-carboxylate (20C, 0.71 g, 1.5 mmol) in pyridine (20 mL) were added n-hexanoyl chloride (0.85 mL, 6.0 mmol) and 4- (d nethylamino)pyridine (18 mg, 0.15 mmol) and stirred for 2 h. The reaction mixture was extracted with ethyl acetate (2 X) after dilution with water. The combined organic extracts were washed with water (1 X), 0.2 N HCI (2 X), water (1 X) and brine (1 X) and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.78 g (90%) of 21 A.
21B: Benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(N-benzyloxy- carbonylamino-N'-benzyloxycarbonylimino)-2-n-hexanoyloxycyclopentan-l-carboxylate
To a solution of benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-tert- butoxycarbonylamino-2-(3'-mefhylbutanoyloxy)cyclopentan-l-carboxylate (21A, 0.78 g, 1.35 mmol) in dichloromethane ((50 mL) was added trifluoroacetic acid (3.5 mL) and stirred for 2 h. The solvent was evaporated, the residue was co-evaporated with ether (2 X) and washed with ether- hexane and dried. The residue was then dissolved in dimethyl formamide (8 mL) and to this solution were added triethylamine (T.4 mL, 10.0 mmol), 1,3-bis (benzyloxycarbonyl)-2-methyl-2-thiopseudourea (20A, 0.48 g, 1.35 mmol) and mercury(II) chloride (0.36 g, 1.35 mmol) and the mixture was stirred for 2 h. After dilution with ethyl acetate (25 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.53 g (50%) of 21B.
21: To a solution of benzyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(N- benzyloxycarbonylamino-N'-benzyloxycarbonylimino)-2-n-hexanoyloxycyclopentan-l- carboxylate (21B, 0.32 g, 0.40 mmol) in ethanol (30 mL) and water (7 mL) were added 4 drops of HCI and 10% Pd/C (70 mg) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was filtered through a pad of Celite and silica gel and the filtrate was concentrated and dried to give 0.14 g (66%) of 21.
Anal, calcd. for C2iH38N θs»2HCl*H2θ: %C 48.74 %H 8.18 %N 10.83
Found: %C 48.72 %H 8.22 %N 10.58
MS (ES+): 427.3 (M + l)
Example 22
(15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxycarbonyl- amino- imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid
Figure imgf000054_0001
A mixture of ethyl (15,25,3R,4R, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(N- benzyloxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example 2, 0.32 g, 0.65 mmol) in methanol (3 mL) and IN sodium hydroxide (1.5 mL) was stirred at room temperature for 2 h. The reaction mixture was neutralized with IN HCI. The precipitate was collected by filtration, washed with water and dried to give 0.18 g (60%) of 22.
Anal, calcd. for C23H3 N4O6: %C 59.72 %H 7.41 %N 12.11
Found: %C 59.55 %H 7.22 %N 11.94
MS (ES+): 463.5 (M+ l)
Example 23
(15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-methoxycarbonyl- amino- imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid
Figure imgf000054_0002
A mixture of ethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-ethoxy- carbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example 3, 0.6 g, 1.45 mmol) in methanol (3 mL) and IN sodium hydroxide (1.5 mL) was stirred at room temperature for 2 h. The reaction mixture was neutralized with IN HCI, concentrated and the residue was suspended in water. The precipitate was collected by filtration, washed with water and dried to give 0.17 g (30%) of 23.
Anal, calcd. for Ci7H3oN4θ6«0.25H2O: %C 52.23 %H 7.73 %N 14.33
Found: %C 51.98 %H 7.66 %N 14.220 MS (ES+): 387.3 (M+ l)
Example 24
(15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-tert-butoxycarbonyl- amino-5 imino)methyl]anιino-2-hydroxycyclopentan-l-carboxylic acid
Figure imgf000055_0001
A mixture of ethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-tert- butoxyoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example 4, 0.56 g, 1.23 mmol) in methanol (3 mL) and IN sodium hydroxide (2.5 mL) was stirred at o room temperature for 3 h. The reaction mixture was neutralized with IN HCI, concentrated and the residue was suspended in water. The precipitate was collected by filtration, washed with water and dried to give 0.25 g (47%) of 24.
Anal, calcd. for C2oH36N4θ6.0.5H2O: %C 54.90 %H 8.29 %N 12.815 Found: %C 54.49 %H 8.44 %N 12.75
MS (ES+): 430.1 (M + l)
Example 25
(15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-ethoxycarbonylamino-imino) methyl]amino-2-lιydroxycyclopentan-l-carboxylic acid
Figure imgf000056_0001
25A: Benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(N-benzyloxy- carbonylamino-N'-ethoxycarbonylimino)-2-hydroxycyclopentan-l-carboxylate
To a solution of benzyl (15,25,3R,422,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-tert- butoxycarbonylamino-2-hydroxycyclopentan- 1-carboxylate (example 20C, 1.0 g, 2.10 mmol) in dichloromethane ((25 mL) was added trifluoroacetic acid (6.0 mL) and stirred for 2 h. The solvent was evaporated, the residue was washed with ether- hexane and dried. The residue was then dissolved in dimethyl formamide (10 mL) and to this solution were added triethylamine (1.46 mL, 10.5 mmol), l-benzyloxycarbonyl-3-ethoxycarbonyl-2-methyl-2- thiopseudourea (IB, 0.93 g, 3.15 mmol) and mercury (II) chloride (0.85 g, 3.15 mmol) and the mixture was stirred for 16 h. After dilution with ethyl acetate (50 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate was concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 1.0 g (76%) of 25 A.
25: To a solution of benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(N- benzyloxycarbonylamino-N ' -ethoxycarbonylimino)-2-hydroxycyclopentan- 1 -carboxylate (25 A , 0.51 g, 0.82 mmol) in ethanol (18 mL) and water (2 mL) were added 4 drops of HCI and 10% Pd/C (100 mg) and the mixture was hydrogenated at 40 psi for 16 h. The mixture was filtered through a pad of Celite and silica gel and the filtrate was concentrated and the residue was purified on silica gel column using chloroform (7): methanol (3): ammonium hydroxide (0.2) mixture as an eluent to give 0.27 g (82%) of 25.
Anal, calcd. for Ci8H32N4θ6«0.5H2O: %C 52.80 %H 8.12 %N 13.68 Found: %C 52.91 %H 7.91 %N 13.61
MS (ES+): 401.2 (M+ l) Example 26
(15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-acetyloxymethoxy- carbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid
Figure imgf000057_0001
26A: Benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-amino-2-hydro- xycyclopentan-1-carboxylate
To a mixture of benzyl (15,25,3R,422,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-tert- butoxycarbonylamino-2-hydroxycyclopentan-l-carboxylate (10.3 g, 21.6 mmol) in THF (100 mL) and ether (300 mL) was added 7.5N HCI in ether (40 mL, 300 mmol)) and the mixture was stirred at room temperature for 16 h. The solvent was removed, the residue was suspended in ether- hexane mixture and the precipitate was collected by filtration, washed with ether- hexane and dried to give 8.6 g (96%) of 26 A as hydrochloride.
26B: Benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyl- oxycarbonylamino-N'-tof-butoxycarbonylimino)methyl]amino-2-hydroxycyclo- pentan-1- carboxylate
To a solution of benzyl (15,25,3R,422,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-amino-2- hydroxycyclopentan- 1-carboxylate hydrochloride (26A, 6.1 g, 14.8 mmole) in dimethyl formamide (60 mL) were added triethylamine (7.4 mL, 53.2 mmol), 1-benzyloxy- carbonyl-3- tert-butoxycarbonyl-2-methyl-2-thiopseudourea (2A, 5.1 g, 15.8 mmol) and mercury (II) chloride (4.3 g, 15.8 mmol) and the mixture was stirred for 2 h. After dilution with ethyl acetate (250 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 6.4 g (66%) of 26B.
26C: Benzyl (lS,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyl- oxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
To a solution of benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-tert- butoxycarbonylamino-N'-benzyloxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan- 1- carboxylate (26B, 6.4 g, 9.8 mmol) in dichloromethane (100 mL) was added trifluoroacetic acid (18.0 mL) and was stirred for 4 h. After concentration, the residue was taken in ethyl acetate and aqueous sodium bicarbonate. The organic layer was separated, dried, filtered and concentrated. The residue was purified on silica gel column using chloroform: methanol as an eluent to give 4.8 g (89 % ) of 26C .
26D: Benzyl (1S,2S,3R,4R, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy carbonylamino-N' -acetyloxymethoxycarbonylimino)methyl]amino-2-hydroxycyclo- pentan- 1-carboxylate
To a solution of benzyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- benzyloxycarbonylan ino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (26C, 0.55 g, 1.0 mmol) in hexamethylphosphoramide (5.0 mL) was added acetyloxymethyl 4-nitrophenyl carbonate (0.76 g, 3.0 mmol, prepared by using the method disclosed in Alexander et al. J. Med. Chem. 1988, 31, 318-322) and heated at 45 °C for 16 h. An additional amount of acetyloxymethyl 4-nitrophenyl carbonate (0.25 g, 1 mmol) was added to the reaction mixture and again heated at 45 °C for 8 h. The mixture was cooled and diluted with water. After saturating with salt, the mixture was extracted with ethyl acetate (3 X). The combined organic extracts were washed with water and brine and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using ethyl acetate: hexane as an eluent to give 0.37 g (55%) of 26D. 26: To a solution of benzyl (1 ,25,322,422, 1 '5)-(-)-3-(l ' -acetylamino-2 ' -ethyl)butyl-4-[(N- benzyloxy carbonylamino-N ' -acetyloxymethoxycarbonylimino)methyl] amino-2- hy droxy cyclopentan- 1-carboxylate (26D, 0.32 g, 0.48 mmol) in ethanol (40 mL) and water (13 mL) was added 10% Pd/C (70 mg) and the mixture was hydrogenated at 40 psi for 2 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.15 g (70%) of 26.
Anal, calcd. for C19H32N4O8: %C 51.34 %H 7.26 %N 12.60
Found: %C 51.50 %H 7.14 %N 12.15
MS (ES+): 445.5 (M+ l)
Example 27
(15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(α-acetyloxyethoxy- carbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid o
Figure imgf000058_0001
27A: Benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino)-N'-(l-acetyloxyethoxycarbonylimino)methyI]amino-2-hydroxy- cyclopentan-1-carboxylate
To a solution of benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- benzyloxycarbonylammo-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example 26C, 0.55 g, 1.0 mmol) in hexamethylphosphoramide (5.0 mL) was added α-acetyloxy ethyl 4- nitrophenyl carbonate (0.8 g, 3.0 mmol, prepared by using the literature ref.: Alexander et al. J. Med. Chem. 1988, 31, 318-322) and heated at 45 °C for 16 h. Additional amount of α- acetyloxymethyl 4-nitrophenyl carbonate (0.27 g, 1 mmol) was added to the reaction mixture and again heated at 45 °C for 8 h. The mixture was cooled and diluted with water. After saturating with salt, the mixture was extracted with ethyl acetate (3 X). The combined organic extracts were washed with water and brine and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using ethyl acetate: hexane as an eluent to give 0.4 g (58%) of 27A.
27: To a solution of benzyl (15,25,322,4R, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(N- benzyloxycarbonylamino)-N'-(α-acetyloxymethoxycarbonylimino)methyl]amino-2- hy droxy cyclopentan- 1-carboxylate (27 A, 0.35 g, 0.51 mmol) in ethanol (20 mL) and water (5 mL) was added 10% Pd/C (70 mg) and the mixture was hydrogenated at 40 psi for 2 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.14 g (60%) of 27.
Anal, calcd. for C2oH3 N4θ8»0.5H2θ: %C 51.38 %H 7.55 %N 11.98
Found: %C 51.74 %H 7.42 %N 11.70
MS (ES+): 459.2 (M + l)
Example 28
(15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-trimethylacetyloxy- methoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid
Figure imgf000059_0001
28A: Benzyl (15,2S,3R,422,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino)-N'-(l-trimethylacetyloxymethoxycarbonylimino)methyl]amino-2- hydroxycyclopentan-1-carboxylate
To a solution of benzyl (15,25,322,422, l'5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(N- benzyloxycarbonylamino-imino)methyl] amino-2-hydroxycyclopentan- 1 -carboxylate (example 26C, 0.83 g, 1.5 mmol) in hexamethylphosphoramide (10.0 mL) was added trimethylacetyloxymethyl 4-nitrophenyl carbonate (example 10A, 0.9 g, 3.0 mmol) and heated at 45 °C for 16 h. Additional amount of trimethylacetyloxymethyl 4-nitrophenyl carbonate (0.3 g, 1 mmol) was added to the reaction mixture and again heated at 45 °C for 8 h. The mixture was cooled and diluted with water. After saturating with salt, the mixture was extracted with ethyl acetate (3 X). The combined organic extracts were washed with water and brine and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using ethyl acetate: hexane as an eluent to give 0.22 g (20%) of 28A. 28: To a solution of benzyl (15,25,322,422, 1 '5)-(-)-3-(l ' -acetylamino-2 '-efhyl)butyl-4-[(N- benzyloxycarbonylammo)-N'-(l-trimethylacetyloxymethoxycarbonylimino)methyl]- amino-2- hy droxy cyclopentan- 1-carboxylate (28 A, 0.21 g, 0.31 mmol) in ethanol (20 mL) and water (5 mL) was added 10% Pd/C (40 mg) and the mixture was hydrogenated at 40 psi for 2 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.1 g (66%) of 28.
Anal, calcd. for C22H38N4θs»H2θ: %C 52.37 %H 7.99 %N 11.10 Found: %C 52.27 %H 7.92 %N 10.72
MS (ES+): 487.5 (M+ l)
Example 29
(15,25,3R,4R,l'5)-(-)-3-(l'-Acetylamino-2'-ethyl)butyl-4-[(N-(α-trimethylacetyloxy- ethoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid
Figure imgf000060_0001
29A: Benzyl (15,25,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino)-N'-(α-trimethylacetyloxyethoxycarbonylimino)methyl]amino-2- hydroxycycϊopentan-1-carboxylate
To a solution of benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- benzyloxycarbonylamino-ήnino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example 26C, 0.55 g, 1.0 mmol) in hexamethylphosphoramide (6.0 mL) was added α- trimethylacetyloxy ethyl 4-nitrophenyl carbonate (0.8 g, 3.0 mmol, prepared by using the method disclosed in Alexander et al. J. Med. Chem. 1988, 31, 318-322) and heated at 45 °C for 16 h. An additional amount of α-trimethylacetyloxymethyl 4-nitrophenyl carbonate (0.27 g, 1 mmol) was added to the reaction mixture and again heated at 45 °C for 8 h. The mixture was cooled and diluted with water. After saturating with salt, the mixture was extracted with ethyl acetate (3 X) . The combined organic extracts were washed with water and brine and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using ethyl acetate: hexane as an eluent to give 0.15 g (20%) of 29 A.
29: To a solution of benzyl (15,25,3R,422, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(N- benzyloxycarbonylamino)-N'-(α-trimethylacetyloxyethoxycarbonylimino)methyl]- amino-2- hydroxycyclopentan- 1-carboxylate (29A, 0.15 g, 0.21 mmol) in ethanol (12 mL) and water (3 mL) was added 10% Pd/C (40 mg) and the mixture was hydrogenated at 40 psi for 2 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.055 g (52%) of 29.
Anal, calcd. for C23H4oN θ8»0.5H2O: %C 54.21 %H 8.11 %N 10.99 Found: %C 54.55 %H 8.01 %N 11.02
MS (ES+): 501.5 (M+ l)
Example 30 (15,25,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-phenylacetyloxymeth- oxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid O
Figure imgf000061_0001
30A: Benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino)-N'-(phenylacetyloxymethoxycarbonylimino)methyl]amino-2-hydro- xycyclopentan-1-carboxylate
To a solution of benzyl (15,25,3R,422,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- benzyloxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example 26C, 0.83 g, 1.5 mmol) in hexamethylphosphoramide (10.0 mL) was added phenylacetyloxymethyl 4-nitrophenyl carbonate (example 12A, 0.99 g, 3.0 mmol) and heated at 45 °C for 16 h. An additional amount of phenylacetyloxymethyl 4-nitrophenyl carbonate
(0.33 g, 1 mmol) was added to the reaction mixture and again heated at 45 °C for 8 h. The mixture was cooled and diluted with water. After saturating with salt, the mixture was extracted with ethyl acetate (3 X). The combined organic extracts were washed with water and brine and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using ethyl acetate: hexane as an eluent to give 0.0.35 g (31 %) of 30A.
30: To a solution of benzyl (15,25,322,422, l'5)-(-)-3-(l ' -acetylamino-2 ' -ethyl)butyl-4-[(N- benzyloxy carbonylamino) -N ' -(phenylacetyloxymethoxy carbonylimino)methyl] - amino-2- hydroxycyclopentan-1-carboxylate (30A, 0.34 g, 0.45 mmol) in ethanol (28 mL) and water (7 mL) was added 10% Pd/C (70 mg) and the mixture was hydrogenated at 40 psi for 2 h. After removing the catalyst by filtration, the filtrate was concentrated and the residue was purified on silica gel column using chloroform: methanol as an eluent to give 0.11 g (47 %) of 30.
Anal, calcd. for
Figure imgf000061_0002
%C 56.72 %H 7.04 %N 10.58
Found: %C 56.76 %H 7.03 %N 10.39
MS (ES+): 521.5 (M+ l) Example 31
5
(15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(2'-L-amino-3'-phenyl- propanoylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid
Figure imgf000062_0001
0 31A: Benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L- benzyloxycarbonylamino-3'-phenylpropanoylamino)-N'-(benzyloxycarbonylimino)- methyl]amino-2-hydroxycyclopentan-l-carboxylate
To a solution of N-benzyloxycarbonyl L-phenylalanine (0.26 g, 0.87 mmol) in ethyl acetate (20 mL) was added 1, l'-carbonyldiimidazole (0.14 g, 0.87 mmol) and the mixture was stirred5 for 0.25 h. To this solution was added N- hydroxysuccinimide (0.1 g, 0.87 mmol) and stirred for 2 h. The reaction mixture was washed with water and the organic layer separated, dried, filtered and concentrated to give 0.34 g of N-benzyloxycarbonyl L-phenylalanine succinimido ester. To a mixture of benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N- o (benzyloxycarbonylamino-imino)methyl] amino-2-hydroxycyclopentan- 1 -carboxylate (example
26C, 0.37 g, 0.67 mmol) in dichloromethane (20 mL) and saturated aqueous sodium bicarbonate (20 mL) was added above prepared N-benzyloxycarbonyl L-phenylalanine succinimido ester (0.34 g, 0.87 mmol) and the mixture was stirred for 16 h at room temperature. The organic layer was separated, aqueous layer was further extracted with5 dichloromethane (20 mL) and the combined organic layers were dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.29 g (62%) of 31A.
31 : To a solution of benzyl (15,25,3R,4R, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[N-(2'-L- o benzyloxycarbonylamino-3 '-phenylpropanoylamino)-N'-(benzyloxycarbonyl- imino)methyl]amino-2-hy droxy cyclopentan- 1-carboxylate (3 IA, 0.29 g, 0.41 mmol) in ethanol (22 mL) and water (6 mL) was added 10% Pd/C (50 mg) and cone. HCI (3 drops) and the mixture was hydrogenated at 40 psi for 1 h.. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.19 g (66%) of 31. 5
Anal, calcd. for
Figure imgf000062_0002
%C 48.15 %H 7.77 %N 10.80 Found: %C 48.27 %H 7.30 ' %N 10.86
MS (ES+): 476.5 (M+ l)
Example 32
(15,25,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(2'-L-aminopropanoyl- amino- iminomethyl]amino-2-hydroxycyclopentan-l-carboxylic acid
Figure imgf000063_0001
0 32A: Benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L- benzyIoxycarbonyIaminopropanoylamino)-N'-(benzyloxycarbonylimino)methyl]- amino-2- hydroxycyclopentan-1-carboxylate
To a solution of N-benzyloxycarbonyl L-alanine (0.22 g, 1.0 mmol) in ethyl acetate (20 mL) was added 1, l'-carbonyldiimidazole (0.16 g, 1.0 mmol) and the mixture was stirred for 0.255 h. To this solution was added N- hydroxysuccinimide (0.11 g, 1.0 mmol) and stirred for 2 h. The reaction mixture was washed with water and the organic layer separated, dried, filtered and concentrated to give 0.32 g of N-benzyloxycarbonyl L-alanine succinimido ester.
To a mixture of benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N- o (benzyloxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example
26C, 0.44 g, 0.8 mmol) in dichloromethane (20 mL) and saturated aqueous sodium bicarbonate (20 mL) was added above prepared N-benzyloxycarbonyl L-alanine succinimido ester (0.32 g, 1.0 mmol) and the mixture was stirred for 16 h at room temperature. The organic layer was separated, aqueous layer was further extracted with dichloromethane (20 mL) and the5 combined organic layers were dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.0.3 g (60%) of 32A.
32: To a solution of benzyl (15,25,3R,422, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[N-(2'-L- o benzyloxycarbonylaminopropanoylamino)-N'-(benzyloxycarbonylimino)methyl]- amino-2- hydroxy- cyclopentan- 1-carboxylate (32A, 0.3 g, 0.48 mmol) in ethanol (24 mL) and water (6 mL) was added 10% Pd/C (50 mg) and cone. HCI (3 drops) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.22 g (86%) of 32. 5 Anal, calcd. for Cι8H33N5θ5«2HCl«2H2θ«0.5C2HsOH: %C 42.93 %H 7.96 %N 13.18 Found: %C 42.45 %H 7.53 %N 13.02
MS (ES+): 400.4 (M+ l)
Example 33
(15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(2'-L-amino-3'-methylpen- l o tanoylamino-iminomethyl]amino-2-hydroxycyclopentan-l-carboxylic acid
Figure imgf000064_0001
33A: Benzyl (15,25,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L- benzyloxycarbonylamino-3'-methylpentanoylamino)-N'-(benzyIoxycarbonylimino)- methyl]amino-2-hydroxy- cyclopentan-1-carboxylate
15 To a solution of N-benzyloxycarbonyl L-isoleucine (0.22 g, 0.82mmol) in ethyl acetate (20 mL) was added 1, l'-carbonyldiimidazole (0.13 g, 0.82 mmol) and the mixture was stirred for 0.25 h. To this solution was added N- hydroxysuccinimide (0.09 g, 0.82 mmol) and stirred for 2 h. The reaction mixture was washed with water and the organic layer separated, dried, filtered and concentrated to give 0.3 g of N-benzyloxycarbonyl L-isoleucine succinimido ester.
20
To a mixture of benzyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N- (benzyloxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (example 26C, 0.3 g, 0.54 mmol) in dichloromethane (20 mL) and saturated aqueous sodium bicarbonate (20 mL) was added above prepared N-benzyloxycarbonyl L-isoleucine succinimido ester (0.3 25 g, 0.82 mmol) and the mixture was stirred for 16 h at room temperature. The organic layer was separated, aqueous layer was further extracted with dichloromethane (20 mL) and the combined organic layers were dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.4 g (93 %) of 33A.
30
33: To a solution of benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L- benzyloxycarbonylamino-3'-methylpentanoylamino)-N'-(benzyloxycarbonyl- imino)methyl]amino-2-hydroxycyclopentan- 1-carboxylate (33A, 0.4 g, 0.5 mmol) in ethanol (24 mL) and water (6 mL) was added 10% Pd/C (100 mg) and cone. HCI (3 drops) and the 35 mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.12 g (36%) of 33.
Anal, calcd. for
Figure imgf000065_0001
%C 38.25 %H 7.79 %N 10.62
Found: %C 38.53 %H 7.63 %N 10.23 MS (ES+): 442.5 (M + l)
Example 34
Ethyl (lS,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-acetyloxymeth- oxycarbonylamino-N'-acetyloxymethoxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan-1-carboxylate
Figure imgf000065_0002
34A: l,3-Bis(acetyloxymethoxycarbonyl)-2-methyl-2-thiopseudourea
A mixture of acetyloxymethyl chloroformate (1.71 g, 11.2 mmol, prepared from a literature procedure: Folkmann et al. Synthesis, 1990, 1159-1166) and 2-methyl-2-thiopseudourea sulfate (1.6 g, 5.6 mmol) in dichloromethane (10 mL) and aqueous saturated sodium bicarbonate (10 mL) was stirred at room temperature, for 16 h. The organic layer was separated, washed with water, and dried. After filtration, the filtrate was concentrated and the residue was purified by silica gel column using Hexane: ethyl acetate as an eluent to give 0.66 g (36%) of 34A.
34: To a solution of ethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-amino-2- hydroxycyclopentan-1-carboxylate trifluoroacetate (0.3 g, 0.71 mmole, disclosed in WO 99/33781) in dimethyl formamide (10 mL) were added triethylamine (0.32 mL, 2.3 mmol), l,3-bis(acetyloxymethoxycarbonyl)-2-methyl-2-thiopseudourea (34A, 0.23 g, 0.71 mmol) and mercury (II) chloride (0.19 g, 0.71 mmol) and the mixture was stirred for 2 h. After dilution with ethyl acetate (50 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.2 g (48%) of 34.
Anal, calcd. for C25H40N4O12: %C 51.01 , %H 6.84 %N 9.51
Found: %C 51.34 %H 7.20 %N 9.12
MS (ES+): 589.6 (M+ l) Example 35
(15,25,3R,4R,l'S)-(-)-3-(l'-Acetylamino-2'-ethyl)butyl-4-[(N-acetyloxymethoxy- 5 carbonylamino-N'-acetyloxymethoxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan- l-carboxylic acid
Figure imgf000066_0001
35A: Benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-acetyloxy- methoxycarbonylamino-N'-acetyloxymethoxycarbonylimino)methyl]amino-2- l o hydroxycyclopentan-1-carboxylate
To a solution of benzyl (15,25,3R,422,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-amino-2- hydroxycyclopentan- 1-carboxylate hydrochloride (26A, 0.41 g, 1.1 mmol) in dimethyl formamide (10 mL) were added triemylamine (0.45 mL, 3.3 mmol), 1,1'- bis(acetyloxymethoxycarbonyl)-2-methyl-2-thiopseudourea (34A, 0.35 g, 1.1 mmol) and
15 mercury (II) chloride (0.3 g, 1.1 mmol) and the mixture was stirred for 2 h. After dilution with ethyl acetate (50 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.15 g (21 %) of 35A.
20
35: To a solution of benzyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N- acetyloxymethoxycarbonylamino-N'-acetyloxymethoxycarbonylimino)methyl]- amino-2- hydroxycyclopentan- 1-carboxylate (35A, 0.15 g, 0.23 mmol) in ethanol (16 mL) and water (4 mL) was added 10% Pd/C (50 mg) and the mixture was hydrogenated at 40 psi for 1 h. The 25 mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.056g (42%) of 35.
Anal, calcd. for C23H3δN4θi2«H2θ: %C 47.74 %H 6.62 %N 9.68
Found: %C 48.17 %H 6.63 %N 9.50
30 MS (ES+): 561.5 (M+ l)
Example 36
Ethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-2,2,2-trifluoro- ethoxycarbonylamino-N' -2,2, 2-trifluor oethoxycarbonylimino)methyl] amino-2- hydroxycyclopentan-1-carboxylate
Figure imgf000067_0001
36A: l,3-Bis(2,2,2-trifluoroethoxycarbonyl)-2-methyl-2-thiopseudourea
To a solution of 2, 2, 2-trifluor oethanol (3.22 g, 32.2 mmol) in dichloromethane (25 mL) was added ethyl chlorothioformate (5.0 g, 40 mmol) over a period of 2 min. , followed by dropwise addition of FeCb in nitromethane (0.35 g FeCk in 0.7 mL nitromethane) over a period of 5 min. The reaction mixture was further stirred for 0.5 h, and diluted with dichloromethane (100 mL). The mixture was washed with IN HCI (100 mL) and water (4 X 100 mL), and organic layer separated and dried. After filtration, the filtrate was concentrated to give 6.7 g of the residue of 2,2,2-trifluoroethyl ethylthioformate. To this residue were added 1,2- dichloroethane (50 mL) and sulfuryl chloride (15.0 mL) and the solution was heated at gentle reflux for 7 h and then stirred at room temperature for 16 h.
One fourth part of this reaction mixture was added portion wise, over a period of 1 h, to a stirred mixture of 2-methyl-2-thiopseudourea sulfate (2.0 g, 7.2 mmol) in dichloromethane (100 mL) and aqueous sodium bicarbonate (100 mL), while maintaining the pH of the mixture basic by adding 40% sodium hydroxide. The reaction mixture was further stirred for 1 h and the organic layer was separated. After drying, it was filtered and the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.4 g (16%) of 36A.
36: To a solution of ethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-amino-2- hydroxycyclopentan- 1-carboxylate trifluoroacetate (0.43 g, 1.0 mmol, given in WO 99/33781) in dimethyl formamide (10 mL) were added triethylamine (0.49 mL, 3.5 mmol), l,3-bis(2,2,2- trifluoroethoxycarbonyl)-2-methyl-2-thiopseudourea (36A, 0.34 g, 1.0 mmol) and mercury(II) chloride (0.27 g, 1.0 mmol) and the mixture was stirred for 2 h. After dilution with ethyl acetate (50 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.1 g (16%) of 36.
Anal, calcd. for C23H34N4O8F6: %C 45.40 %H 5.63 %N 9.21
Found: %C 44.90 %H 5.56 %N 8.91
MS (ES+): 609.3 (M+ l)
Example 37
Ethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-ethoxycarbonyl- amino- N'-ethoxycarbonylimino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000068_0001
37A: l,3-Bis(ethoxycarbonyl)-2-methyl-2-thiopseudourea
2-Methyl-2-thiopseudourea sulfate (15.0 g, 53.9 mmol) was suspended in 20 mL of water and cooled to 5°C. Ethyl chloroformate (29.2 g, 269 mmol) was added and the mixture was stirred for 5 min. Sodium hydroxide (25%, w/w) was added dropwise until pH reached 8. The white solid was collected by filtration and dried to give 22.8 g (88%) of 37A.
37: To a solution of methyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-amino-2- hydroxycyclopentan- 1-carboxylate trifluoroacetate (0.62 g, 1.5 mmol, given in WO 99/33781) in dimethyl formamide (15 mL) were added triethylamine (0.62 mL, 4.5 mmol), 1,3-bis- (ethoxycarbonyl)-2-methyl-2-fhiopseudourea (37A, 0.35 g, 1.5 mmol) and mercury(II) chloride (0.41 g, 1.5 mmol) and the mixture was stirred for 2 h. After dilution with ethyl acetate (100 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.3 g (41 %) of 37.
Anal, calcd. for C22H38N4O8: %C 54.31 %H 7.87 %N 11.51
Found: %C 54.51 %H 7.96 %N 11.40
MS (ES+): 487.6 (M+ l) Example 38
Ethyl (15525,3R,4R,l'5)-(-)-3-(l'-acetyIamino-2'-ethyI)butyl-4-[(hydroxylamino- imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000069_0001
38A: Ethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-amino-2- hydroxycyclopentan-1-carboxylate
To a mixture of ethyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-tert- butoxycarbonylamino-2-hy droxy cyclopentan- 1-carboxylate (20.0 g, 48.2 mmol) in THF (2000 mL) and ether (600 mL) was added 7.5N HCI in ether (80 mL, 600 mmol)) and the mixture was stirred at room temperature for 16 h. The solvent was removed, the residue was suspended in ether- hexane mixture and the precipitate was collected by filtration, washed with ether- hexane and dried to give 16 g (94%) of 38 A as hydrochloride. 5 38B: Ethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-cyanamino-2- hydroxycyclopentan-1-carboxylate
To a solution of ethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-amino-2- hydroxycy clopentan- 1-carboxylate hydrochloride (38 A, 0.7 g, 2.0 mmole) in dimethyl acetamide (5 mL) were added triethylamine (0.35 mL, 2.5 mmol) followed by 1- 0 cyanoimidazole (0.32 g, 3.4 mmol) after 15 min. stirring at room temperature. The reaction mixture was further stirred for 6 h at 100 °C. After cooling, the reaction mixture was diluted with water and extracted (3 X) with ethyl acetate. The combined organic layers were dried, filtered and the filtrate concentrated to give 0.6 g of crude 38B. 5 38: A mixture of hydroxylamine hydrochloride (1.4 g, 20 mmol) and sodium carbonate (1.06 g, 10 mmol) in methanol (15 mL) was stirred at room temperature for 0.5 h. The solid was removed by filtration and the filtrate was added to the previously obtained crude 38B and was stirred at room temperature for 24 h. The reaction mixture was concentrated and the residue was suspended in a mixture of chloroform: methanol (1: 1). The solid was removed by o filtration, the filtrate concentrated and the residue was purified by silica gel column using chloroform (80): methanol (18): ammonium hydroxide (2) mixture as an eluent to give 40 mg (5%) of 38.
Anal, calcd. for Ci7H32N4θ5»2.5H2θ«0.25NH4Cl: %C 47.39 %H 8.89 %N 13.825 Found: %C 47.11 %H 7.92 %N 14.06
MS (ES+): 373.4 (M+ l) Example 39
(15,25,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(hydroxylamino-imino) methyl]amino-2-hydroxycyclopentan-l-carboxylic acid
Figure imgf000070_0001
39A: Benzyl (15,25,3R,42?,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-cyanamino-2- hydroxycyclopentan-1-carboxylate To a solution of benzyl (15,25,322,422, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-amino-2- hydroxycyclopentan- 1-carboxylate hydrochloride (26A, 0.83 g, 2.0 mmole) in dimethyl acetamide (5 mL) were added triethylamine (0.35 mL, 2.5 mmol) followed by 1- cyanoimidazole (0.32 g, 3.4 mmol) after 15 min. stirring at room temperature. The reaction mixture was further stirred for 6 h at 100 °C. After cooling, the reaction mixture was diluted with water and extracted (3 X) with ethyl acetate. The combined organic layers were dried, filtered and the filtrate concentrated to give 0.7 g of crude 39 A.
39B: Benzyl (15,25,3R,42?,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(hydroxyl- amino- imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate A mixture of hydroxylamine hydrochloride (1.4 g, 20 mmol) and sodium carbonate (1.06 g, 10 mmol) in methanol (15 mL) was stirred at room temperature for 0.5 h. The solid was removed by filtration and the filtrate was added to the previously obtained crude 39 A and was stirred at room temperature for 24 h. The reaction mixture was concentrated and the residue was suspended in a mixture of chloroform: methanol (1: 1). The solid was removed by filtration, the filtrate concentrated and the residue was purified by silica gel column using chloroform (80): methanol (18): ammonium hydroxide (2) mixture as an eluent to give 0.2 g (23 %) of 39B.
39: To a solution of benzyl (15,25,3R,422, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4- [(hydroxylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (39B, 0.2 g, 0.46 mmol) in methanol (16 mL) and water (4 mL) was added 10% Pd/C (40 mg) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.04 g (25%) of 39.
Anal, calcd. for Ci5H28N4θ5»2HCl«H2O: %C 41.38 %H 7.41 %N 12.87 Found: %C 40.35 %H 7.34 %N 13.27
MS (ES+): 345.1 (M+ l)
Example 40
40: l-[(4'-Aminomethylcarbonylamino)benzoyloxymethyl] (15,25,3R,4R,l'5)-(-)-3-(l' acetylamino-2'-ethyl)butyl-4-(amino-imino)methyl]amino-2-hydroxycyclo- pentan- -1- carboxylate
Figure imgf000071_0001
40A: 4-[N-(Benzyloxycarbonyl)glycylamino]benzoic acid:
Methyl chloroformate (1.8 mL, 23.3 mmol) was added to a mixture of N- benzyloxycarbonylglycine (5.0 g, 23.9 mmol) and triethylamine (3.35 mL, 24.2 mmol) in THF (60 mL) at -20 °C over a period of 10 min. and further stirred for 20 min. To this mixture was then added, a solution of 4-aminobenzoic acid (3.28 g, 23.9 mmol) and triethylamine (3.35 mL, 24.2 mmol) in THF (45 mL) drop wise and stirred at the same temperature for 1 h. The mixture was brought to room temperature and stirred for 16 h, which was then concentrated and the residue was dissolved in 50% acetic acid (30 mL) and cooled. Water (180 mL) was added and the precipitate was collected by filtration to give 1.9 g (24%) of 40A.
40B: Chloromethyl 4-[N-(benzyloxycarbonyI)glycylamino]benzoate: A solution of chloromethyl chlorosulfate (0.8 g, 4.8 mmol) in dichloromethane (4.0 mL) was added to a mixture of 4-[N-(benzyloxycarbonyl)glycylamino]benzoic acid (40A, 1.12 g, 3.42 mmol), sodium bicarbonate (1.26 g, 15.0 mmol) and tetrabutylammonium hydrogensulfate (0.2 g, 0.59 mmol) in dichloromethane (20 mL) and water (20 mL) drop wise over a period of 5 min. and the mixture was stirred for 3 h. Organic phase was separated and the aqueous phase was extracted with dichloromethane (2 X). The combined organic phases were concentrated. The residue was taken in ethyl acetate, washed with brine and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 1.0 g (78%) of 40B.
40C: l[(4'-N-Benzyloxocarbonylaminomethylcarbonylamino)benzoyloxymethyl]
(15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-tert-butoxycarbonylamino-2- hydroxycyclopentan-1-carboxylate A mixture of chloromethyl 4-[N-(benzyloxycarbonyl)glycylarnino]benzoate (40B, 1.0 g, 2.6 mmol) and sodium iodide (2.25 g, 15 mmol) in acetone (20 mL) was stirred at room temperature for 16 h. The solvent was evaporated under reduced pressure, the residue was taken in dichloromethane (40 mL), washed with 5 % sodium thiosulfate and water. The organic layer was dried and filtered. The filtrate on concentration gave 1.2 g of a brown residue. The residue was dissolved in dimethyl acetamide (10 mL) and added to a mixture of (15,25,322,422, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-(tert-butoxycarbo- nylamino)-2- hydroxycyclopentan-1 -carboxylic acid (20B, 0.77 g, 2.0 mmol) and diisopropylamine (0.26 g, 2.6 mmol) in dimethyl acetamide (30 mL) at 0 °C. The reaction mixture was further stirred for 2 h at this temperature and diluted with water and ethyl acetate. Organic layer was separated, aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with sodium bicarbonate, water and brine and dried. After filtration, the filtrate was concentrated, and the residue was purified on silica gel column using hexane: ethyl acetate as eluent to give 0.9 g (61 %) of 40C.
40D: l-[(4'-Benzyloxycarbonylaminomethylcarbonylamino)benzoyloxymethyl]
(15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(N-benzyloxycarbonyl- amino-N'- benzyloxycarbonylimino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
To a mixture of l-[(4'-benzyloxycarbonylaminomethylcarbonylamino)benzoyloxy- methyl] (15,25,322,4R, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-tert-butoxycarbonyl- amino-2- hy droxy cyclopentan- 1-carboxylate (40C, 1.1 g, 1.5 mmol) in dichloromethane (75 mL) was added trifluoroacetic acid (7.0 mL) and stirred for 16 h. The solvent was evaporated and the residue was stirred with ether and hexane. The supernatent was decanted and the residue was dried under reduced pressure and dissolved in dimethyl formamide (20 mL). To this solution were added triethylamine (1.05 mL, 7.5 mmol), l,3-bis-(benzyloxycarbonyl)-2-methyl-2- thiopseudourea (20 A, 0.65 g, 1.8 mmol) and mercury (II) chloride (0.49 g, 1.8 mmol) and stirred for 2 h. After dilution with ethyl acetate (100 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.16 g (11 %) of 40D.
40: To a solution of l-[(4'-benzyloxycarbonylaminomethylcarbonylamino)benzoyl- oxymethyl] (15,25,322,4/2, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-(N-benzyloxy- carbonylammo-N'-benzyloxycarbonylimino)methyl]amino-2-hydroxycyclopentan-l-carboxylate (40D, 0.11 g, 0.12 mmol) in ethanol (8 mL) and water (2 mL) was added 10% Pd/C (25 mg) and cone. HCI (2 drops) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.064 g (71 %) of 40.
Anal, calcd. for C25H38N6θ7«3HCl«3H2θ«C2HsOH: %C 43.58 %H 7.18 %N 11.29 Found: %C 43.24 %H 6.48 %N 11.48 MS (ES+): 535.6 (M+ l)
Example 41
41: l-[(4'-Aminomethylcarbonyloxy)benzoyloxymethyl] (15,25,3R,4R,l'5)-(-)-3-(l'- acetylamino-2'-ethyl)butyl-4-(amino-imino)methyl]amino-2-hydroxycyclopentan-l- carboxylate
Figure imgf000073_0001
41A: 4-[N-(Benzyloxycarbonyl)glycyloxy]benzoic acid:
Isobutyl chloroformate (3.1 mL, 23.3 mmol) was added to a mixture of N- benzyloxycarbonylglycine (5.0 g, 23.9 mmol) and triethylamine (3.35 mL, 24.2 mmol) in THF (60 mL) at -20 °C over a period of 10 min. and further stirred for 20 min. To this mixture was then added, a solution of 4-hydroxybenzoic acid (3.28 g, 23.9 mmol) and triethylamine (3.35 mL, 24.2 mmol) in THF (45 mL) drop wise and stirred at the same temperature for 1 h. The mixture was brought to room temperature and stirred for 16 h, which was then concentrated and the residue was dissolved in 50% acetic acid (30 mL) and cooled. Water (180 mL) was added and the precipitate was collected by filtration to give 1.9 g (24%) of 41A.
41B: Chloromethyl 4-[N-(benzyloxycarbonyl)glycyloxy]benzoate:
A solution of chloromethyl chlorosulfate (1.2 g, 7.4 mmol) in dichloromethane (4.0 mL) was added to a mixture of 4-[N-(benzyloxycarbonyl)glycyloxy]benzoic acid (41A, 1.75 g, 5.3 mmol), sodium bicarbonate (2.0 g, 23.8 mmol) and tetrabutylammomum hydrogensulfate (0.23 g, 0.7 mmol) in dichloromethane (20 mL) and water (20 mL) drop wise over a period of 5 min. and the mixture was stirred for 3 h. Organic phase was separated and the aqueous phase was extracted with dichloromethane (2 X). The combined organic phases were concentrated. The residue was taken in ethyl acetate, washed with brine and dried. After filtration, the filtrate was concentrated and the residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 2.0 g (98%) of 41B.
41C: l[(4'-N-Benzyloxycarbonylaminomethylcarbonyloxy)benzoyloxymethyl] (15,25,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-^rt-butoxycarbonylamino-2- hydroxycyclopentan-1-carboxylate A mixture of chloromethyl 4-[N-(benzyloxycarbonyl)glycyloxy]benzoate (41B, 2.0 g, 5.3 mmol) and sodium iodide (4.5 g, 30.0 mmol) in acetone (30 mL) was stirred at room temperature for 16 h. The solvent was evaporated under reduced pressure, the residue was taken in dichloromethane (80 mL), washed with 5% sodium thiosulfate and water. The organic layer was dried and filtered. The filtrate on concentration gave 2.4 g of a brown residue. The residue (1.55 g, 3.3 mmol) was dissolved in dimethyl acetamide (10 mL) and added to a mixture of (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(tert- butoxycarbonylamino)-2-hydroxycyclopentan-l-carboxylic acid (20B, 1.16 g, 3.0 mmol) and diisopropylamine (0.0.33 g, 3.3 mmol) in dimethyl acetamide (30 mL) at 0 °C. The reaction mixture was further stirred for 2 h at this temperature and diluted with water and ethyl acetate. Organic layer was separated, aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with sodium bicarbonate, water and brine and dried. After filtration, the filtrate was concentrated, and the residue was purified on silica gel column using hexane: ethyl acetate as eluent to give 1.6 g (73 %) of 41C.
41D: l-[(4'-N-Benzyloxycarbonylaminomethylcarbonyloxy)benzoyloxymethyl]
(15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(N-benzyloxycarbonyl- amino-N'- benzyloxycarbonylimino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
To a mixture of l-[(4'-benzyloxycarbonylaminomethylcarbonyloxy)benzoyloxymethyl]
(15,25,322,422, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-tert-butoxycarbonylamino-2- hydroxycy clopentan- 1-carboxylate (40C, 1.22 g, 1.7 mmol) in dichloromethane (75 mL) was added trifluoroacetic acid (7.0 mL) and stirred for 16 h. The solvent was evaporated and the residue was stirred with ether and hexane. The supernatent was decanted and the residue was dried under reduced pressure and dissolved in dimethyl formamide (20 mL). To this solution were added triethylamine (1.0 mL, 7.0 mmol), 1 ,3-bis-(benzyloxy- carbonyl)-2-methyl-2- thiopseudourea (20A, 0.73 g, 2.05 mmol) and mercury (II) chloride (0.56 g, 2.05 mmol) and stirred for 2 h. After dilution with ethyl acetate (100 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.11 g (7%) of 41D.
41: To a solution of l-[(4'-benzyloxycarbonylaminomethylcarbonyloxy)benzoyloxy- methyl] (15,25,322,422, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-(N-benzyloxycarbonyl- amino-N'- benzyloxycarbonylimino)methyl]amino-2-hydroxycyclopentan- 1-carboxylate (41D, 0.11 g, 0.12 mmol) in ethanol (8 mL) and water (2 mL) was added 10% Pd/C (25 mg) and cone. HCI (2 drops) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.06 g (70%) of 41.
Anal, calcd. for C25H37Nsθ8»5HCl«3.5 θ«C2H5θH: %C 39.21 %H 6.70 %N 8.89 Found: %C 39.33 %H 6.19 %N 8.25
MS (ES+): 536.7 (M+ l) Example 42
42: n-Hexyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(amino- imino)methyl]amino-2-hydroxycyclopentan-l-carbqxylate
Figure imgf000075_0001
42A: n-Hexyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-fc/f-butoxy- carbonylammo-2-hydroxycyclopentan-l-carboxylate
To a mixture of (15,25,3R,422,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-tgrt-butoxy- carbony lamino-2-hy droxy cy clopentan- 1 -carboxylic acid (20B, 1.5 g, 3.9 mmol) in dichloromethane (40 mL) was added 1, l'-carbonyldiimidazole (1.3 g, 7.6 mmol) and stirred at room temperature for 2 h. To this mixture was then added n-hexanol (1.46 mL, 11.6 mmol) and the reaction mixture was stirred for 16 h. After dilution with water, the reaction mixture was extracted with dichloromethane (2 X). The combined organic layers were dried, filtered and concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 1.1 g (60%) of 42A.
42B: n-Hexyl (15,25,3R,422,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(N-benzyl- oxycarbonylamino-N'-benzyloxycarbonylimino)methyl]amino-2-hydroxycyclo- pentan-1- carboxylate To a mixture of n-hexyl (15,25,322,422, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-tert- butoxycarbonylamino-2-hydroxycyclopentan- 1-carboxylate (42A, 1.0 g, 2.1 mmol) in ether (30 mL) and THF (10 mL) was added 7.5N HCI in ether (4.0 mL, 30 mmol) and the mixture was stirred at room temperature for 16 h. After concentration, the residue was suspended in ether- hexane and the solid was collected by filtration, washed with a mixture of ether- hexane and dried to give 0.78 g (90%) of amine as hydrochloride. Amine was dissolved in dimethyl formamide (20 mL). To this solution were added triethylamine (0.94 mL, 6.7 mmol), 1,3-bis- (benzyloxycarbonyl)-2-methyl-2-thiopseudo- urea (20A, 0.82 g, 2.3 mmol) and mercury (II) chloride (0.62 g, 2.3 mmol) and stirred for 2 h. After dilution with ethyl acetate (100 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.73 g (56%) of 42B.
42: To a solution of n-hexyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-efhyl)butyl-4-(N- benzyloxycarbonylamino- ' -benzyloxycarbonylimino)methyl] amino-2-hydroxycyclo pentan- 1 - carboxylate (42B, 0.73 g, 1.1 mmol) in ethanol (40 mL) and water (5 mL) was added 10% Pd/C (100 mg) and cone. HCI (2 drops) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.42 g (88%) of 42.
Anal, calcd. for C2ιH«N4θ4»HCl«1.5H2θ: %C 52.98 %H 9.31 %N 11.76 Found: %C 52.84 %H 8.93 %N 11.85
MS (ES+): 413.2 (M+ l)
Example 43
43: 2-Methylpropyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(amino- imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000076_0001
43A: 2-Methylpropyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-tert- butoxycarbonylamino-2-hydroxycyclopentan-l-carboxylate To a mixture of (15,25,3R,422, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-tert-butoxy- carbonylamino-2-hydroxycyclopentan-l-carboxylic acid (20B, 1.5 g, 3.9 mmol) in dichloromethane (40 mL) was added 1, l'-carbonyldiimidazole (1.3 g, 7.6 mmol) and stirred at room temperature for 2 h. To this mixture was then added 2-methylpropanol (1.1 mL, 11.6 mmol) and the reaction mixture was stirred for 16 h. After dilution with water, the reaction mixture was extracted with dichloromethane (2 X). The combined organic layers were dried, filtered and concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.91 g (53%) of 43A.
43B: 2-Methylpropyl (15,25,3R,422,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(N- benzyloxycarbonylamino-N'-benzyloxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan-1-carboxylate
To a mixture of 2-methylpropyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-tert- butoxycarbonylamino-2-hydroxycy clopentan- 1-carboxylate (43 A, 0.91 g, 2.0 mmol) in ether (30 mL) and THF (10 mL) was added 7.5N HCI in ether (4.0 mL, 30 mmol) and the mixture was stirred at room temperature for 16 h. After concentration, the residue was suspended in ether- hexane and the solid was collected by filtration, washed with a mixture of ether- hexane and dried to give 0.8 g (99%) of amine as hydrochloride. The amine was dissolved in dimethyl formamide (20 mL). To this solution were added triethylamine (0.97 mL, 7.0 mmol), l,3-bis(benzyloxycarbonyl)-2-methyl-2-thiopseudo- urea (20A, 0.86 g, 2.4 mmol) and mercury (II) chloride (0.65 g, 2.4 mmol) and stirred for 2 h. After dilution with ethyl acetate (100 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.68 g (50%) of 43B.
43: To a solution of 2-methylpropyl (15,25,322,4R, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)- butyl- 4-(N-benzyloxycarbonylamino-N'-benzyloxycarbonylimino)methyl]amino-2- hydroxycy clopentan- 1-carboxylate (43B, 0.68 g, 1.0 mmol) in ethanol (40 mL) and water (5 mL) was added 10% Pd/C (100 mg) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.25 g (57%) of 43.
Anal, calcd. for Ci9H36N4θ «2.75H2O: %C 52.57 %H 9.63 %N 12.90
Found: %C 52.17 %H 8.76 %N 13.00
MS (ES+): 385.3 (M + l)
Example 44
44: α-(Ethoxycarbonyloxy)ethyl (15,25,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)- butyl-4- (amino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000077_0001
44A: α-(Ethoxycarbonyloxy)ethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)- butyl- 4-fert-butoxycarbonylamino-2-hydroxycyclopentan-l-carboxylate
1-Iodoethyl ethyl carbonate (1.27 g, 5.2 mmol; prepared from that disclosed in Svahn et al. J. Med. Chem. 1986, 29, 448-453; Fuji oto et al. J. Antibiotics 1987, XL, 370-384) was added to a mixture of (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)- butyl-4-tert- butoxycarbony lamin)-2-hy droxy cy clopentan- 1 -carboxylic acid (20B, 1.0 g, 2.6 mmol) and diisopropylamine (0.0.53 g, 5.2 mmol) in dimethyl acetamide (30 mL) at 0 °C. The reaction mixture was further stirred for 2 h at this temperature and diluted with water and ethyl acetate. The organic layer was separated, aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with sodium bicarbonate, water and brine and dried. After filtration, the filtrate was concentrated, and the residue was purified on silica gel column using hexane: ethyl acetate as eluent to give 0.9 g (68%) of 44 A. 44B: α-(Ethoxycarbonyloxy)ethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)- butyl- 4-(N-benzyloxycarbonylamino-N'-benzyloxycarbonylimino)methyl]amino-2- hydroxycyclopentan-1-carboxylate
To a mixture of α-(ethoxycarbonyloxy)ethyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'- ethyl)butyl-4-tert-butoxycarbonylamino-2-hydroxycyclopentan-l-carboxylate (44A, 0.9 g, 1.8 mmol) in ether (30 mL) and THF (10 mL) was added 7.5N HCI in ether (4.0 mL, 30 mmol) and the mixture was stirred at room temperature for 16 h. After concentration, the residue was suspended in ether- hexane and the solid was collected by filtration, washed with a mixture of ether- hexane and dried to give 0.79 g (99%) of amine as hydrochloride. The amine was dissolved in dimethyl formamide (20 mL). To this solution were added triethylamine (0.88 mL, 6.3 mmol), l,3-bis-(benzyloxycarbonyl)-2-methyl-2-thiopseudourea (20A, 0.76 g, 2.1 mmol) and mercury (II) chloride (0.59 g, 2.1 mmol) and stirred for 2 h. After dilution with ethyl acetate (100 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.84 g (65 %) of 44B.
44: To a solution of α-(ethoxycarbonyloxy)ethyl (15,25,322,422, l'5)-(-)-3-(l '-acetyl- amino-2'- ethyl)butyl-4-(N-benzyloxycarbonylamino-N'-benzyloxycarbonylimino)- methyl] amino-2- hydroxycyclopentan- 1-carboxylate (44B, 0.84 g, 1.1 mmol) in ethanol (40 mL) and water (5 mL) was added 10% Pd/C (100 mg) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.25 g (49%) of 44.
Anal, calcd. for C2oH36N4θ7*H2θ: %C 51.93 %H 8.28 %N 12.11
Found: %C 51.68 %H 8.11 %N 12.05
MS (ES+): 444.9 (M + l)
Example 45
45: α-Acetyloxyethyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(amino- imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000078_0001
45A: α-Acetyloxyethyl (15,2S,3R,422,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-t:e^- butoxycarbonylamino-2-hydroxycyclopentan-l-carboxylate
1-Iodoethyl acetate (1.1 g, 5.2 mmol; prepared from that disclosed in Svahn et al. J. Med. Chem. 1986, 29, 448-453; Fujimoto et al. J. Antibiotics 1987, XL, 370-384) was added to a mixture of (15,25,3R,4R, 1 '5)-(-)-3-(l ' -acetylamino-2 ' -ethyl)butyl-4-tert-butoxycarbonylamino- 2-hy droxy cyclopentan- 1 -carboxylic acid (20B, 1.0 g, 2.6 mmol) and diisopropylamine (0.53 g, 5.2 mmol) in dimethyl acetamide (30 mL) at 0 °C. The reaction mixture was further stirred for 2 h at this temperature and diluted with water and ethyl acetate. Organic layer was separated, aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with sodium bicarbonate, water and brine and dried. After filtration, the filtrate was concentrated, and the residue was purified on silica gel column using hexane: ethyl acetate as eluent to give 0.7 g (57%) of 45A.
45B: α-Acetyloxyethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(N- benzyloxycarbonylamino-N'-benzyloxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan-1-carboxylate
To a mixture of α-acetyloxyethyl (15,25,322,422, l'5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-tert- butoxycarbonylamino-2-hydroxycyclopentan- 1-carboxylate (45A, 0.7 g, 1.5 mmol) in ether (30 mL) and THF (10 mL) was added 7.5N HCI in ether (4.0 mL, 30 mmol) and the mixture was stirred at room temperature for 16 h. After concentration, the residue was suspended in ether- hexane and the solid was collected by fitration, washed with a mixture of ether- hexane and dried to give 0.61 g (99%) of amine as hydrochloride. Amine was dissolved in dimethyl formamide (20 mL). To this solution were added triethylamine (0.73 mL, 5.3 mmol), 1,3-bis- (benzyloxycarbonyl)-2-methyl-2-thiopseudo- urea (20A, 0.64 g, 1.8 mmol) and mercury (II) chloride (0.49 g, 1.8 mmol) and stirred for 2 h. After dilution with ethyl acetate (100 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.47 g (46%) of 45B.
45: To a solution of α-acetyloxyethyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-
4-(N-benzyloxycarbonylamino-N'-benzyloxycarbonylimino)methyl]amino-2- hy droxy cyclopentan- 1-carboxylate (45B, 0.47 g, 0.69 mmol) in ethanol (40 mL) and water (5 mL) was added 10% Pd/C (100 mg) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.15 g (48 %) of 45.
Anal, calcd. for Ci9H34N θ6»2H2O: %C 50.65 %H 8.50 %N 12.44 Found: %C 50.38 %H 7.62 %N 11.79
MS (ES+): 415.4 (M+ l)
Example 46
46: tert-Butylcarbonyloxomethyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)- butyl- 4-(amino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000079_0001
46A: tert-Butylcarbonyloxymethyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)- butyl- 4-tert-butoxycarbonylamino-2-hydroxycyclopentan-l-carboxylate
Iodomethyl pivalate (0.74 g, 5.2 mmol; prepared from the literature references: svahn et al. J. Med. Chem. 1986, 29, 448-453; Fujimoto et al. J. antibiotics 1987, XL, 370-384) was added to a mixture of (15,25,322,422, 1 '5)-(-)-3-(l ' -acetylamino-2 ' -ethyl)butyl-4-tert- butoxycarbony lamino-2-hydroxycy clopentan- 1 -carboxylic acid (20B, 1.0 g, 2.6 mmol) and diisopropylamine (0.53 g, 5.2 mmol) in dimethyl acetamide (30 mL) at 0 °C. The reaction mixture was further stirred for 2 h at this temperature and diluted with water and ethyl acetate. Organic layer was separated, aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with sodium bicarbonate, water and brine and dried. After filtration, the filtrate was concentrated, and the residue was purified on silica gel column using hexane: ethyl acetate as eluent to give 0.7 g (59%) of 46A.
46B: ^rt-Butylcarbonyloxymethyl (15,25,322,422,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)- butyl-4-(N-benzyloxycarbonylamino-N'-benzyloxycarbonylimino)methyl]amino-2- hydroxycyclopentan-1-carboxylate
To a mixture of tert-butylcarbonyloxymethyl (15,25,3R,422,l'5)-(-)-3-(l'-acetylamino-2'- ethyl)butyl-4-tert-butoxycarbonylamino-2-hy droxy cyclopentan- 1-carboxylate (46 A, 0.7 g, 1.5 mmol) in ether (30 mL) and THF (10 mL) was added 7.5N HCI in ether (4.0 mL, 30 mmol) and the mixture was stirred at room temperature for 16 h. After concentration, the residue was suspended in ether- hexane and the solid was collected by fitration, washed with a mixture of ether- hexane and dried to give 0.61 g (99%) of amine as hydrochloride. Amine was dissolved in dimethyl formamide (20 mL). To this solution were added triethylamine (0.73 mL, 5.3 mmol), l,3-bis-(benzyloxycarbonyl)-2-methyl-2-thiopseudourea (20A, 0.64 g, 1.8 mmol) and mercury (II) chloride (0.49 g, 1.8 mmol) and stirred for 2 h. After dilution with ethyl acetate (100 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.54 g (50%) of 46B. 46: To a solution of tert-butylcarbonyloxymethyl (15,25,3R,4R, 1 '5)-(-)-3-(l '-acetyl amino-2'- ethyl)butyl-4-(N-benzyloxycarbonylamino-N'-benzyloxycarbonylimino)- methyl] amino-2- hydroxycyclopentan-1-carboxylate (46B, 0.54 g, 0.76 mmol) in ethanol (40 mL) and water (5 mL) was added 10% Pd/C (100 mg) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.10 g (26 %) of 46.
Anal, calcd. for C2iH38N4θ6«3.5H2O: %C 49.88 %H 8.97 %N 11.08
Found: %C 50.11 %H 7.99 %N 11.09
MS (ES+): 443.0 (M + l) Example 47
47: α-(methoxycarbonyloxy)ethyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)- butyl- 4-(amino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000081_0001
47A: α-(methoxycarbonyloxy)ethyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl- 4-tert-butoxycarbonylamino-2-hydroxycyclopentan-l-carboxylate
1-Iodoethyl methyl carbonate (1.22 g, 5.2 mmol; prepared from the literature references: svahn et al. J. Med. Chem. 1986, 29, 448-453; Fujimoto et al. J. antibiotics 1987, XL, 370- 384) was added to a mixture of (15,25,322,422, l'5)-(-)-3-(l ' -acetylamino-2 ' -ethyl)butyl-4-tert- butoxycarbonylamino-2-hydroxycyclopentan-l -carboxylic acid (20B, 1.0 g, 2.6 mmol) and dusopropylamine (0.53 g, 5.2 mmol) in dimethyl acetamide (30 mL) at 0 °C. The reaction mixture was further stirred for 2 h at this temperature and diluted with water and ethyl acetate. Organic layer was separated, aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with sodium bicarbonate, water and brine and dried. After filtration, the filtrate was concentrated, and the residue was purified on silica gel column using hexane: ethyl acetate as eluent to give 0.67 g (54%) of 47 A.
47B: α-(Methoxycarbonyloxy)ethyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl- 4-(N-benzyloxycarbonylamino-N'-benzyloxycarbonylimino)methyl]- amino-2- hydroxycyclopentan-1-carboxylate To a mixture of α-(methoxycarbonyloxy) ethyl (15,25,322,4R, 1 '5)-(-)-3-(l ' -acetylamino-2 '- ethyl)butyl-4-tert-butoxycarbonylamino-2-hydroxycyclopentan-l-carboxylate (47A, 0.67 g, 1.4 mmol) in ether (30 mL) and THF (10 mL) was added 7.5N HCI in ether (4.0 mL, 30 mmol) and the mixture was stirred at room temperature for 16 h. After concentration, the residue was suspended in ether- hexane and the solid was collected by filtration, washed with a mixture of ether- hexane and dried to give 0.57 g (99%) of amine as hydrochloride. Amine was dissolved in dimethyl formamide (20 mL). To this solution were added triethylamine (0.69 mL, 4.9 mmol), l,3-bis-(benzyloxycarbonyl)-2-methyl-2-fhiopseudourea (20A, 0.6 g, 1.7 mmol) and mercury (II) chloride (0.46 g, 1.7 mmol) and stirred for 2 h. After dilution with ethyl acetate (100 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.49 g (50%) of 47B. 47: To a solution of α-(methoxycarbonyloxy)ethyl (15,25,3R,4R,l'5)-(-)-3-(l '-acetyl- amino- 2'-ethyl)butyl-4-(N-benzyloxycarbonylamino-N'-benzyloxycarbonylimino)- methyl]amino-2- hydroxycyclopentan- 1-carboxylate (47B, 0.48 g, 0.7 mmol) in ethanol (40 mL) and water (5 mL) was added 10% Pd/C (100 mg) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.13 g (40%) of 47.
Anal, calcd. for Ci9H34N4θ7«2H2O: %C 48.92 %H 8.21 %N 12.01
Found: %C 48.48 %H 7.82 %N 12.89
MS (ES+): 431.4 (M + l)
Example 48
48: α-(iso-PropyIoxycarbonyIoxy)ethyl (15,25,3R,4R,l'5)-(-)-3-(l'-acetylamino-2'- ethyl)butyl-4-(amino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate
Figure imgf000083_0001
48A: α-(iso-Propyloxycarbonyloxy)ethyl (15,25,322,4R,l'5)-(-)-3-(l'-acetylamino-2'- ethyl)butyl-4-ter?-butoxycarbonylamino-2-hydroxycyclopentan-l-carboxylate
1-Iodoethyl iso-propyl carbonate (1.4 g, 5.2 mmol; prepared from the literature references: svahn et al. J. Med. Chem. 1986, 29, 448-453; Fujimoto et al. J. antibiotics 1987, XL, 370- 384) was added to a mixture of (15,25,3R,422,l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-tert- butoxycarbonylamino-2-hydroxycyclopentan-l -carboxylic acid (20B, 1.0 g, 2.6 mmol) and dusopropylamine (0.53 g, 5.2 mmol) in dimethyl acetamide (30 mL) at 0 °C. The reaction mixture was further stirred for 2 h at this temperature and diluted with water and ethyl acetate. Organic layer was separated, aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with sodium bicarbonate, water and brine and dried. After filtration, the filtrate was concentrated, and the residue was purified on silica gel column using hexane: ethyl acetate as eluent to give 0.81 g (62%) of 48 A.
48B: α-(iso-Propyloxycarbonyloxy)ethyl (15,25,3R,422,l'5)-(-)-3-(l'-acetylamino-2'- ethyl)butyl-4-(N-benzyloxycarbonylamino-N'-benzyloxycarbonylimino)methyl]- amino-2- hydroxycyclopentan-1-carboxylate
To a mixture of α-(iso-propyloxycarbonyloxy)ethyl (15,25,3R,4R,l'5)-(-)-3-(l '-acetyl- amino- 2 '-ethyl)butyl-4-tert-butoxycarbonylamino-2-hydroxycy clopentan- 1-carboxylate (48 A, 0.81 g, 1.6 mmol) in ether (30 mL) and THF (10 mL) was added 7.5N HCI in ether (4.0 mL, 30 mmol) and the mixture was stirred at room temperature for 16 h. After concentration, the residue was suspended in ether- hexane and the solid was collected by filtration, washed with a mixture of ether- hexane and dried to give 0.7 g (99%) of amine as hydrochloride. Amine was dissolved in dimethyl formamide (20 mL). To this solution were added triethylamine (0.78 mL, 5.6 mmol), l,3-bis-(benzyloxycarbonyl)-2-methyl-2-thiopseudourea (20A, 0.69 g, 1.9 mmol) and mercury (II) chloride (0.52 g, 1.9 mmol) and stirred for 2 h. After dilution with ethyl acetate (100 mL), the mixture was filtered and the filtrate was washed with water and brine. The organic layer was dried, filtered and the filtrate concentrated. The residue was purified on silica gel column using hexane: ethyl acetate as an eluent to give 0.78 g (67%) of 48B.
48: To a solution of α-(iso-propyloxycarbonyloxy)ethyl (15,25,322,422, l'5)-(-)-3-(l'- acetylamino-2'-ethyl)butyl-4-(N-benzyloxycarbonylamino-N'-benzyloxycarbonylimino)- methyl] amino-2-hydroxy cyclopentan- 1-carboxylate (48B, 0.48 g, 0.66 mmol) in ethanol (40 mL) and water (5 mL) was added 10% Pd/C (100 mg) and the mixture was hydrogenated at 40 psi for 1 h. The mixture was passed through a pad of Celite and silica gel, and the filtrate was concentrated and dried to give 0.17 g (52%) of 48.
Anal, calcd. for C2iH3sN4θ7*2H2θ: %C 51.00 %H 8.56 %N 11.33
Found: %C 49.72 %H 8.05 %N 12.06
Compounds of the present invention are useful as prodrugs for substituted cyclopentane and substituted cyclopentene compounds which are useful as neuraminidase inhibitors, or as active neuraminidase inhibitors themselves.
For the purposes of this disclosure, the term "prodrag" denotes a derivative of cyclopentane or cyclopentene, which derivative, when administered to a warm-blooded animal, "cleaves" in such a manner as to release the active drug form at its target site or sites of activity. The enzymatic and/or chemical hydrolytic "cleavage" of the compounds of the instant invention occurs in a manner such that the active drag form is released while the remaining "cleaved" moiety remains nontoxic and is metabolized in such a manner that nontoxic, virologically inert products are produced.
The prodrug compounds of the present invention can be used to treat any condition for which the parent cyclopentane or cyclopentene containing drug, medicament or pharmaceutical is useful for. The prodrugs may be administered in low amounts relative to the amounts of neuraminidase inhibitor that would ordinarily be administered.
Dosage and Formulation
The compounds of this invention can be administered as treatment for viral infections by any means that produces contact of the active agent's site of action with the viral neuraminidase in the body of a human, mammal, bird, or other animal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
The dosage administered will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms, the kind of concurrent treatment; the frequency of treatment; and the effect desired. A daily dosage of active ingredient can be expected to be about 0.001 to 1000 milligram (mg) per kilogram (kg) of body weight, with the preferred dose being 0.1 to about 30 mg/kg. Dosage forms (compositions suitable for administration) contain from about 1 mg to about 500 mg of prodrug per unit. In these pharmaceutical compositions, the compound of the present invention will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.
The prodrug can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. It can also be administered parenterally, in sterile liquid dosage forms. The prodrug can also be administered intranasally (nose drops) or by inhalation of a drug powder mist. Other dosage forms are potentially possible such as administration transdermally, via a patch mechanism or ointment.
Gelatin capsules contain the prodrug and powdered carriers, such as lactose, starch, cellulose derivatives, biocompatible polymers, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar-coated or film-coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. They may also contain buffering agents, surfactants and preservatives. Liquid oral products can be developed to have sustained-release properties. They may also contain cyclodextrin derivatives to enhance the solubility of the active ingredient and to promote its oral uptake.
In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water-soluble salt of the active ingredient, suitable stabilizing agents, and, if necessary, buffering agents. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.
Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company and in the Handbook of Pharmaceuticals Excipients, American Pharmaceutical Association, both standard reference texts in this field.
Useful pharmaceutical dosage forms for administration of the compounds according to the present invention can be illustrated as follows: Hard Shell Capsules
A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered prodrug, 150 mg of lactose, 50 mg of cellulose, and 6 5 mg of magnesium stearate.
Soft Gelatin Capsules
A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil, or0 olive oil is prepared and injected by means of a positive displacement pump into molten gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules are washed and dried. The prodrug can be dissolved in a mixture of polyethylene glycol, glycerin and sorbitol to prepare a water miscible medicine mix. 5 Tablets
A large number of tablets are prepared by conventional procedures so that the dosage unit was 100 mg of active ingredient, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch, and 98.8 mg of lactose. o Appropriate aqueous and non-aqueous coatings may be applied to increase palatability improve elegance and stability or delay absorption.
Immediate Release Tablets/Capsules 5 These are solid oral dosage forms made by conventional and novel processes. These units are taken orally without water for immediate dissolution and delivery of the medication. The prodrug is mixed in a liquid containing ingredient such as sugar, gelatin, pectin, and sweeteners. These liquids are solidified into solid tablets or caplets by freeze drying and solid state extraction techniques. The compounds may be compressed with viscoelastic and o thermoelastic sugars and polymers or effervescent components to produce porous matrices intended for immediate release, without the need of water.
Moreover, the compounds of the present invention can be administered in the form of nose drops, metered dose nasal or buccal inhalers. The drug is delivered from a nasal solution5 as a fine mist or from a powder as an aerosol.
Various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. 0
The foregoing disclosure includes all the information deemed essential to enable those skilled in the art to practice the claimed invention. Because the cited applications may provide further useful information, these cited materials are hereby incorporated by reference in their entirety.

Claims

Claims:What is claimed is:
1. A compound represented by the formulae:
wherein Ri is H
Figure imgf000088_0001
, Rs,
Figure imgf000088_0002
— (CH2)nOR5 — (CEb n-N-Rβ , or ; each R2 and R3 individually is H, (CH2)mOH, -C(O)OR, -C(O)Rs, -C(O)SR, (CH2)m-C(O)-
Figure imgf000088_0003
an amino acid and/or a dipeptide; 5 f
I I
— C— (CH2)m-0-C(0)— R"5 (CH2)m-C-0-C(0)R"5
R'< R'< R is Rs, H,
(CH2)m-0-C(0)-0-R"5
Figure imgf000089_0001
Figure imgf000089_0002
Figure imgf000089_0003
R4 is H, OH, -OC(O)-Rs, -OC(O)-N-R5(R's), -O-C(O)-O-Rs;
each Rs, R'5 and Rs" is independently H, alkyl, substituted alkyl, aryl, substituted aryl, alkenyl, alkynyl, substituted alkenyl, substituted alkynyl, heterocycle, substituted heterocycle, alkylaryl, substituted alkylaryl, cycloalkyl, substituted cycloalkyl, or -CH2CO2 alkyl; and wherein Rs can also be (dialkyl)CO alkyl;
Figure imgf000089_0004
each R7 and R'7 individually is alkyl, alkylaryl, substituted alkylaryl, cycloalkyl, substituted cycloalkyl;
Rs is alkyl, or halo substituted alkyl;
n= l-5 and m=0-4; and pharmaceutically acceptable salts thereof.
2. The compound of claim 1 wherein each R7 and RW is individually selected from the group consisting of CH3, C2H5, n-C3H?, and n-C H9.
3. The compound of claim 1 wherein each R7 and R'7 individually is C2H5 or n-
4. The compound of claim 1 wherein Rs is selected from the group consisting of
Figure imgf000090_0001
5. The compound of claim 1 wherein Rs is CH3.
6. The compound of claim 1 wherein R7 = R' 7 = C2H5 and Rs = CH3.
7. The compound of claim 1 wherein
Figure imgf000090_0002
R7=R'7= C2H5 , R4 = OH , Rs=CH3.
8. The compound of claim 1 wherein Ri is CH3, R3 is H, R4 is OH, R7=R'7
Figure imgf000090_0003
R2=C(O)OR9 wherein R9 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, phenyl, substituted phenyl, alkoxycarbonylalkyl and substituted alkoxycarbonylalkyl.
9. The compound of claim 1 wherein
Figure imgf000090_0004
and R2 is a peptide.
10. A composition for inhibiting influenza virus neuraminidase comprising a pharmaceutically acceptable carrier in an amount effective for inhibiting influenza virus neuraminidase of a compound of claim 1.
11. A method for inhibiting influenza virus that comprises administering to a patient in need thereof a compound of claim 1 in an amount effective for inhibiting influenza virus neuraminidase.
12. A method for treating influenza virus infection comprising administering to a patient in need thereof a compound of claim 1 in an amount effective for inliibiting influenza virus neuraminidase.
13. A method for preparing a compound according to claim 1 represented by formula A comprising the following steps: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an acid to provide the corresponding amine compound; 6) Reacting the product from step 5 to provide the corresponding guanylated compound; and optionally 7) Hydrolyzing the product from step 6 to obtain the corresponding acid.
14. A method for preparing a compound according to claim 1 represented by formula B which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an alkanesulphonyl halide to provide the corresponding O-SO2 alkyl derivative; 6) Treating the product from step 5 with a base to provide the corresponding unsaturated compound; 7) Treating the product from step 6 with an acid to provide the corresponding amine; and 8) Reacting the product from step 7 to provide the corresponding guanylated compound.
15. A process for preparing a compound according to claim 1 represented by structure A which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an acid to provide the corresponding amine compound; 6) Reacting the product from step 5 to provide the corresponding guanylated compound; and optionally 7) Hydrolyzing the product from step 6 to obtain the corresponding acid; 8) reacting the product from step 7 with a base to provide the corresponding salt; 9) reacting the product from step 8 with RiX wherein X is a halide to provide the desired product.
16. A process for preparing a compound according to claim 1 represented by structure B which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an alkanesulphonyl halide to provide the corresponding O-SO2 alkyl derivative; 6) Treating the product from step 5 with a base to provide the corresponding unsaturated compound; 7) Treating the product from step 6 with an acid to provide the corresponding amine; 8) Reacting the product from step 7 to provide the corresponding guanylated compound; 9) reacting the product from step 9 with a base to provide the corresponding salt; 10) reacting the product from step 9 with RiX wherein X is a halide to provide the desired product.
17. A process for preparing a compound according to claim 1 represented by structure A which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Hydrolyzing the product obtained from step 4 with a base to give the corresponding salt; 6) Reacting the product from step 5 with RiX wherein X is a halide; 7) Hydrolyzing the product from step 6 to provide the corresponding amine; and 8) Reacting the product from step 7 to provide the corresponding guanylated compound.
18. A process for preparing a compound according to claim 1 represented by structure B which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an alkanesulphonyl halide to provide the corresponding O-SO2 alkyl derivative; 6) Treating the product from step 5 with a base to provide the corresponding unsaturated compound; 7) Hydrolyzing a product obtained from step 6 with a base to give the corresponding salt; 8) Reacting the product from step 7 with RiX wherein X is a halide; 9) Hydrolyzing the product from step 8 to provide the corresponding amine; and 10) Reacting the product from step 9 to provide the corresponding guanylated compound.
19. A process for preparing a compound according to claim 1 represented by formula A which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Converting a compound obtained from step 4 to the corresponding acid; 6) Reacting the product from step 5 with RiOH in the presence of a coupling agent to provide the corresponding ester; 7) Hydrolyzing the product from step 6 to provide the corresponding amine; and 8) Reacting the product from step 7 to provide the corresponding guanylated compound.
20. A process for preparing a compound according to claim 1 represented by formula B which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an alkanesulphonyl halide to provide the corresponding O-SO2 alkyl derivative; 6) Treating the product from step 5 with a base to provide the corresponding unsaturated compound; 7) Converting a compound obtained from step 6 to the corresponding acid; 8) Reacting the product from step 7 with RiOH in the presence of a coupling agent to provide the corresponding ester; 9) Hydrolyzing the product from step 8 to provide the corresponding amine; and 10) Reacting the product from step 9 to provide the corresponding guanylated compound.
21. A process for preparing a compound according to claim 1 represented by formula A which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Converting a compound obtained from step 4 to the corresponding acid; 6) Reacting the product from step 5 with an alkylchloroformate in the presence of a base to form a mixed anhydride; 7) Reacting the product from step 6 with RiOH; 8) Hydrolyzing the product from step 7 to provide the corresponding amine; and 9) reacting the product from step 8 to provide the corresponding guanylated compound.
22. A process for preparing a compound according to claim 1 represented by formula B which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an alkanesulphonyl halide to provide the corresponding O-SO2 alkyl derivative; 6) Treating the product from step 5 with a base to provide the corresponding unsaturated compound; 7) Converting a compound obtained from step 6 to the corresponding acid; 8) Reacting the product from step 7 with an alkylchloroformate in the presence of a base to form a mixed anhydride; 9) Reacting the product from step 8 with RiOH; 10) Hydrolyzing the product from step 9 to provide the corresponding amine; and 11) Reacting the product from step 10 to provide the corresponding guanylated compound.
23. A process for preparing a compound according to claim 1 represented by formula A which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to its corresponding alkali salt by reacting with a base; 4) Reacting the product from step 3 with RiX or with RiOH in the presence of a coupling agent to form the corresponding ester, X is a halide; 5) Hydrogenating the product from step 4; 6) Acetylating the product from step 5; 7) Hydrolyzing the product from step 6 to provide the corresponding amine; and 8) Reacting the product from step 7 to provide the corresponding guanylated compound.
24. The process of preparing a compound according to claim 1 represented by the formula B which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroxunmoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to its corresponding alkali salt by reacting with a base; 4) Reacting the product from step 3 with RiX or with RiOH in the presence of a coupling agent to form the corresponding ester. X is a halide; 5) Hydrogenating the product from step 4; 6) Acetylating the product from step 5; 7) Reacting the product from step 6 with an alkanesulphonyl halide to provide the corresponding O-SO2 alkyl derivative; 8) Reacting the product from step 7 with a base to provide the corresponding unsaturated compound; 9) Hydrolyzing the product from step 8 to provide the corresponding amine; and 10) Reacting the product from step 9 to provide the corresponding guanylated compound.
25. The process for preparing a compound according to claim 1 represented by the formula A which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an acid to provide the corresponding amine compound; 6) Reacting the product from step 5 with a protected guanylated agent; 7) Hydrolyzing the product from step 6 to provide the corresponding acid; 8) Converting the product from step 7 to the corresponding ester; 9) Removing the protecting group.
26. The process for preparing a compound according to claim 1 represented by formula B which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an alkanesulphonyl halide to provide the corresponding O-SO2 alkyl derivative; 6) Treating the product from step 5 with a base to provide the corresponding unsaturated compound; 7) Treating the product from step 6 with an acid to provide the corresponding amine; 8) Reacting the product from step 7 with a protected guanylated agent; 9) Hydrolyzing the product from step 8 to provide the corresponding acid; 10) Converting the product from step 9 to the corresponding ester; 11) Removing the protecting group.
27. A process for preparing a compound according to claim 1 represented by formula A which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an acid to provide the corresponding amine compound; 6) Reacting the product from step 5 with a cyanogen halide to provide the corresponding cyananine; and 7) Reacting the product from step 6 with a hydroxylamine.
28. A process for preparing a compound according to claim 1 represented by formula B which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an alkanesulphonyl halide to provide the corresponding O-SO2 alkyl derivative; 6) Treating the product from step 5 with a base to provide the corresponding unsaturated compound; 7) Treating the product from step 6 with an acid to provide the corresponding amine; 8) Reacting the product from step 7 with a cyanogen halide to provide the corresponding cyananine; and 9) Reacting the product from step 8 with a hydroxylamine.
29. A process for preparing a compound according to claim 1 represented by formula A which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an acid to provide the corresponding amine compound; 6) Reacting the product from step 5 with a guanylating agent; 7) Reacting the product from step 6 with RsO C(O)X or R9O C(O))C6H4 «NO2 in the presence of a base.
30. A process for preparing a compound according to claim 1 represented by formula B which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an emylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating me amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an alkanesulphonyl halide to provide the corresponding O-SO2 alkyl derivative; 6) Treating the product from step 5 with a base to provide the corresponding unsaturated compound; 7) Treating the product from step 6 with an acid to provide the corresponding amine; 8) Reacting the product from step 7 with a guanylating agent; 9) Reacting the product from step 8 with R9O C(O)X or R9O C(O))CeH4«NO2 in the presence of a base.
31. A process for preparing a compound according to claim 1 represented by formula A which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an acid to provide the corresponding amine compound; 6) Reacting the product from step 5 to provide the corresponding guanylated ester compound and converting the ester into an acid; 7) Reacting the product from step 6 with an alcohol; 8) Reacting the product from step 7 with R9O C(O)X or R9O C(O))CeH4«NO2 in the presence of a base.
32. A process for preparing a compound according to claim 1 represented by formula B which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an alkanesulphonyl halide to provide the corresponding O-SO2 alkyl derivative; 6) Treating the product from step 5 with a base to provide the corresponding unsaturated compound; 7) Treating the product from step 6 with an acid to provide the corresponding amine; 8) Reacting the product from step 7 to provide the corresponding guanylated ester compound and converting the ester into an acid; 9) Reacting the product from step 8 with an alcohol; 10) Reacting the product from step 9 with R9O C(O)X or R9O C(O))CeH4«NO2 in the presence of a base.
33. A process for preparing a compound according to claim 1 represented by formula A which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an acid to provide the corresponding amine compound; 6) Reacting the product from step 5 with a guanylating agent.
34. A process for preparing a compound according to claim 1 represented by formula B which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an alkanesulphonyl halide to provide the corresponding O-SO2 alkyl derivative; 6) Treating the product from step 5 with a base to provide the corresponding unsaturated compound; 7) Treating the product from step 6 with an acid to provide the corresponding amine; 8) Reacting the product from step 7 with a guanylating agent.
35. A process for preparing a compound according to claim 1 represented by formula A which comprises: 1) Reacting a lactarm with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alfyl-nitrobutane/trialkylarnine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an acid to provide the corresponding amine compound; 6) Reacting the product from step 5 with a guanylating agent; 7) Reacting the product from step 6 with an amino acid.
36. A process for preparing a compound according to claim 1 represented by formula B which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an alkanesulphonyl halide to provide the corresponding O-SO2 alkyl derivative; 6) Treating the product from step 5 with a base to provide the corresponding unsaturated compound; 7) Treating the product from step 6 with an acid to provide the corresponding amine and; 8) Reacting the product from step 7 with an amino acid.
37. A process for preparing a compound according to claim 1 represented by formula A which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an acid to provide the corresponding amine compound; 6) Reacting the product from step 5 to provide the corresponding guanylated ester compound and converting the ester into an acid; 7) Reacting the product from step 6 with an alcohol; and 8) Reacting the product from step 7 with an amino acid.
38. A process for preparing a compound according to claim 1 represented by formula B which comprises: 1) Reacting a lactam with an alcohol in the presence of an acid followed by reacting with an anhydride or halide and a base to give the corresponding alkoxycarbonyl protected amine-cyclopentene carboxylate; 2) Reacting the compound from step 1 with an alkyl-nitrobutane/trialkylamine combination and phenylisocyanate to provide a cycloadduct; or reacting the compound from step 1 with an ethylbutyrohydroximinoxyl halide and a trialkylamine to provide a cycloadduct; 3) Converting the cycloadduct from step 2 to the corresponding amine; 4) Acylating the amine from step 3 to provide the corresponding acylamine compound; 5) Reacting the product from step 4 with an alkanesulphonyl halide to provide the corresponding O-SO2 alkyl derivative; 6) Treating the product from step 5 with a base to provide the corresponding unsaturated compound; 7) Treating the product from step 6 with an acid to provide the corresponding amine; 8) Reacting the product from step 7 to provide the corresponding guanylated ester compound and converting the ester into an acid; 9) Reacting the product from step 8 with an alcohol; and 10) Reacting the product from step 9 with an amino acid.
39. A compound according to claim 1 being selected from the group consisting of:
Methyl (15,25,322,422, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-ethoxycarbonyl-amino- imino)methyl]amino-2-hydroxycyclopentan- 1 -carboxylate ;
Ethyl (15,25,3R,422, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxy- carbonylamino- imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (15,25,3R,422, 1 '5)-(-)-3-(l ' -acetylamino-2 '-efhyl)butyl-4-[(N-methoxycarbonyl amino- imino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylate ; Ethyl (15,25,322,422, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(N-tert-butoxycarbo- nylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (15,25,322,4R, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(N-ethoxycarbonyl- amino- imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Methyl (15,25,3R,422, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)buty 1-4- [(N-acetyloxy- methoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Methyl (15,25,3R,4R, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)buty 1-4- [(N-acetyloxy- methoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (15,25,3R,4R, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4- [(N-acetyloxymeth- oxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (15,25,3R,4R, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N(α-acetyloxyeth- oxycarbonylaιnino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (15,25,3R,422, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(N-trimefhylacetyl- oxymethoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (15,25,3R,4R, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-(α-trimethyl- acetyloxyethoxycarbonylammo-imino)methyι] amino-2-hydroxy cyclopentan- 1 -carboxylate ;
Ethyl (15,25,3R,422, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(N-phenylacetyloxy- methoxycarbonylamino-imino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylate ;
Ethyl (15,25,3R,4R, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-2,2,2-trichloro- ethoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (15,25,3R,4R, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-2,2,2-trifluoro- ethoxycarbonylamino-imino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylate ;
Ethyl (15,25,3R,4R, l'5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L-amino-3'- phenylpropanoylamino)-imino]methylamino-2-hydroxycyclopentan- 1 -carboxylate ;
Ethyl (15,25,3R,4R, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[N-(2'-L-aminoprop- anoylamino)-imino]methylamino-2-hydroxycyclopentan-l-carboxylate;
Ethyl (15,25,3R,4R, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4- [(2 ' -L-amino-3 '- methylpentanoylamino)-imino]methylamino-2-hydroxycyclopentan-l-carboxylate;
Methyl (15,25,322,4R, 1 '5)-(-)-3-(l '-acetylamino-2 '-ethyl)butyl-4-[N-(2'-L-amino- propanoylamino)-imino]methylamino-2-hydroxycyclopentan-l-carboxylate;
Methyl (15,25,322,422,1 '5)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[N-(2'-L-amino-3'- phenylpropanoylamino)-imino]methylamino-2-hydroxycyclopentan-l-carboxylate;
(15,25,322,422, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-(amino-imino)methyl- amino-2-(3 '- methy lbutanoyl)hy droxy cy clopentan- 1 -carboxylic acid;
(15,25,3R,422, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-(anήno-imino)methylamino-2-n- hexanoyloxy cy clopentan- 1 -carboxylic acid;
(15,25,322,422, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-benzyloxycarbonyl- amino- imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid;
(15,25,322,422, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-methoxycarbonyl- amino- imino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylic acid;
(15,25,322,422, 1 '5)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-t^rt-butoxycarbonyl- amino- imino)methyl]amino-2-hydroxy cyclopentan- 1 -carboxylic acid;
(15,25,3R,422, 1 '5)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(N-ethoxycarbonylamino-hnino) methyl]amino-2-hydroxycyclopentan-l-carboxylic acid;
(1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(N-acetyloxymethoxy- carbonylamino-imino)methy 1] amino-2-hy droxy cyclopentan- 1 -carboxylic acid ;
(1S,2S,3R,4R, 1 'S)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(α-acetyloxyethoxy- carbonylamino- imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid;
(1S,2S,3R,4R, 1 'S)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(N-trimethylacetyloxy- methoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid;
(1S,2S,3R,4R, 1 'S)-(-)-3-(l '-Acetylamino-2'-ethyl)butyl-4-[(N-(α-trimethylacetyloxy- ethoxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid;
(1S,2S,3R,4R, 1 'S)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(N-phenylacetyloxymeth- oxycarbonylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid;
(lS,2S,3R,4R, l 'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(2'-L-amino-3'-phenyl- propanoylamino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylic acid;
(lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(2'-L-aminopropanoyl- amino- iminomethyl]amino-2-hydroxycyclopentan-l-carboxylic acid; 98 (1S,2S,3R,4R, 1 'S)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4- [(2 '-L-amino-3 '-mefhylpen-
99 tanoylamino-iminomethyl]amino-2-hydroxycyclopentan-l-carboxylic acid;
100
101 Ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(N-acetyloxymeth-
102 oxycarbonylamino-N'-acetyloxymethoxycarbonylimino)methyl]amino-2-hydroxy- cyclopentan-
103 1-carboxylate;
104
105 (lS,2S,3R,4R, l'S)-(-)-3-(l '-Acetylamino-2'-ethyl)butyl-4-[(N-acetyloxymethoxy-
106 carbonylamino-N ' -acetyloxymethoxycarbonylimino)methyl] amino-2-hy droxy- cyclopentan- 1 -
107 carboxylic acid;
108
109 Ethyl (1S,2S,3R,4R,1 'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-2,2,2-trifluoro- iio ethoxy carbonylamino-N '-2,2, 2-trifluoroethoxy carbonylimino)methyl] amino-2- lii hydroxycyclopentan- 1 -carboxylate ;
112
113 Ethyl (lS,2S,3R,4R, l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-[(N-ethoxycarbonyl- amino-N'-
114 ethoxycarbonylimino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
115
116 Ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-[(hydroxylamino-
117 imino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylate ;
118
119 (1S,2S,3R,4R, 1 'S)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-[(hydroxylamino-imino)
120 methyl]amino-2-hydroxycyclopentan-l-carboxylic acid;
121
122 l-[(4'-Aminomethylcarbonylamino)benzoyloxymethyl] (lS,2S,3R,4R, l'S)-(-)-3-(l '-
123 acetylamino-2'-ethyl)butyl-4-(amino-imino)methyl]amino-2-hydroxycyclo- pentan- -1-
124 carboxylate;
125
126 l-[(4'-Aminomethylcarbonyloxy)benzoyloxymethyl] (lS,2S,3R,4R, S)-(-)-3-(l'-acetylamino-
127 2 ' -ethyl)butyl-4-(amino-imino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylate ;
128
129 n-Hexyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)butyl-4-(amino-imino)methyl]amino-
130 2-hy droxy cyclopentan- 1 -carboxylate ;
131
132 2-Methylpropyl (lS,2S,3R,4R,l'S)-(-)-3-(l'-acetylamino-2'-ethyl)butyl-4-(amino-
133 imino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylate ;
134
135 α-(Ethoxycarbonyloxy)ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-efhyl)- butyl-4-
136 (amino-imino)methyl] amino-2-hy droxy cyclopentan- 1 -carboxylate ;
137
138 α-Acetyloxyethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2 '-ethyl)butyl-4-(amino-
139 imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate;
140 141 tert-Butylcarbonyloxomethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l '-acetylamino-2'-ethyl)- butyl-4-
142 (amino-imino)methy 1] amino-2-hy droxy cyclopentan- 1 -carboxylate ;
143
144 α-(methoxycarbonyloxy)ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(r-acetylamino-2'-ethyl)- butyl-4-
145 (ainino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate; and
146
147 α-(iso-Propyloxycarbonyloxy)ethyl (1S,2S,3R,4R, 1 'S)-(-)-3-(l ' -acetylamino-2 '-ethyl)butyl-4-
148 (amino-imino)methyl]amino-2-hydroxycyclopentan-l-carboxylate; and pharmaceutically
149 acceptable salts thereof.
150
PCT/US2001/005862 2000-02-24 2001-02-26 Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors WO2001062242A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001243253A AU2001243253A1 (en) 2000-02-24 2001-02-26 Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18466600P 2000-02-24 2000-02-24
US60/184,666 2000-02-24

Publications (1)

Publication Number Publication Date
WO2001062242A1 true WO2001062242A1 (en) 2001-08-30

Family

ID=22677845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/005862 WO2001062242A1 (en) 2000-02-24 2001-02-26 Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors

Country Status (2)

Country Link
AU (1) AU2001243253A1 (en)
WO (1) WO2001062242A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092555A1 (en) * 2001-05-11 2002-11-21 Sankyo Company, Limited Sialic acid derivatives
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6833140B2 (en) * 2001-06-11 2004-12-21 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
JP2007521291A (en) * 2003-07-09 2007-08-02 パラテック ファーマシューティカルズ インコーポレイテッド Prodrugs of 9-aminomethyltetracycline compounds
US7790708B2 (en) 2001-06-11 2010-09-07 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2011123856A1 (en) * 2010-04-02 2011-10-06 Tsrl, Inc. Neuraminidase inhibitors
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN102603577A (en) * 2011-01-19 2012-07-25 董慧珍 Derivatives of anti-influenza and anti-avian influenza medicament and application thereof
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
CN104496857A (en) * 2014-12-10 2015-04-08 广东东阳光药业有限公司 Compound serving as neuraminidase inhibitor and application of compound in medicament
US9533943B2 (en) 2003-07-09 2017-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
WO2017051761A1 (en) * 2015-09-25 2017-03-30 芳男 ▲浜▼田 Novel prodrug
CN107903302A (en) * 2017-11-22 2018-04-13 韶远科技（上海)有限公司 A kind of preparation method of gamma-lactams bridging dipeptide compounds
JP2018515614A (en) * 2015-05-15 2018-06-14 リクスト・バイオテクノロジー，インコーポレイテッド Oxabicycloheptane prodrug
US11931354B2 (en) 2013-04-09 2024-03-19 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047194A1 (en) * 1996-06-14 1997-12-18 Biocryst Pharmaceuticals, Inc. Substituted cyclopentane compounds useful as neuraminidase inhibitors
WO1999033781A1 (en) * 1997-12-17 1999-07-08 Biocryst Pharmaceuticals, Inc. Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
WO2001000571A1 (en) * 1999-06-28 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Process for preparing substituted cyclopentane derivatives and novel crystalline structures thereof
WO2001000558A1 (en) * 1999-06-28 2001-01-04 Biocryst Pharmaceuticals, Inc. Preparation of substituted cyclopentane and cyclopentene compounds and certain intermediates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047194A1 (en) * 1996-06-14 1997-12-18 Biocryst Pharmaceuticals, Inc. Substituted cyclopentane compounds useful as neuraminidase inhibitors
WO1999033781A1 (en) * 1997-12-17 1999-07-08 Biocryst Pharmaceuticals, Inc. Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
WO2001000571A1 (en) * 1999-06-28 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Process for preparing substituted cyclopentane derivatives and novel crystalline structures thereof
WO2001000558A1 (en) * 1999-06-28 2001-01-04 Biocryst Pharmaceuticals, Inc. Preparation of substituted cyclopentane and cyclopentene compounds and certain intermediates

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS, (COLUMBUS, OHIO, USA); ABDEL-MAGID ET AL.: "Process for preparing substituted cyclopentane derivatives and their crystalline structures", XP002940829, accession no. STN Database accession no. 2001:12411 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS, (COLUMBUS, OHIO, USA); BABU ET AL.: "Bcx-1812 (RWJ-270201): discovery of a novel highly potent orally active and selective influenza neuraminidase inhibitor through structure-based drug design", XP002941096, accession no. STN Database accession no. 2000:605951 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS, (COLUMBUS, OHIO, USA); CHAND ET AL.: "Preparation of substituted cyclopentane and cyclopentene compounds and certain intermediates", XP002941095, accession no. STN Database accession no. 2001:12400 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS, (COLUMBUS, OHIO, USA); SORBERA ET AL.: "RWJ-270201: anti-influenza neuraminidase(sialidase) inhibitor", XP002940828, accession no. STN Database accession no. 2000:307903 *
DRUGS FUTURE, vol. 25, no. 3, 2000, pages 249 - 251 *
J. MED. CHEM., vol. 43, 2000, pages 3482 - 3486 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092555A1 (en) * 2001-05-11 2002-11-21 Sankyo Company, Limited Sialic acid derivatives
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6833140B2 (en) * 2001-06-11 2004-12-21 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US7790708B2 (en) 2001-06-11 2010-09-07 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8168623B2 (en) 2001-06-11 2012-05-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US9238616B2 (en) 2001-06-11 2016-01-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
JP2007521291A (en) * 2003-07-09 2007-08-02 パラテック ファーマシューティカルズ インコーポレイテッド Prodrugs of 9-aminomethyltetracycline compounds
JP4738333B2 (en) * 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド Prodrugs of 9-aminomethyltetracycline compounds
US9533943B2 (en) 2003-07-09 2017-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US8906412B2 (en) 2004-11-04 2014-12-09 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2011123856A1 (en) * 2010-04-02 2011-10-06 Tsrl, Inc. Neuraminidase inhibitors
CN103108861A (en) * 2010-04-02 2013-05-15 Tsrl公司 Neuraminidase inhibitors
CN102603577A (en) * 2011-01-19 2012-07-25 董慧珍 Derivatives of anti-influenza and anti-avian influenza medicament and application thereof
US11931354B2 (en) 2013-04-09 2024-03-19 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
CN104496857A (en) * 2014-12-10 2015-04-08 广东东阳光药业有限公司 Compound serving as neuraminidase inhibitor and application of compound in medicament
US11236102B2 (en) 2015-05-15 2022-02-01 Lixte Biotechnology, Inc. Oxabicycloheptane prodrugs
JP2018515614A (en) * 2015-05-15 2018-06-14 リクスト・バイオテクノロジー，インコーポレイテッド Oxabicycloheptane prodrug
US10618908B2 (en) 2015-05-15 2020-04-14 Lixte Biotechnology, Inc. Oxabicycloheptane prodrugs
JP2020180130A (en) * 2015-05-15 2020-11-05 リクスト・バイオテクノロジー，インコーポレイテッド Oxabicycloheptane prodrugs
JP7187023B2 (en) 2015-05-15 2022-12-12 リクスト・バイオテクノロジー，インコーポレイテッド Oxabicycloheptane prodrug
JP7187023B6 (en) 2015-05-15 2023-01-05 リクスト・バイオテクノロジー，インコーポレイテッド Oxabicycloheptane prodrug
US11866444B2 (en) 2015-05-15 2024-01-09 Lixte Biotechnology, Inc. Oxabicycloheptane prodrugs
WO2017051761A1 (en) * 2015-09-25 2017-03-30 芳男 ▲浜▼田 Novel prodrug
CN107903302B (en) * 2017-11-22 2021-05-14 韶远科技（上海)有限公司 Preparation method of gamma-lactam bridged dipeptide compound
CN107903302A (en) * 2017-11-22 2018-04-13 韶远科技（上海)有限公司 A kind of preparation method of gamma-lactams bridging dipeptide compounds

Also Published As

Publication number Publication date
AU2001243253A1 (en) 2001-09-03

Similar Documents

Publication Publication Date Title
WO2001062242A1 (en) Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
EP1040094B9 (en) Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
US7803785B2 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
JP2706646B2 (en) Carboxyalkyl peptide derivatives
US7449493B2 (en) Diamines as modulators of chemokine receptor activity
JP2003534312A (en) Cyclic amino acid derivatives useful as drugs
JPS6323897A (en) Taftsin analog, manufacture and medicinal composition
IE913572A1 (en) Novel compounds
EP1845104A1 (en) Par-2 agonist
RU2181123C2 (en) Pharmaceutical composition with fungicide activity and derivatives of dipeptide of alpha-amino acid or its derivative and cyclopentane-beta-amino acid or its derivative
Kleemann et al. Renin inhibitory pentols showing improved enteral bioavailability
US6762316B1 (en) Preparation of substituted cyclopentane and cyclopentene compounds and certain intermediates
CA2377287A1 (en) Preparation of substituted cyclopentane and cyclopentene compounds and certain intermediates
US20110053858A1 (en) Heterocyclic peptide ketoamides
JP2023529885A (en) Synthesis of (2S,5R)-5-(2-chlorophenyl)-1-(2&#39;-methoxy-[1,1&#39;-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid
US8859505B2 (en) Cysteine protease inhibitors
US6518299B1 (en) Substituted pyrrolidine compounds useful as neuraminidase inhibitors
CA2633072C (en) Analgesic compounds and process of manufacture
RU2365585C2 (en) Antiinflammatory medications
US20070259955A1 (en) Process for the Preparation of Nateglinide
JP3129370B2 (en) Appetite suppressant
CN105143192A (en) Formation of n-protected bis-3, 6-(4-aminobutyl)-2, 5-diketopiperazine through a cyclic alpha-n-protected amino ester
AU2003212040C1 (en) Substituted Cyclopentane And Cyclopentene Compounds Useful As Neuraminidase Inhibitors
JP2006076882A (en) New dipeptide compound and medicinal use thereof
JPH09188631A (en) Fas ligand solubilization inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP